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CHAPTER 1 
Introduction 
1.1 Motivation 
 
Each year, an estimated 300,000 new cases of breast cancer are diagnosed (1).  Fortunately, 
many new molecularly specific, effective treatments are available for these patients. However, 
clinical selections of the most efficacious drug regimen for an individual breast tumor remain 
rather arbitrary, based on static measurements of the presence or absence of several biomarkers, 
including the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2) 
in the diagnostic biopsy. Furthermore, therapy effectiveness is most commonly determined by 
tumor size regression, or growth in the case of ineffective treatments. Therefore, treatments may 
not be identified as ineffective until weeks or months after treatment is initiated. Due to the 
heterogeneity of tumor genotype and phenotype, sub-populations of cells, innately within the 
original tumor or arising as a result of treatment, can cause therapy relapse (2). A technology 
capable of quickly and accurately predicting and monitoring therapy effectiveness is imperative 
for guiding therapeutic decisions, especially as additional drugs are approved for clinical use.   
This dissertation develops a light-based technology, optical metabolic imaging (OMI), for 
monitoring metabolism changes due to anti-cancer therapy and for predicting tumor response to 
anti-cancer therapy.  Current methods, such as palpation, fluorodeoxyglucose positron emission 
tomography (FDG-PET), magnetic resonance imaging (MRI), and ultra-sound size 
measurements to assess therapeutic response lack the resolution and/or sensitivity to provide 
accurate measures of response (3-7).  OMI measures the fluorescence intensity and lifetime of 
intrinsic cellular metabolism coenzymes, nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FAD), which provide a robust measure of cellular metabolism (8, 9).  
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Furthermore, OMI is high-resolution and non-invasive, which allows longitudinal studies of tumor 
heterogeneity.   
Preliminary (Appendix C) and early studies (Chapters 3-4) demonstrated the unique 
sensitivity of OMI to drug-induced metabolism changes.  Therefore, an organoid-based platform 
was developed to enable high-throughput screening of drug response. Organoids are 
macrosuspensions derived from primary tumors and contain all the innate cells and 
microenvironment of the tumor (10, 11).  Therefore, organoids are an attractive, relevant platform 
to test drug response.  The second part of this dissertation (Chapters 5-6, Appendices 4-5) 
characterizes OMI in excised tissues and organoids, and robustly validates an organoid-OMI 
screen for predicting drug response for breast cancer patients.   
1.2 Specific Aims  
The objectives of this dissertation are to fully characterize OMI endpoints and OMI 
analysis, develop OMI for monitoring anti-cancer drug-induced cellular metabolism changes in 
vivo, and demonstrate feasibility of an organoid-OMI technology for clinical translation.    
Aim 1: Characterize subpopulation analysis of OMI data to quantify heterogeneous 
cell populations.  Tumor heterogeneity contributes to therapy resistance; and this aim develops 
OMI analysis techniques to identify and quantify heterogeneity within OMI data.  Subpopulation 
analysis (SPA) techniques were developed to quantify heterogeneous cell populations within OMI 
data. OMI-SPA was characterized by simulation experiments and validated with cell co-culture 
experiments. Generic simulation experiments characterized the relationships between sample size, 
data standard deviation, and subpopulation mean separation distance required for OMI-SPA to 
identify subpopulations. 
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Aim 2: Determine the sensitivity of OMI to breast cancer subtypes and therapeutic 
response in vitro and validate OMI measures of response in human breast cancer xenografts 
in vivo. OMI endpoints, redox ratio, mean NADH lifetime, and mean FAD lifetime, were analyzed 
across a panel of breast cancer cells, including ER+, HER2+, and triple negative, and validated 
with assays of cellular metabolism. Responsive and resistant cells were treated with the clinically 
used HER2-inhibitor trastuzumab, to determine OMI sensitivity to therapeutic response.  
Additionally, OMI variables were analyzed to assess statistical correlation or independence with 
other OMI variables and biochemical assays of cellular metabolism.  In vivo OMI was also 
performed on xenograft models of HER2 overexpressing breast cancers responsive, resistant, and 
partially responsive to the HER2 inhibitor, trastuzumab.  In vivo OMI endpoints of response were 
compared to current clinical measures (FDG-PET). Tumor size and immunohistochemical (IHC) 
endpoints (proliferation, cell death) served as gold standards of drug response.  
Aim 3: Characterize OMI endpoints in excised tissues.  There are many challenges to 
in vivo OMI measurements.  However, freshly excised or frozen tissues are more accessible, can 
be obtained during routine medical procedures, and enable OMI technologies to be implemented 
remotely.  This aim compares OMI endpoints of tissue in vivo, excised tissue over 48hr, and flash-
frozen and thawed tissues, in order to determine if excised or frozen tissues can be used when in 
vivo experiments are not feasible. 
Aim 4:  Validate organoid-OMI measured tumor response with in vivo OMI in human 
breast cancer xenografts and compare organoid-OMI measured tumor response with 
measures of response in human breast cancers. Organoid culture of primary human tumor tissue 
is an attractive platform for testing and predicting drug response.  Organoids contain all the original 
cells and microenvironment of the original tumor and therefore, may respond to treatments in a 
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similar manner.  In this aim, organoids were generated from two xenograft models of breast cancer, 
one responsive and one resistant to trastuzumab.  The organoids were treated with a panel of anti-
cancer drugs and imaged over a 72hr time course.  Organoid response to the drugs was assessed 
from the OMI index, a combination variable of individual OMI endpoints. Organoid-OMI 
response was compared to in vivo drug response of the breast cancer xenografts, as measured by 
changes in tumor size, and to gold standard IHC.  Heterogeneity of drug response was assessed by 
subpopulation analysis of the OMI index. Additionally, feasibility for growing organoids from 
primary, human breast tumor biopsies was demonstrated.  Organoids were generated from six 
primary human tumors and were treated with clinically relevant anti-cancer drugs. OMI was 
performed on the organoids over a 72hr time course and OMI data was analyzed to identify 
heterogeneity in response.  OMI measured response was compared to measurements of cell death 
and proliferation within the organoids after 72hr of drug treatment.   
1.3 Dissertation Outline 
This dissertation has been organized in the following manner: 
Chapter 1 is the introduction and provides the motivation behind the research and outlines 
the specific aims that are addressed.  Chapter 1 also includes a brief summary of the chapters. 
Chapter 2 provides background information on breast cancer and breast cancer treatment 
strategies, cellular metabolism, and optical technologies.  In particular, fluorescence lifetime 
imaging is discussed.   
Chapter 3 reports and fully characterizes the subpopulation analysis technique developed 
for identifying heterogeneity in cell populations of OMI data.  This work presents specific and 
generalized simulation experiments to demonstrate the limits of the subpopulation analysis 
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technique.  Additionally, the technique is tested on experimental data of two co-culture cells lines.  
This work was published in 2015 in Biomedical Optics Express (12). 
Chapter 4 contains the cell line and in vivo OMI experiments which characterized the OMI 
technology and demonstrated different metabolic profiles in trastuzumab responsive and resistant 
cells upon treatment with trastuzumab.  First, this chapter provides the results of a cyanide 
experiment which validate the imaging of NADH and FAD, two co-enzymes of metabolism.  This 
chapter also reports the basal OMI endpoints of a panel of cell lines.  Finally, this chapter explores 
changes in OMI endpoints when responsive and resistant cells are exposed to the anti-HER2 
antibody, trastuzumab.  In vivo xenograft experiments of three different models confirm the cell 
line results.  Furthermore, FDG-PET was performed on a parallel cohort of mice to directly 
compare OMI measured drug response with a clinically used technology.  This work was published 
in 2013 in Cancer Research (13).  
Chapter 5 demonstrates the stability of OMI endpoints in freshly excised and frozen tissues.  
Performed on the hamster cheek pouch model, this work quantifies the timeline for obtaining OMI 
measurements in freshly excised tissues before significant changes in metabolism occur.  This 
work was published in 2012 in the Journal of Biomedical Optics (14). 
 Chapter 6 reports the OMI-organoid experiment results.  First, OMI-organoid drug 
response was tested in two xenograft models and the OMI-predicted drug response correlated with 
in vivo tumor growth.   Next, feasibility with organoid generation and OMI-measurements was 
shown for 6 different primary human breast cancer samples.  This work also demonstrates the 
utility of single-cell analysis and sub-population modeling techniques to identify heterogeneity in 
cellular metabolism following drug treatment.  This work was published in 2014 in Cancer 
Research (15). 
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 Chapter 7 provides a summary of the major results and objectives of this dissertation.  The 
impact of this research is also discussed and several future directions are recommended.  Finally, 
Chapter 7 also contains a discussion of this work’s contribution to the field and societal impact. 
 Appendix A contains supplementary tables and figures for Chapter 3.  
 Appendix B contains supplementary tables and figures for Chapter 4. 
 Appendix C reports a preliminary study in which the optical redox ratio was explored in 
ER and HER2 overexpressing breast cancer cell lines.  In this study, the NADH and FAD 
fluorescence was obtained on a confocal fluorescence microscope.  This work was published in 
2012 in Biomedical Optics Express (16).  
 Appendix D contains the image analysis protocol that was developed to automatically 
segment NADH and FAD autofluorescence images into individual nucleus, cytoplasm, and cell 
regions.  This enabled fast processing of OMI data sets and heterogeneity analysis of single-cell 
data.  This work was published in 2014 as an SPIE Proceedings paper (17).   
Appendix E explores the use of frozen tissues to generate organoids.  These experiments 
compare two different freezing protocols, flash freezing in liquid nitrogen and slow freezing in 
DMSO, for the preservation of bulk tissues for subsequent thawing, organoid generation, and OMI 
measures of drug response.  This work is currently in preparation for publication. 
 Appendix F reports changes in collagen content and organization due to trastuzumab 
treatment in two xenograft models, one resistant and one responsive to trastuzumab.  Collagen can 
be imaged with second harmonic generation imaging which provides high resolution images of 
collagen fibers which can be quantitatively assessed for collagen density and alignment.  This work 
was published in 2015 in Journal of Biomedical Optics (18). 
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CHAPTER 2 
Background 
2.1 Clinical Problem: Treatment Selection in Breast Cancer 
Introduction 
Each year, approximately 300,000 new cases of breast cancer are discovered and 
approximately 40,000 women die from breast cancer (1).  While primary breast cancer tumors are 
usually painless and have relatively few major complications, the tumors can metastasize and travel 
throughout the body, causing malignant tumors in essential organs which can result in death.  The 
probability of death from breast cancer varies widely across patients with differing tumor size, 
estrogen receptor status, and age of diagnosis (2).  Breast cancer treatment and prognosis are greatly 
correlated with tumor expression of certain receptors, such as the estrogen receptor (ER) and the 
human epidermal growth factor receptor 2 (HER2).   
Due to the wide range of genetic mutations and phenotypes present in cancers, a host of 
drugs are available and in development for targeted therapeutic action.  Yet, few biomarkers exist 
to direct drug selection.  Often, patients are prescribed a fixed drug regimen and tumor response 
(based on tumor size) is determined weeks or months after treatment begins. Clinical treatment 
decisions and pre-clinical drug development studies would greatly benefit from the development 
of robust biomarkers of tumor response. 
Risk Factors 
 Breast cancer can occur in both genders; however, it is more prevalent in women than men 
(3).   Genetic, hormonal, and dietary factors are thought to contribute to the likelihood of the 
development of breast cancer (4).  Additional risk factors include age, ethnicity, and environmental 
factors, such as exposure to radiation (1).   
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Breast cancer can be caused by genetic mutations.  Five to ten percent of all women with 
breast cancer have a mutation of the BRCA-1 and BRCA-2 genes (5).  Individuals with either but not 
both mutations do not have an increased incidence of  breast cancer (5).  The estimated lifetime risk 
of developing breast cancer for women with both mutations is estimated between 40-85% (5). 
   
 
Figure 2.1: Breast Cancer Incidence.  Incidence of American women with breast 
cancer across five ethnic groups: whites, Hispanics, African Americans, 
Asians/Pacific Islanders, and American Indians/Alaskan Natives (1). 
 
 Breast cancer incidence and mortality rates are linked with ethnicity (Fig. 2.1).  According to 
reports from the National Cancer Institute, white American women have the highest incidence of 
breast cancer.  However, African-American women have the highest mortality rates from breast 
cancer.  Incidence and mortality of breast cancer is lowest in Hispanics, Asians/Pacific Islanders, and 
American Indians/Alaskan Natives (1). 
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Diagnosis 
 The diagnostic process for breast cancer has evolved to include many procedures and imaging 
modalities.  The initial suspicious lump is generally discovered by the patient or doctor during a 
physical examination (3).  Symptoms of breast cancer include presence of a lump or thickening of the 
breast, change in the size or shape of the breast, changes in the skin of the breast, and fluid discharge 
(6).  Usually the lump is painless, but on retrospect, the patient may remember mild discomfort from 
the area (3).   
 Several imaging modalities are used to detect lumps in the breast that are too small to be found 
in a physical exam.  A mammogram is an x-ray image of the breast tissue which can show lumps and 
calcified tissues (6).  Due to increased rates of survival and treatment outcomes with early cancer 
detection, women over 40 are encouraged to annual mammogram screenings for breast cancer (1). 
An ultrasound can be used to determine whether the lump is solid or fluid filled (6).  MRI images are 
also used to distinguish normal breast tissue from benign lesions (6).    
Fine needle aspiration and core needle biopsy procedures extract cells of suspicious lumps for 
histological analysis.  In fine-needle aspiration, a needle is used to extract a small amount of liquid 
from the cyst or lump to determine the pathology of the suspicious lesion (3).  Fine-needle aspiration 
is performed on large tumors and fluid filled tumors.  A core needle biopsy is used to extract cells of 
lesions for histological analysis (3).  Open surgical biopsy can also be performed if the lump is too 
small for the needle biopsies or if the needle biopsies are inconclusive (3).  
 Histopathology of the biopsied tissue provides characterization of the tumor and guides 
therapy selection.  Pathologists inspect the cells for the presence of abnormal or cancerous cells.  The 
biopsied cells are also stained for expression of ER and HER2 to determine if the patient is eligible 
for targeted therapies.   
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Common Breast Cancers 
 A carcinoma is a malignant tumor derived from epithelial cells (3).  In breast tissue, epithelial 
cells line the ducts, acini, or lobules which are the locations where breast cancer can develop (3).  
When examined microscopically, cancer cells exhibit changes within the cell different from normal 
epithelial cells (3).   When viewed macroscopically, the changes within the cells cause alterations in 
the arrangement of cells in relation to each other leading to the tumor appearance (3).  Breast cancer 
can be divided into two main categories: in situ carcinoma (Fig. 2.2) and invasive carcinoma (Fig. 
2.3).  In situ carcinoma is where the proliferating, malignant cells are confined by the basement 
membrane surrounding the ducts.  Between 1 and 5% of breast cancer cases are independent in situ 
carcinoma (4). Invasive carcinomas are cases where the proliferating cells invade the breast stroma 
and tissue spaces (3).   
 
   
 
Figure 2.2: Carcinoma In Situ. In ductal carcinoma in 
situ, diseased tumor cells are confined by the duct (6). 
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Figure 2.3: Invasive Carcinoma.  Invasive 
carcinoma cells outgrow the duct and spread into the 
surrounding tissue (6). 
 
 
2.2 Role of Receptors in Breast Cancer 
Estrogen Receptor (ER) 
 
 The estrogen receptor (ER) has several functions in breast cancer tumors.  The ER can act as 
a transcription factor.  In this pathway, estrogen binds to the ER causing it to phosphorylate, which 
dissociates several attached proteins such as heat shock protein 90 (HSP-90), resulting in an ER with 
a different conformation in an active form (7).  The activated ER binds with other factors, co-
activators or co-repressors, in the nucleus to moderate gene transcription (7).  ER can also activate 
non-genomic pathways in the cytoplasm.  In one example, the activated ER activates the mitogen-
activated protein kinase pathway (MAPK) which increases cellular metabolism and promotes cell 
growth (7).  Hormonal therapies, such as tamoxifen, bind ER without activating it, reducing the 
oncogenic effects of ER signaling. 
Human Epidermal Growth Factor Receptor 2 (HER2) 
 HER2 is overexpressed in approximately 30% of primary breast cancer tumors and is 
associated with more aggressive tumors, increased recurrence, and poor patient outcomes (8).  HER2 
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is commonly expressed in breast tissue, including non-cancerous cells; thus, overexpression beyond 
the basal expression of normal tissue is clinically monitored.  Breast tumors are tested for HER2 
overexpression by fluorescence in situ hybridization which labels copies of the HER2 gene with 
fluorescence tags (9).  The HER2 pathway is thought to activate PI3K, a major driver of cellular 
metabolism (Fig. 2.4).  HER2 inhibitors prolong survival in responsive patients by impairing the 
oncogenic effects of HER2 signaling (10). 
 
Figure 2.4: HER2 and PI3K Pathway. HER2 pathway activation 
activates PI3K and AKT (11). 
 
 
2.3 Current Breast Cancer Treatments 
 Treatments for breast cancer include surgical intervention, chemotherapy, radiation, and 
targeted therapeutics.  Often, breast cancer treatment involves a multimodal approach, using several 
different therapies to combat different aspects of the disease.  Age, menopausal state, disease stage, 
histology, and receptor expression influence the selection of therapy to optimize treatment to each 
specific cancer.   
 Traditionally, mastectomy was the most common surgical intervention and treatment of breast 
cancers (12).  Mastectomy was preferred because other surgical interventions, such as lumpectomies, 
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had a high recurrence, 25-50% while only 1-2% of mastectomy patients had recurrence; however 
lumpectomy procedures have greatly improved (12).  Surgical management for malignant breast 
cancers is frequently paired with radiation therapy, chemotherapy, and targeted therapies.    During 
surgery, lymph nodes are removed and dissected to determine whether metastases from the breast 
cancer tumors have migrated to the lymph nodes and throughout the body.   
 The treatment of inoperable late-stage or inflammatory breast cancer is a similar multimodal 
approach.  A biopsy first provides histology of the breast cancer revealing ER status, progesterone 
receptor status, and HER2 status.  Radiation, hormonal, and chemotherapy treatments are attempted 
initially (13).  Upon favorable prognosis with the initial therapy, surgery may be performed (13).  
Stage IV, recurrent, and metastatic breast cancer is combated with a variety of surgical, radiation, and 
hormonal therapies.   
 In addition to surgical interventions, chemotherapy and radiation therapy are often utilized to 
combat breast cancer.  Radiation therapy uses high-energy electromagnetic radiation to kill cancer 
cells.  Radiation therapy is often used in conjunction with breast conserving surgeries, lumpectomy, 
because this combination has the same outcomes as mastectomy (14, 15).  Systemic chemotherapy 
may also be used to target local and metastatic breast cancer.  Chemotherapy is often used in 
combination with other agents, additional chemotherapy drugs, hormonal agents, or targeted drugs. 
Targeted Breast Cancer Therapies 
 
Recent breast cancer research has focused on therapeutic agents targeting specific 
pathways within the cancerous cell.  Breast cancers expressing ER are often treated with 
tamoxifen, an ER antagonist.  Breast tumors which overexpress HER2 display more aggressive 
cancer progression (8). Trastuzumab and lapatinib, two therapeutic agents that inhibit HER2, 
prolong survival in patients with HER2-overexpressing breast cancers.   
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Recent studies have proven that tamoxifen is an effective hormonal drug for the systemic 
treatment of breast cancer (16).  Tamoxifen prevents estrogen from binding to breast cancer cells, 
preventing the activation of ER.  An analysis of 80,273 women in 71 trials of tamoxifen found that 
after five years, the death rate by breast cancer was reduced by 31% (16).  In this trial, worse outcomes 
were associated with ER-negative receptor status and a longer duration of treatment (16).  Current 
recommendations are that tamoxifen treatment be terminated after five years due to the development 
of tamoxifen resistant tumors (17, 18).   Tamoxifen can be an advantageous anti-cancer agent for 
breast cancer cases of ER-positive tumors.  Currently several aromatase inhibitors are in clinical trials 
as possible alternatives to tamoxifen (13).   
Breast cancers that overexpress HER2 are treated with HER2 inhibitors such trastuzumab and 
lapatinib.  A high concentration of HER2 receptors expressed by breast cancer cells is associated with 
increased tumor progression and metastases (9).   Trastuzumab is a monoclonal antibody that binds 
HER2, while lapatinib is a small molecular inhibitor which binds both HER2 and the epridermal 
growth factor receptor.  Both trastuzumab and lapatinib prolong survival in patients with HER2 
overexpressing breast cancers (19-21).  Trastuzmab specifically binds to the extracellular domain of 
HER2 and prevents activation of the intracellular HER2 tyrosine kinase.  Furthermore, trastuzumab 
has additional mechanisms of action, including blockade of HER2 dimerization, increased HER2 
endocytosis and degradation, and induction of antibody-dependent cellular cytotoxicity (ADCC) (22, 
23). Trastuzumab induces cytostatic effects by arresting the cell cycle in the G1 phase and inhibits 
signaling involved in cell survival (24, 25).   Lapatinib is a small molecule inhibitor which binds 
HER2 and prevents the formation of activated HER2 dimers, preventing the activation of the HER2 
cascade and reducing the oncogenic effects of HER2 signaling (19).   
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Due to the importance of choosing the correct treatment for breast cancer patients, tumor 
biopsies are screened for hormone receptors.  Currently, malignancy, ER, and HER2 expression is 
determined by histology staining and fluorescence in situ hybridization (FISH) of the biopsy 
specimen.  Treatment plans are determined based on the stage and size of the tumor and presence 
or absence of ER and HER2. 
2.4 Tumor Heterogeneity and Resistance 
Another factor influencing treatment decisions and ultimately limiting the clinical outcome 
of breast cancers is resistance to chemotherapy and targeted therapies.  Only 57% of patients with 
ER-positive breast cancers respond to tamoxifen therapy (26).  Similarly, approximately one-third 
of breast tumors that overexpress HER2 do not respond to trastuzumab and lapatinib therapy (21), 
and about 40% of patients do not respond to paclitaxel, a chemotherapy (27).  Resistance to 
therapies can be innate or acquired. 
Drug resistance by tumors may arise from subpopulations of cancer cells within the tumor 
that are resistant to the given treatment (28, 29).  These subpopulations of cells are inherent to 
tumors due to the highly mutagenic nature of cancer (28).  In this model, individual cells with 
differing genotypes can arise within tumors and lead to sub-populations of cells that express 
different oncogenic transformations, possibly respond differently to therapies, and can repopulate 
the tumor (Fig. 2.5).  However, recent research has demonstrated varying behaviors among tumors 
with identical genes, suggesting that cancer cell behavior is influenced by more than just genetic 
mutations (30).  Novel therapeutics are in development to overcome clinical resistance to these 
therapeutic inhibitors (10).  Early identification of the tumors that will respond to targeted therapies 
versus those that are resistant, will expedite clinical decisions regarding course of treatment, and 
will improve the clinical outcomes of breast cancer patients.  
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Figure 2.5. Theories of tumor heterogeneity. (29) 
 
Alternative Treatment Options for Resistant Tumors 
If a tumor is resistant to traditional therapies, patient treatment can be tailored to improve 
clinical outcome. For example, the patient can receive more aggressive surgical intervention and 
experimental drugs and drug combinations. Many new drugs, including HER3, mTOR, and PI3K 
inhibitors, are in development to overcome therapy resistance (31-39).   
In HER2 overexpressing cancers, possible mechanisms to overcome trastuzumab 
resistance include inhibition of down-stream effectors of HER2 that may be activated, even in the 
absence of HER2 signaling.  For example, HER2 signaling activates PI3K/Akt/mTOR, which 
regulates cellular glucose metabolism (31). In a tumor with HER2-overexpression, mutations 
within the PI3K signaling pathway can allow continued PI3K activation even when HER2 is 
inhibited by trastuzumab or lapatinib (31, 33, 37). In this way, a heterogeneous tumor may contain 
subpopulations of tumor cells with varying levels of response to HER2 inhibition. Indeed, efforts 
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to overcome HER2 inhibitor resistance include combined therapy of HER2 inhibitors with PI3K 
inhibitors (31, 37).  Combined treatment to target HER2 and PI3K may increase therapy efficacy 
and decrease tumor recurrence.  Similarly, HER3 can dimerize with HER2 to produce similar 
signaling effects within cells; therefore, HER3 inhibitors are being explored for combined 
treatment with trastuzumab (31).   
2.5 Cellular Metabolism  
Introduction to Cellular Metabolism 
 Cellular metabolism encompasses the biochemical processes within a cell which generate 
energy.  Typically, these processes are broadly categorized into aerobic and anaerobic respiration.  
In mammalian cells, anaerobic respiration includes glycolysis, the breakdown of glucose into 
pyruvate, which occurs without oxygen in the cytoplasm.  Aerobic respiration includes oxidative 
phosphorylation, the citric acid cycle, and the electron transport chain.  These processes occur in 
the mitochondria and require oxygen.  Nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FAD) are coenzymes that serve as electron carriers during cellular 
metabolism processes (Fig. 2.6) (40). 
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Figure 2.6: Cellular respiration and the roles of NADH and FAD. 
Motivation for Using Cellular Metabolism as a Measure of Tumor Response to Therapy 
Cancer cells often exhibit abnormal cellular metabolism.  Unlike normal cells that rely on 
oxidative phosphorylation to generate ATP, or that use glycolysis under anaerobic conditions, 
cancer cells often generate ATP through aerobic glycolysis (41).  This observation is generally 
expressed as the Warburg effect.  Interestingly, oncogenic protein signaling in breast cancer cells 
often drives metabolism processes.  
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Figure 2.7: Role of HER2 in cellular metabolism. HER2 activation pathway and effect on 
cellular metabolism through PI3K in anti-HER2 drug sensitive and resistant cells. (42) 
 
Many up-regulated oncogenes, including ER and HER2, directly affect or activate down-
stream regulators of cellular metabolism pathways.  ER regulates gene expression of glucose 
transporter proteins and proteins involved in oxidative phosphorylation and the citric acid cycle 
such as isocitrate dehydrogenase which actively reduces NAD+ to NADH (43-46).  HER2 mediates 
metabolism through signaling of the PI3K/AKT/mTOR pathway which directs transcription of 
glycolytic enzymes (47, 48).  In mouse models of HER2 overexpressing breast cancer, trastuzumab 
and lapatinib inhibited PI3K activity and decreased glucose uptake (Fig. 2.7) (32, 34, 36, 42).  
Furthermore, drug resistant cancers often display abnormal utilization of cellular 
metabolism pathways. Resistance to therapeutic agents, including the HER2 inhibitors lapatinib 
and trastuzumab, activates hypoxia signaling in the presence of adequate oxygen, consistent with 
the activation of aerobic glycolysis. Furthermore, PI3K pathway activation, which is a major driver 
of aerobic glycolysis, is often elevated in trastuzumab- or lapatinib-resistant breast cancer cells 
(32, 37, 49, 50).  Possible mechanisms of trastuzumab resistance include metabolic activation by 
proteins outside of the PI3K/AKT/mTOR pathway (Fig. 2.7) and continued activation of 
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PI3K/AKT/mTOR despite HER2 inhibition (31, 32, 35, 49, 51). Therefore, cellular metabolism 
may be a powerful reporter of cellular malignancy and therapeutic efficacy due to the direct 
relationships between oncogene driven PI3K/AKT/mTOR activation and inhibition by anti-cancer 
drugs.  
Metabolism Imaging Modalities 
Current methods to monitor cellular metabolism and assess therapy response include 
immuno-histochemical (IHC) assessment of metabolic regulators, fluorodeoxyglucose positron 
emission tomography (FDG-PET), diffuse optical tomography (DOT), and metabolic flux 
analyses (37, 52-56). FDG-PET and IHC endpoints have been evaluated clinically as biomarkers 
of response (52, 55, 57-61).  Evidence of metabolism-based contrast for tumor response to targeted 
inhibitors was demonstrated with the use of FDG-PET, which is capable of detecting areas of high 
glucose uptake, such as is seen in many solid tumors (62). A preliminary study of lapatinib-treated 
breast cancers showed changes in cellular metabolism, as measured by FDG-PET, after 1 month 
of lapatinib treatment (60). Yet, these currently available technologies provide only low resolution 
images and cannot resolve sub-populations of cells that may cause therapy relapse.  FDG-PET and 
other technologies that monitor therapy response are limited to the evaluation of the single regimen 
received by the patient, and cannot predict a more efficacious treatment regimen if non-response 
is detected.  Given the high cost and limitations of these procedures, it is unlikely that these will 
be adopted as standard of care, underscoring the need for more efficient, accurate, and cost-
effective methods of identifying receptor expression and therapeutic response.   
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2.6 Fluorescence Lifetime Imaging 
Fluorescence  
 Particular molecules, called fluorophores, are capable of emitting a photon of longer 
wavelength when excited by a photon of an optimal energy.  This phenomenon is illustrated in the 
Joblonski diagram (Fig. 2.8).  Several biomolecules are natural fluorophores, including collagen, 
tryptophan, NADH, FAD, and elastin.  These fluorophores are often referred to as 'auto-
fluorescent' because the addition of fluorescent dyes or antibodies is not required for imaging 
contrast. 
 
Figure 2.8: Jablonski Diagram of Fluorescence.  When a fluorophore is 
excited by a photon (hυexcitation), the fluorophore enters an excited state.  
Sometime later, the fluorophore returns to ground state and emits a photon 
(hυemission) (63). 
 
Multiphoton Fluorescence 
 Multi-photon fluorescence microscopy uses the additive effect of two photons with one-
half the energy necessary to excite the fluorophore (Fig. 2.9).  The localized focus point of the 
excitation beam and negligent probability of two-photon excitation occurring outside the focal 
point of the beam, allows single pixel illumination and wide-field emission collection to increase 
depth-resolution and signal-to-noise ratio of weak fluorophores (Fig. 2.9) (64). In addition, multi-
photon excitation wavelengths are double that of single photon fluorescence. This shifts the 
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excitation of NADH and FAD into the near infrared (NIR) optical window where light absorption 
by tissue constituents is minimized (Fig. 2.10). 
 
Figure 2.9:  Multiphoton fluorescence. Focal point of single photon (A) and two photon (B) 
fluorescence (65).  
 
 
Figure 2.10: Relative absorbance of tissue constituents. Deeper tissue 
penetration is achieved by using excitation light in the NIR optical 
window (66). 
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Fluorescence Lifetime Imaging 
Fluorescence lifetime imaging (FLIM) measures the average time a fluorophore is excited, 
or the time between an excitation photon absorption and emission photon.  Fluorescence lifetime 
values report differences in the conformation and binding of the fluorophore as well as 
microenvironment changes, including pH, temperature, and proximity to quenchers such as free 
oxygen (64).  A fluorescence decay curve plots the intensity of fluorescence of a region or pixel 
over time following excitation and is a cumulative recording of multiple events (Fig. 2.11). 
Fluorescence lifetime decays can be modeled as an exponential decay, or as a multi-exponential 
decay in the case of multiple lifetimes present in the sample (Fig. 2.11). Fluorescence lifetimes 
can be measured by time correlated single photon counting (TCSPC).  TCSPC electronics time 
individual fluorescence events and generate fluorescence decay curves with repeated observations. 
TCSPC is the optimal fluorescence lifetime imaging technique for high accuracy of lifetime 
measurements and the low light levels observed with endogenous fluorophores (64). 
 
Figure 2.11:  Fluorescence lifetime decay curve.  After deconvolving the 
system response, decay data is modeled as an exponential decay to extract 
lifetime parameters, 𝐼(𝑡) = 𝛼1𝑒𝑥𝑝
−𝑡/𝜏1 + 𝛼2𝑒𝑥𝑝
−𝑡/𝜏2 + 𝐶, where I(t) is the 
fluorescence intensity at time t after the excitation pulse, 1 and 2 are the 
weighted contributions of the short and long lifetime components (1+2) 
= 1 and 1 and 2 are the short and long lifetime components, respectively, 
and C accounts for background light. 
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The fluorescence lifetimes of NADH and FAD are affected by the fluorophore 
microenvironment, with influencing factors including local oxygen levels, temperature, pH, 
fluorophore confirmation, and protein binding (64, 67). Fluorescence lifetime values remain fairly 
unexplored as reporters of cellular metabolism; however, exploratory studies have observed 
differences in NADH lifetime values in malignant and pre-malignant tissues (68, 69). Typically, 
in tissues, NADH and FAD molecules exist in two configurations, either unbound (free in solution) 
or protein-bound (67, 70).  The fluorescence lifetime of protein-bound FAD and free NADH is 
short due to dynamic quenching of the adenine moiety (67, 70, 71).  Therefore, the free FAD and 
protein-bound NADH have longer lifetimes.   
Optical Imaging of Metabolism 
Dynamic profiles of cellular metabolism can be obtained with optical metabolic imaging 
(OMI). OMI probes the endogenous fluorescence properties of two coenzymes involved in 
metabolism, reduced nicotinamide adenine dinucleotide (NAD(P)H) and flavin adenine 
dinucleotide (FAD).  Optical imaging is an ideal modality for probing chemical specificity and 
molecular contrast within tissues, including auto-fluorescence imaging of NADH and FAD, which 
allows quantitative measurements of cellular metabolism.  In oxidative phosphorylation, NADH 
is oxidized to NAD+ and FAD is reduced to FADH2 (Fig. 2.12).  In glycolysis, NAD+ is reduced 
to NADH (Fig. 2.12).  Because fluorescence intensity is proportional to fluorophore concentration, 
the optical redox ratio (NADH fluorescence intensity divided by FAD fluorescence intensity) 
represents relative amounts of glycolysis and oxidative phosphorylation within a cell (72). 
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Figure 2.12: Optical redox ratio. The optical redox ratio is 
the relative intensity of cellular NADH fluorescence to FAD 
fluorescence. 
 
The optical redox ratio is a proven method of probing cellular metabolism and has been 
used to differentiate cancerous from non-cancerous tissues in a variety of models including oral  
and breast cancer (69, 72-77).  Ostrander et al. showed the optical redox ratio is sensitive to ER 
expression in breast cancer cell cultures and that treatment with tamoxifen decreased the redox 
ratio of those cells that were responsive to tamoxifen, but not those that lacked the estrogen 
receptor (77).   The optical redox ratio is used to examine changes in cellular metabolism due to 
receptor expression and cellular response to targeted therapies. 
The fluorescence lifetimes report changes in the microenvironment of NAD(P)H and FAD 
and are especially sensitive to the binding state of the fluorophore, as well as local temperature, 
pH, and proximity to quenchers such as molecular oxygen (64).  Both NAD(P)H and FAD 
fluorescence lifetimes can be either short or long, depending on the binding state of NAD(P)H and 
FAD (free or bound to an enzyme complex) (67, 70). Previous studies have shown that OMI 
endpoints are sensitive to metabolism differences between cancer subtypes (78-80).  Additionally, 
the OMI endpoints provide dynamic readouts of cellular metabolism and detect pre-malignant 
transformations within tissues (68, 69), classify subtypes of breast cancer cells (78, 79), and detect 
28 
 
response to anti-cancer drugs (80).  Furthermore, fluorescence microscopy is uniquely suited to 
study tumor heterogeneity in cells and tissues due to the high resolution capabilities of microscopy 
and molecular specificity attained by probing endogenous fluorophores.  For this reason, OMI 
endpoints are attractive biomarkers of therapeutic response because they directly report cellular 
function, rather than a static measure of the genetic code. 
FLIM Instrumentation 
 
Figure 2.13:  Multiphoton fluorescence microscope used to obtain NADH and FAD 
fluorescence lifetime images. 
 
 A custom built, commercial multi-photon fluorescence microscope (Bruker) is used to 
acquire NADH and FAD autofluorescence images (Fig. 2.13).  In this experimental set up, a 
titanium: sapphire laser (Coherent Inc.) provides the excitation light and is tuned to 750 nm for 
excitation of NADH and 890 nm for FAD excitation.  A 40X water-immersion objective (1.15 
NA) or a 40X oil-immersion objective (1.3 NA) couples the excitation and emission light through 
an inverted microscope (TiE, Nikon).  A GaAsP PMT (H7422P-40, Hamamatsu) detects emitted 
photons.  A pre-amplifier and TCSPC electronics (SPC-150 card) enable fluorescence lifetime 
imaging. 
Selection of Imaging Parameters 
 Imaging parameters were optimized for excitation of NADH and FAD.  Excitation 
wavelengths and emission filters were chosen to ensure adequate isolation of NADH and FAD 
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fluorescence.  The peak excitation wavelength for NADH is near 350 nm and emission spans 400-
500 nm (Fig. 7) (81).  FAD excitation peak is near 450 nm.  FAD emission spans 500-600 nm (Fig. 
2.14) (81).  For multiphoton excitation, NADH is excited at 750 nm and FAD is excited at 890 
nm.  Emission between 400-480 nm is collected for NADH, with the assumption that FAD 
excitation at 750 nm and emission at 400-480 nm is negligible.  For FAD, 500-600 nm emission 
light is collected.  Isolation of NADH and FAD fluorescence can be verified by a cyanide 
experiment.  Average laser power, pixel dwell time, and lifetime imaging time are optimized to 
ensure adequate signal for lifetime decays without damage or photobleaching of the sample.  The 
average laser power is 7.5-7.8 mW for NADH and 8.4-8.6 mW for FAD. A pixel dwell time of 4.8 
s is used.   Images of 256x256 pixels are acquired using an integration time of 60 seconds.  For 
consistent redox ratio measurements, system parameters, including laser power, PMT voltage, and 
integration time are maintained across all imaging sessions. 
 
 
 
Figure 2.14.  NADH and FAD Fluorescence Emission Spectra.  Fluorescence 
emission spectra for NADH (triangle) and FAD (circle, square) (81). 
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2.7 Organoid Culture 
 
Primary tumors can be cultured ex vivo as organoids, which contain the malignant tumor 
cells and the supporting cells from the tumor environment, such as fibroblasts, leukocytes, 
endothelial cells, and hematopoietic cells (82). Interactions between cancer cells and stromal cells 
have been shown to mediate therapeutic resistance in tumors (83). Therefore, organoid cultures 
provide an attractive platform to test cancer cell response to drugs in a relevant, "body-like" 
environment. Furthermore, multiple organoids can be generated from one biopsy, enabling high-
throughput tests of multiple drug combinations with a small amount of tissue to identify the most 
effective treatment for an individual patient. 
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3.1 Abstract 
 The genetic and phenotypic heterogeneity of cancers can contribute to tumor 
aggressiveness, invasion, and resistance to therapy.  Fluorescence imaging occupies a unique niche 
to investigate tumor heterogeneity due to its high resolution and molecular specificity.  Here, 
heterogeneous populations are identified and quantified by combined optical metabolic imaging 
and subpopulation analysis (OMI-SPA).  OMI probes the fluorescence intensities and lifetimes of 
metabolic enzymes in cells to provide images of cellular metabolism, and SPA models cell 
populations as mixed Gaussian distributions to identify cell subpopulations.  In this study, OMI-
SPA is characterized by simulation experiments and validated with cell experiments.  To generate 
heterogeneous populations, two breast cancer cell lines, SKBr3 and MDA-MB-231, were co-
cultured at varying proportions.  OMI-SPA correctly identifies two populations with minimal mean 
and proportion error using the optical redox ratio (fluorescence intensity of NAD(P)H divided by 
the intensity of FAD), mean NAD(P)H fluorescence lifetime, and OMI index.  Simulation 
experiments characterized the relationships between sample size, data standard deviation, and 
subpopulation mean separation distance required for OMI-SPA to identify subpopulations. 
3.2 Introduction 
Solid tumors are highly heterogeneous, both across patients and within individual tumors.  
Tumor heterogeneity may contribute to tumor aggression, invasion, metastases, and therapy 
resistance (1-3).  Studies of tumor heterogeneity are challenging because traditional cell and tissue 
analyses require pooling of proteins, RNA, or DNA from hundreds to thousands of cells, which 
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provides information on the protein and genetic expression of the majority of cells but may mask 
unique expression profiles and phenotypes of heterogeneous populations.  Therefore, a technology 
capable of resolving cancer cell behaviors at single cell resolution is imperative for studies of 
tumor heterogeneity.   
Breast cancers are often classified into three subtypes based on the expression or lack of 
expression of oncogenic proteins within the malignant cells.  In particular, estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), are used to 
classify breast cancers and inform clinical therapy selection. Breast cancer clinical subtypes 
include: triple negative (not expressing any of the three receptors), ER positive (expressing ER but 
lacking HER2 overexpression), and HER2 overexpressing (overexpressing HER2 receptors, ER 
and PR may be expressed or not).   Primary tumors are heterogeneous, containing subpopulations 
of cells with different genetic profiles and protein expression (1, 4, 5).  Therapy selection is often 
based on the expression or lack of expression of ER and HER2 in a small sampling of cells, a 
biopsy.   However, due to heterogeneity across large tumors and within the biopsy itself, 
populations of cells with different receptor expression and/or adaptations that make them resistant 
to therapy, may escape clinical detection (1). This suggests that different portions of a tumor may 
respond differently to treatment, and while therapies are selected to target the majority of cells, 
there may be subpopulations of malignant cells not adequately targeted.  Subpopulations of cells 
with stem cell like behaviors may contribute to drug resistance and recurrent tumor growth (6).  
Cancer stem cells comprise between 3 and 35% of the number of cells within a solid breast tumor 
(6). 
Fluorescence microscopy is uniquely suited to study tumor heterogeneity in cells and 
tissues due to the high resolution capabilities of microscopy and molecular specificity attained by 
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probing fluorophores.  Dynamic profiles of cellular metabolism can be obtained with optical 
metabolic imaging (OMI). OMI probes the endogenous fluorescence properties of two coenzymes 
involved in metabolism, reduced nicotinamide adenine dinucleotide (NAD(P)H) and flavin 
adenine dinucleotide (FAD). NAD(P)H and FAD are used in multiple metabolism processes 
including glycolysis and oxidative phosphorylation. The endpoints of OMI include the redox ratio, 
NAD(P)H fluorescence lifetime, FAD fluorescence lifetime, and a combination variable, the OMI 
index. The redox ratio is the intensity of NAD(P)H fluorescence relative to the intensity of FAD 
fluorescence and provides relative information on the global metabolism of the cell (7, 8).  The 
redox ratio is sensitive to shifts in metabolic pathways (7, 9).  The fluorescence lifetimes report 
changes in the microenvironment of NAD(P)H and FAD and are especially sensitive to the binding 
state of the fluorophore, as well as local temperature, pH, and proximity to quenchers such as 
molecular oxygen (10).  Both NAD(P)H and FAD fluorescence lifetimes can be either short or 
long, depending on the binding state of NAD(P)H and FAD (free or bound to an enzyme complex) 
(11, 12). Previous studies have shown that OMI endpoints are sensitive to metabolism differences 
between cancer subtypes (9, 13, 14).  Additionally, the OMI endpoints provide dynamic readouts 
of cellular metabolism and detect pre-malignant transformations within tissues (15, 16), classify 
subtypes of breast cancer cells (9, 13), and detect response to anti-cancer drugs (14). 
This study describes and validates OMI subpopulation analysis (OMI-SPA) for 
identification and quantification of cellular heterogeneity.  OMI can be performed at high 
resolution to allow reporting of OMI endpoints at the single-cell level.  Heterogeneity of the cell 
population can then be assessed by subpopulation analysis (SPA).  SPA uses mixed distribution 
Gaussian models with multiple components to fit the population density representation of the data.  
In this study, we used both computational simulation and co-cultured experiments to validate OMI-
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SPA for identification and quantification of cellular subpopulation heterogeneity. Simulation 
experiments demonstrate the population characteristics required for robust SPA identification of 
two subpopulations.  These experiments were validated by OMI-SPA of heterogeneous samples 
created by co-culturing two different breast cancer cell lines, a triple negative breast cancer (MDA-
MB-231) and a HER2+ cell line (SKBr3) at varying proportions.  These two cell lines were chosen 
to represent cell populations responsive (SKBr3) and resistant (MDA-MB-231) to the anti-HER2 
antibody, trastuzumab.  The OMI endpoints and morphology of these two cells are sufficiently 
different to allow computational separation and heterogeneity analysis.   
3.3 Methods 
3.3.1 SKBr3 and MDA-MB-231 Specific Simulations 
The average and standard deviation for the experimentally measured redox ratio, NAD(P)H 
mean lifetime, and FAD mean lifetime for the SKBr3 cells and MDA-MB-231 cells cultured 
independently were determined and used to generate model data sets. A random number generator 
(Matlab) was used to generate a data set of repeated observations within the distributions of the 
OMI endpoints for a population of N cells, containing a percent SKBr3 cells and b percent MDA-
MB-231 cells. N, a, and b were varied to investigate the ability of OMI-SPA to identify two 
populations under a range of conditions.  N ranged from 25 to 1000 cells and a varied from 0 to 1 
(b = 1-a, and varied from 1 to 0).  These simulate data sets were then evaluated with subpopulation 
analysis (Methods 2.2). 
3.3.2 Subpopulation Analysis (SPA) 
Each cell population is modeled as a Gaussian mixture distribution model (9, 14, 17),  
𝑓(𝑦; Φ𝑔) =  ∑ 𝜋𝑖𝜙(𝑦; 𝜇𝑖, 𝑉𝑖)
𝑔
𝑖=1 ,  
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where g is the number of components, 𝜙(𝑦; 𝜇𝑖, 𝑉𝑖) represents a normal probability density function 
with mean i and variance Vi, and i is the mixing proportion.  g represents the unknown 
parameters, (i, i, Vi): i =1…g in a g-component model. The mixture model is fitted by maximum 
likelihood using the expectation maximization algorithm to determine the optimum parameters, 
(, , V), (Matlab).  In the simulation and co-culture experiments, data is modeled three times as 
Gaussian mixture distribution models with 1-3 components (g = 1, 2, or 3).  Fit parameters for 
each model including the Akaiki information criteria (AIC), population means, population 
standard deviations, and proportions, were recorded.  The AIC information criteria is a measure of 
model goodness of fit and is minimized in the optimal model (18).  The most representative model 
of the data was selected as the model with the lowest AIC. 
3.3.3 Cell culture 
MDA-MB-231 and SKBr3 cells were grown separately in DMEM with 10% fetal bovine 
serum and 1% penicillin: streptomycin. Cells were plated at a density of 106 cells per 35-mm glass 
bottom petri dish (MatTek Corp.), 48 hours before imaging, in the following proportions based on 
cell count (Table 3.1): 100% (106) MDA-MB-231 cells; 70% (7 x 105) MDA-MB-231 cells and 
30% (3 x 105)  SKBr3 cells; 50% (5 x 105)  MDA-MB-231 cells and 50% (5 x 105) SKBr3 cells; 
30% (3 x 105) MDA-MB-231 cells and 70% (7 x 105) SKBr3 cells; and 100% (106) SKBr3 cells.  
Two 35-mm glass bottom petri dishes were plated per group. 
3.3.4 Fluorescence lifetime instrumentation  
Fluorescence lifetime imaging was performed on a custom built multi-photon microscope 
(Bruker), which has previously been described (9, 14, 19).  Excitation and emission light are 
coupled through a 40X oil immersion (1.3 NA) objective of an inverted microscope (Nikon, TiE). 
For NAD(P)H excitation, a titanium:sapphire laser (Coherent Inc.) was tuned to 750 nm (average 
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power 7.5-7.9 mW). For FAD excitation, the laser was tuned to 890 nm (average power 8.4-6 
mW).  Bandpass filters, with a 440-480 nm passband for NAD(P)H and a 500-600 nm passband 
for FAD, isolated emission light. A pixel dwell time of 4.8 s was used to acquire 256x256 pixel 
images.  Each fluorescence lifetime image was collected using time correlated single photon 
counting electronics (SPC-150, Becker and Hickl) and a GaAsP PMT (H7422P-40, Hamamatsu).  
Photon count rates were maintained above 5x105 for the entire 60 second image acquisition time, 
ensuring no photobleaching occurred and adequate signal for fluorescence lifetime decay fits. 
3.3.5 Cell imaging 
Cells were imaged directly through the bottom of 35mm glass-bottom petri dishes (MatTek 
Corp). For each dish, six representative fields of view were imaged, for a total number of ~200 
cells per group. First, an NAD(P)H lifetime image was acquired, and then an FAD lifetime image 
was acquired from the same field of view.  Sequential fields of view were separated by at least 1 
field of view, 270 m. 
3.3.6 Generation of redox ratio images 
A fluorescence intensity image was generated by integrating the fluorescence lifetime 
decay over time for each pixel in the lifetime image.  The total number of NAD(P)H photons per 
pixel was then divided by the total number of FAD photons per pixel and used to create a redox 
ratio image for each field of view (Matlab, Mathworks). NAD(P)H and FAD fluorescence specific 
to cellular metabolism is localized in the cytoplasm and mitochondria.  Therefore, the redox ratio 
image was thresholded to remove background and nuclear fluorescence, and the average redox 
ratio for each remaining cell cytoplasm was computed (ImageJ).  Cells were manually segmented 
in ImageJ. 
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3.3.7 Generation of NAD(P)H and FAD lifetime images 
For each pixel, the photon counts for the 9 surrounding pixels were binned (SPCImage). 
Fluorescence lifetime components for each pixel were computed by de-convolving a measured 
system response curve from urea crystals and fitting the fluorescent decay to a two component 
model, 𝐼(𝑡) =  𝛼1 exp (−
𝑡
𝜏1
) + 𝛼2 exp (−
𝑡
𝜏2
) + 𝐶. In this model, I(t) is the fluorescence intensity 
at time t after the laser excitation pulse, 1 and 2 are the fractional contributions of the free and 
bound molecules (i.e. 1 + 2 = 1), 1 and 1 are the fluorescence lifetimes of the short and long 
lifetime components, and C is a constant that accounts for background light. Matrices of the 
lifetime components were exported as ascii files for further processing in ImageJ. The mean 
lifetime, m = 11 +22, was computed for each pixel to create a mean lifetime image for each 
field of view. The NAD(P)H m and FAD m for each cell cytoplasm was computed and recorded.  
The OMI index (14) is a linear combination of mean centered redox ratio, NAD(P)H m, and FAD 
m data and can be computed per cell as follows: 𝑂𝑀𝐼 𝐼𝑛𝑑𝑒𝑥 =  
𝑅𝑅𝑖
〈𝑅𝑅〉
+
𝑁𝐴𝐷(𝑃)𝐻 𝜏𝑚𝑖
〈𝑁𝐴𝐷(𝑃)𝐻 𝜏𝑚〉
−
𝐹𝐴𝐷 𝜏𝑚𝑖
〈𝐹𝐴𝐷 𝜏𝑚〉
. 
3.3.8 OMI-SPA Behavior Simulations 
Simulation experiments were performed to model the behavior of OMI-SPA for 
generalized data.  In the first simulation, populations of cells were generated with a normalized 
mean of 1 and equal proportions of the two populations.  The standard deviation and distance 
between the means was varied from 0-1 and 0-2, respectively.  In the last simulations, the mean 
distance was varied from 0-2, the population proportions varied from 0-1, and the standard 
deviation of the populations was 0.05, 0.1, 0.25, or 0.5.  These normalized standard deviation 
values span the range typically observed in OMI data (9, 14).  Simulated cell populations were 
generated for each mean distance, population proportion, and standard deviation at increasing 
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sample sizes (up to 10,000) to determine the minimum sample size necessary to resolve two 
subpopulations (AIC2 < AIC1 -20). 
 
3.4 Results 
3.4.1 MDA-MB-231 and SKBr3 Simulations 
First, SPA was performed on simulated cell populations using experimentally determined 
mean and standard deviation values of the redox ratio of SKBr3 and MDA-MB-231 cells, 1.92 +/- 
0.39 and 1.06 +/- 0.22, respectively.  The AIC represents a model goodness of fit and is minimized 
in the optimal model (18).  The AIC includes penalties for an increased number of model 
components, to account for increased fitness of models with increased components (18).  The AIC 
for two components is less than the AIC for the single component model (AIC1-AIC2 > 0) at large 
sample sizes and SKBr3 proportions less than 0.8 (Fig. 3.1a).  The error of the SKBr3 redox ratio 
mean is greatest (>10%) at high and low proportions and low sample sizes (Fig. 3.1b).  SKBr3 
redox ratio mean error is minimized (<5%) at high sample sizes and proportions near 50% (Fig. 
3.1b).  Likewise, MDA-MB-231 mean error is maximal (>10%) at small sample sizes and low 
proportions, and minimized (<5%) with high sample sizes and proportions around 50% (Fig. 3.1c).  
The large errors of MDA-MB-231 mean values at SKBr3 population proportions greater than 0.8, 
correspond to data points where the two-component model fit the data less well than the single 
component model.  The population proportion error, or the error of how many cells are attributed 
to each cell subpopulation, is minimal (<5%) at high sample sizes and at SBRr3 proportions less 
than 80% (Fig. 3.1d). 
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Figure 3.1.  Behavior of OMI-SPA to model simulated data using the redox ratio mean and 
standard deviation of SKBr3 and MDA-MB-231 cells.  (a) Difference in the AIC values of 1 
and 2 component Gaussian models of the simulated cell populations as a function of varying 
sample sizes and varying proportions (0% to 100%) of SKBr3 cells.   AIC1-AIC2 > 0 indicates two 
component model is a better fit than the one-component model.  (b) Error of the mean redox ratio 
computed for the SKBr3 subpopulation, and (c) MDA-MB-231 population.  (d) Error of the 
estimated proportion of the SKBr3 subpopulation. 
 
Similar simulations demonstrate the ability of OMI-SPA to identify SKBr3 and MDA-MB-
231 subpopulations using NAD(P)H m values (Fig. 3.2).  The SKBr3 cells have a mean NAD(P)H 
m of 1.31 +/- 0.13 ns and the MDA-MB-231 cells have a mean NAD(P)H m of 0.85 +/- 0.11 ns, 
determined from experiments.  In the simulation, OMI-SPA identifies two populations in all 
simulated data sets with a sample size greater than 75 (Fig. 3.2a) and the error of the SKBr3 and 
MDA-MB-231 subpopulation means identified by the models is within 1% at sample sizes greater 
than 100 and proportions between 20% and 80% (Fig. 3.2b-c).  Likewise, the proportion error is 
minimized (<5%) at sample sizes > 200 and SKBr3 proportions between 20 and 80%. 
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Figure 3.2.  Behavior of OMI-SPA to model data simulated from the mean and standard 
deviations of NAD(P)H m of SKBr3 and MDA-MB-231 cells.  (a) Difference in the AIC values 
of 1 and 2 component Gaussian models of the simulated cell populations as a function of varying 
sample sizes and varying proportion of SKBr3 cells.  (b) Error of the mean NAD(P)H m 
computed for the SKBr3 subpopulation, and (c)  MDA-MB-231 population.  (d) Error of the 
estimated proportion of the SKBr3 subpopulation. 
 
Finally, the simulations were repeated using the mean and standard deviations of the 
SKBr3 and MDA-MB-231 mean FAD lifetimes, which were experimentally measured as 1.09 +/- 
0.10 ns and 1.12 +/- 0.13 ns, respectively.  For most of the simulated cell populations, the two 
component model does not have an AIC value less than the single component fit (Fig. 3.3a).  The 
error of the FAD lifetime values for the modeled SKBr3 and MDA-MB-231 subpopulations was 
within 10% of the true FAD lifetime values except at sample sizes < 100 (Fig. 3.3b-c); however, 
the error of the proportion of cells assigned to each subpopulation was greater than 10% at almost 
all sample sizes and proportions (Fig. 3.3d). 
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Figure 3.3.  Behavior of OMI-SPA to model data simulated from the mean and standard 
deviations of the FAD m of SKBr3 and MDA-MB-231 cells.  (a) Difference in the AIC values 
of 1 and 2 component Gaussian models to the simulated cell populations as a function of varying 
sample sizes (N) and varying proportion of SKBr3 cells.  (b) Error of the mean FAD m computed 
for the SKBr3 subpopulation and (c) MDA-MB-231 population.  (d) Error of the estimated 
proportion of the SKBr3 subpopulation. 
 
A.4.2 MDA-MB-231 and SKBr3 co-culture experiments 
High-resolution images (Fig. 3.4) demonstrate the variability of redox ratios, NAD(P)H 
mean lifetimes, and FAD mean lifetimes between the two cell lines. MDA-MB-231 cells have a 
lower redox ratio, a shorter mean NAD(P)H lifetime, and a longer mean FAD lifetime, than SKBr3 
cells.  The images from the co-culture experiments demonstrate heterogeneity in cellular 
morphology and fluorescence imaging endpoints (Fig. 3.4).  The images from the co-culture 
experiments were examined manually and each cell designated as SKBr3 or MDA-MB-231 based 
on morphology.  Any cells that could not be identified were excluded from the analysis.  While 
the cells were plated at the following proportions, 30/70%, 50/50%, and 70/30%, the manual 
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analysis verified the heterogeneity of the co-cultured experiments and reports the actual 
proportions of the imaged cells for each co-culture group (Table 3.1). 
 
Figure 3.4. Representative OMI images of co-cultured cells. Representative 
images of the redox ratio (NAD(P)H/FAD), NAD(P)H mean lifetime, and FAD 
mean lifetime of MDA-MB-231 cells, SKBr3 cells, and mixed populations. 
 
Table 3.1: Experimental groups for the SKBr3 and MDA-MB-231 co-culture experiments.  
Experimental 
Group 
Portion of MDA-MB-
231 Cells  
Portion of SKBr3 
Cells 
 Plated Observed Plated Observed 
Group 1 0 0 1 1 
Group 2 0.3 0.37 0.7 0.63 
Group 3 0.5 0.60 0.5 0.40 
Group 4 0.7 0.82 0.3 0.18 
Group 5 1 1 0 0 
 
OMI-SPA of the co-culture experiment reveals that the single cell data sets are modeled 
best by a one component Gaussian distribution model and data from the co-culture groups are best 
modeled by two component Gaussian distribution models.  OMI-SPA of the redox ratio correctly 
identifies two populations in all three co-culture experiments (Fig. 3.5).  The mean redox ratio 
values of the SKBr3 modeled populations are within 6% of the true mean redox ratio (defined as 
the mean redox ratio of manually classified SKBr3 cells) (Table 3.2).  Likewise, the mean error of 
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the MDA-MB-231 cells ranges is 5% or less for all co-culture experiments (Table 3.2).  The error 
of the model-estimated proportion of each subpopulation of cells is 5% or less for all three co-
culture groups (Table 3.2).  The error of the standard deviations for the identified SKBr3 
populations ranges from 5% for the 100% SKBr3 culture to 25% for the 30% SKBr3 culture, while 
the standard deviation errors for the MDA-MB-231 model redox ratios is 10% or less for all 
experiments (Table 3.2). 
The mean redox ratio for each population of cells, SKBr3 and MDA-MB-231, was 
compared across all experimental groups to evaluate the stability of the redox ratio when cells are 
grown in different environments.  The MDA-MB-231 cells grown independently of the SKBr3 
cells had a mean redox ratio of 1 and a standard deviation of 0.23.  The mean MDA-MB-231 redox 
ratio was not significantly different for any of the co-culture experiments: 0.97+/- 0.22 for 70% 
MDA-MB-231 cells, 0.99+/-0.2 for 50%, and 0.82 +/- 0.25 for 30%.  Likewise, the redox ratio for 
the SKBr3 cells was similar when the cells were cultured without and with the MDA-MB-231 
cells.  The only statistically significant (p<0.05) difference in redox ratio was observed for the 
SKBr3 cells grown in the 30% SKBr3/70% MDA-MB-231 culture versus the 100% SkBr3 culture, 
1.2+/-0.5 vs. 1.8 +/- 0.39, respectively.  These results suggest that the redox ratio remains relatively 
stable irrespective of whether cells are grown independently or in co-culture. 
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Table 3.2: Mean, proportion (P), and standard deviation and % errors computed from 
the optimal fitting Gaussian distribution model of the co-culture experimental data.   
Proportion SKBr3/ 
MDA-MB-231 
Population 1 (SKBr3) Population 2 (MDA-MB-231) 
Mean 
(%Error*) 
P (%Error) 
Std 
(%Error) 
Mean  
(%Error) 
P (%Error) 
Std  
(%Error) 
Redox 
Ratio 
100%/0% 1.91 (6) 1 (0) 0.39 (5) - - - 
70%/30% 2.11 (3) 0.68 (4) 0.55 (18) 0.82 (0.5) 0.32 (5) 0.23 (6) 
50%/50% 1.88 (2) 0.44 (4) 0.60 (16) 1.02 (3) 0.56 (4) 0.18 (10) 
30%/70% 2.12 (5) 0.23 (5) 0.73 (25) 1.02 (5) 0.77 (5) 0.21 (1) 
0%/100% - - - 1.06 (6) 1 (0) 0.23 (6) 
NAD(P)H 

m 
(ns) 
100%/0% 1.31 (0.1) 1 (0) 0.13 (0.3) - - - 
70%/30% 1.25 (0.2) 0.65 (2) 0.11 (4) 0.83 (3) 0.35 (2) 0.11 (16) 
50%/50% 1.18 (3) 0.44 (4) 0.14 (17) 0.81 (3) 0.56 (4) 0.10 (17) 
30%/70% 1.20 (7) 0.28 (10) 0.18 (28) 0.83 (2) 
0.72 
(10) 
0.10 (11) 
0%/100% - - - 0.85 (0.1) 1 (0) 0.12 (0.2) 
FAD 

m 
(ns) 
100%/0% 1.09 (0.1) 1 (0) 0.10 (0.3) - - - 
70%/30% 1.02 (5) 0.61 (0.02) 0.09 (41) 1.19 (8) 0.39 (2) 0.15 (19) 
50%/50% 1.12 (11) 1 (0.6) 0.14 (28) - - - 
30%/70% 1.03 (6) 0.18 (0.01) 0.10 (1) 1.12 (4) 
0.82 
(0.3) 
0.12 (5) 
0%/100% - - - 1.17 (0.4) 1(0) 0.13 (0.2) 
OMI 
Index 
100%/0% 1.67 (0.1) 1 (0) 0.31 (0.3) - - - 
70%/30% 1.81 (0.02) 0.62 (1) 0.38 (1) 0.47 (1) 0.38 (1) 0.23 (3) 
50%/50% 1.62 (6) 0.40 (0.2) 0.47 (16) 0.49 (4) 
0.60 
(0.2) 
0.20 (11) 
30%/70% 2.06 (2) 0.17 (1) 0.36 (20) 0.56 (0.2) 0.83 (1) 0.23 (2) 
0%/100% - - - 0.54 (0.7) 1 (0) 0.21 (0.2) 
* % error computed for the mean, proportion, and standard deviation of the endpoint values 
between the manually classified SKBr3 and MDA-MB-231 cell populations and the results of the 
best-fit SPA model. 
 
Figure 3.5. Redox ratio histograms. Histograms of redox ratios, quantified per cell, of a 
population of approximately 200 cells of varying percentages of MDA-MB-231 cells and 
SKBr3 cells measured experimentally. The solid blue line represents best mixed-model 
Gaussian distribution fit. The red dashed curves represent the two component contributions, 
if a two component model is optimal. Histograms are normalized to have a total area of 1. 
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The mean NAD(P)H m values of the two cell lines grown independently are 1.3 ns for 
SKBr3 cells and 0.85 ns for the MDA-MB231 cells (Fig. 3.6a-b).  SPA of the NAD(P)H m data 
from the co-culture experiments reveals two populations for all three co-culture groups (Fig. 3.6c-
e).  The errors of the means of the computationally determined SKBr3 and MDA-MB-231 
subpopulations are within 7% of the respective, true NAD(P)H m means (Table 3.2).  Likewise, 
the proportion of cells attributed to each population as determined computationally by the SPA 
models, is within 10% of the true populations and the standard deviation errors within 28% (Table 
3.2).  To demonstrate the cellular heterogeneity visually, the average NAD(P)H m value of each 
cell was used to classify cells as SKBr3 or MDA-MB-231, and cells are color coded red if SKBr3 
and blue if MDA-MB-231 (Fig. 3.7).  An NAD(P)H m cut-off value of 1.06 ns was chosen because 
it is equal-distance, 1.9 standard deviations, from each mean and minimized classification error.  
This NAD(P)H m threshold value yielded an overall accuracy of 95.2% to correctly classify all 
cells, with 94.2% of SKBr3 cells correctly classified and 95.5% of MDA-MB-231 cells correctly 
classified. 
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Figure 3.6. NAD(P)H m histograms. Histograms of NAD(P)H m from populations of 
approximately 200 cells of varying percentages of MDA-MB-231 cells and SKBr3 cells. The 
solid blue line represents the best mixed-model Gaussian distribution fit. The red dashed curves 
represent the two component contributions, if a two component model is optimal. Histograms 
are normalized to have a total area of 1. 
 
 
Figure 3.7. Representative color coded images. Images with cells color coded red if the cell 
mean NAD(P)H m value is greater than 1.06 ns and blue if the NAD(P)H m value is less than 
1.06 ns. 
 
SPA of the heterogeneous co-cultures is less successful at separating the two populations 
using the FAD m (Fig. 3.8, Table 3.2).  While two populations are identified in the 30/70% 
experiments, the model fails to identify two populations in the 50/50% group (Fig. 3.8d).   
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Figure 3.8 FAD m histograms. Histograms of FAD m from populations of approximately 200 
cells of varying percentages of MDA-MB-231 cells and SKBr3 cells. The solid blue line represents 
the best mixed-model Gaussian distribution fit. The red dashed curves represent the two 
component contributions, if a two component model is optimal. Histograms are normalized to have 
a total area of 1. 
 
 
 
 
Figure 3.9 OMI index histograms. Histograms of OMI Index from populations of approximately 
200 cells of varying percentages of MDA-MB-231 cells and SKBr3 cells. The solid blue line 
represents the best mixed-model Gaussian distribution fit. The red dashed curves represent the two 
component contributions, if a two component model is optimal. Histograms are normalized to have 
a total area of 1. 
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The OMI index is a linear combination of mean centered redox ratio, NAD(P)H m, and 
FAD m values computed per cell (14).  The mean OMI index values for SKBr3 and MDA-MB-
231 cells are 1.67 +/- 0.31 and 0.54 +/- 0.22, respectively.  OMI-SPA of the OMI index for the co-
culture experiments resolves a single population for the 100% SKBr3 and 100% MDA-MB-231 
groups and two populations for each of the co-culture groups (Fig. 3.9).  The error of the SKBr3 
subpopulation OMI index means is <6% for all co-culture experiments grant (Table 3.2).  The 
mean error for the OMI index for the modeled populations of MDA-MB-231 cells are all less than 
4% (Table 3.2), and the proportions for the SKBr3 and MDA-MB-231 populations within 1% 
(Table 3.2).  The standard deviation error for the modeled SKBr3 populations is 20% or less for 
all experiments and 11% or less for the MDA-MB-231 populations (Table 3.2). 
3.4.3 Behavior of AIC and SPA 
Simulations were performed to determine the characteristics of data sets from which two 
distinct subpopulations can be resolved.  In the first experiments, populations of size N = 300 were 
generated with a random number generator and each population proportion was 0.5.  All 
populations had a normalized mean of 1, and the distance between the means was varied from 0-
2.  The standard deviation of the populations varied from 0-1.  For these simulations, the two 
component model is most representative of the data (AIC2<AIC1) at low standard deviations and 
at greater distances between the means (Fig. 3.10a).  If a cutoff of AIC2<AIC1 is used to select the 
most representative model, a two component model is most representative when the standard 
deviation < 0.46*(distance between means) + 0.0821.  However, if the difference AIC1-AIC2 must 
be greater than 5% of AIC1, then standard deviations < 0.2563*(Distance between means) + 0.0832 
describes the populations with two components that can be identified by OMI-SPA.  However, 
even though the AIC selects a two component model for these populations, the error of the 
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computed population mean values, standard deviations, and proportions increases with increased 
subpopulation standard deviation and decreased distance between the means (Fig. 3.10b-d).   
 
Figure 3.10. Behavior of OMI-SPA for generalized data. Simulation initial conditions include 
a population of size N = 300 cells, each population proportion was 0.5, and all populations had a 
normalized mean of 1. The distance between the means was varied from 0-2.  The standard 
deviation of the populations varied from 0-1.  (a) AIC difference for the 1 and 2 component models 
to fit the simulated data.  (b) Error of the mean, (c) error of the variance, and (d) error of the 
subpopulation proportions computed for the two-component models of the simulated data. 
 
Similar simulations were performed to determine the sample size necessary to resolve two 
populations of known, normalized mean distances, standard deviations, and proportions (Fig. 
3.11).  In Fig. 3.11, the simulations, in which the normalized distance varied from 0-2 and the 
proportion of each population varied from 0-1, are repeated at increasing standard deviation values 
(a) 0.05, (b) 0.1, (c) 0.25, and (d) 0.5.  These simulations demonstrate that SPA requires a larger 
sample size to identify two subpopulations at smaller distances between the means (Fig. 3.11).  As 
the standard deviation increases, an increased sample size is required to identify subpopulations.  
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SPA fails to identify two subpopulations within a sample size of 10,000, at low mean distances: 
mean distances < 0.3 for a standard deviation of 0.05, mean distances < 0.4 for a standard deviation 
of 0.1, mean distances < 0.6 for a standard deviation of 0.25, and mean distances < 0.8 for a 
standard deviation of 0.5.  Additionally, SPA fails to identify two populations in data sets up to 
10,000 cells, at percentages of 0 and 1, as expected for uni-modal populations.  Increased sample 
sizes are required to identify populations of very small proportions, in the 0.02-0.12 range (Fig. 
3.11c).  The dashed red circle (Fig. 3.11b) and red dashed line (Fig. 3.11d) encompass measured 
subpopulations (9, 14) in breast cancer (see 3.5 Discussion). Altogether, these simulations on 
normalized data sets demonstrate the relationships between mean distance, standard deviation, 
population proportion, and sample size necessary to resolve two subpopulations.  
 
Figure 3.11. Minimum sample size for OMI-SPA for populations of varying parameters. 
Minimum sample size (N), if less than 10,000 cells, required to resolve two populations with 
minimal population mean and proportion error (AIC2<AIC1-20) at varied mean distances (0-2) and 
population proportions (0-1).  Standard deviation of the populations was varied: (a) 0.05, (b) 0.1, 
(c) 0.25, and (d) 0.5.  The red, dashed circle in (b) encompasses the majority of normalized OMI 
endpoint mean distances and proportions of subpopulations observed in patient-derived organoids.  
The red, dashed line (d) represents the normalized distance (1.16) and standard deviation between 
two HER2 positive cell lines, one responsive to trastuzumab and one resistant. 
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3.5. Discussion 
Recent evidence suggests that tumor heterogeneity is a major source of drug resistance (1).  
Cancer stem cell populations may contribute to drug resistance and tumor recurrence (6).  Within 
breast cancers, stem cells can compromise 3-35% of the tumor cells (6).  Therefore, non-invasive 
single cell analysis technologies that can monitor changes in cellular subpopulations over time are 
critically needed to understand and combat drug resistance in tumors.  Optical imaging of 
NAD(P)H and FAD is highly sensitive to metabolic differences among breast cancer subtypes (9, 
14), and can be performed at high resolution for single-cell analysis.  Here, we demonstrate the 
capabilities and limitations of OMI-SPA to quantify subpopulations of cells by co-culture and 
simulation experiments. 
Simulations of the OMI-SPA behavior for co-cultured SKBr3 and MDA-MB-231 cells 
(Fig. 3.1-3) demonstrate that for these two cell lines, OMI-SPA will be able to identify the two 
populations, with minimal mean and proportion error, using the NAD(P)H m values at population 
sizes greater than 50 cells and at proportions between 0.1 and 0.9 (Fig. 3.2).  The normalized 
distance between mean redox ratios for SKBr3 and MDA-MB-231 is greater than that of NAD(P)H 
m (0.57 vs. 0.42), but the normalized average standard deviation is twice as great for the redox 
ratios than NAD(P)H m (0.22 vs. 0.12).  Therefore, the redox ratio simulations demonstrate that 
OMI-SPA can resolve two populations with minimal mean and proportion error at larger sample 
sizes (>100 total cells) and proportions between 20 and 80% SKBr3 (Fig. 3.1).  While the 
normalized average standard deviation of the SKBr3 and MDA-MB-231 FAD m values is 0.10, 
the smallest of these three OMI endpoints, the normalized mean FAD m distance for SKBr3 and 
MDA-MB-231 cells is only 0.06, and OMI-SPA is unable to identify two populations in the FAD 
m simulations due to this small difference in means of the two populations (Fig. 3.3).  This 
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highlights the fact that OMI-SPA can identify two populations only if the two populations have 
sufficiently large mean separation and small standard deviations. Otherwise, OMI-SPA cannot 
identify both subpopulations.   
Co-culture experiments of SKBr3 and MDA-MB-231 cells were performed to test OMI-
SPA on experimental data.  Due to the large differences in mean redox ratio and NAD(P)H m, the 
redox ratio and NAD(P)H m images of co-cultured SKBr3 and MDA-MB-231 cells appear 
heterogeneous (Fig. 3.4).  This highlights the advantage of microscopy techniques that provide 
images for qualitative and quantitative assessment. Furthermore, false-coloring of the images 
based on the cellular NAD(P)H m values visually demonstrates the presence of SKBr3 cells and 
MDA-MB-231 cells in the images of co-cultured cells (Fig. 3.7).  OMI-SPA of the redox ratio and 
NAD m values of the co-cultured SKBr3 and MDA-MB-231 cells identified two subpopulations 
with minimal error (Fig 3.5, 3.6; Table 3.2).  OMI-SPA of the FAD m data failed to resolve two 
populations in the 50%/50% co-culture experiment, which was expected from the simulation data 
that suggested the FADm means were too similar for OMI-SPA to distinguish (Fig. 3.8). 
The OMI index is a linear combination of the redox ratio, NAD(P)H m, and FAD m, and 
provides a single optical variable that is highly sensitive to cellular metabolic changes with 
receptor expression and drug response in breast cancer (14).  Subpopulation analysis of the OMI 
index of co-cultured SKBr3 and MDA-MB-231 cells identifies two subpopulations when grown 
at 30/70%, 50/50%, and 70/30% with minimal error in population means, standard deviations, and 
subpopulation proportions (Fig 3.9, Table 3.2).  In comparison with the three individual OMI index 
constituents, the OMI index has the greatest normalized mean distance between SKBr3 and MDA-
MB-231 cells, 1.02, and a normalized standard deviation, 0.24, indicating robust SPA for these 
two cell lines. 
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Generalized simulations were performed to assess the characteristics of data sets that can 
be accurately modeled as two subpopulations by OMI-SPA.  These generalized simulations can 
be used to predict SPA performance for any two subpopulations by computing a subpopulation 
mean separation distance and standard deviation normalized to the mean of the data set.  The 
results of these simulations (Fig. 3.10-11) demonstrate the relationships between sample size, 
population standard deviation, and distance between means necessary to resolve two populations.  
A larger standard deviation is tolerated if the distance between means is greater (Fig. 3.10) or the 
sample size is larger (Fig. 3.11).  OMI-SPA subpopulation mean, standard deviation, and 
proportion errors increase with increased population standard deviation and decreased distances 
between means (Fig. 3.10).  Cancer stem cells compromise 3-35% of the cells within a tumor (6), 
and the generalized OMI-SPA results (Fig. 3.11) demonstrate the capabilities of OMI-SPA to 
resolve these small populations provided that the stem cells have different OMI endpoints from 
the non-stem cell population. 
The utility of OMI-SPA is to identify subpopulations of cells within unknown, 
heterogeneous populations.   OMI-SPA has been used in xenograft and patient derived- primary 
tumor organoids to identify subpopulations with varied response to anti-cancer drug treatment 
(14).  The normalized mean separation for the OMI index of trastuzumab responsive (BT474, 
ER+/HER2+) cells and resistant cells (HR6, ER+/HER2+) is 1.16 and the normalized OMI index 
standard deviation is 0.42 for responsive cells and 0.28 for resistant cells (9).  The normalized 
simulation experiments (red dashed line; Fig. 3.11d) suggest that OMI-SPA will be able to resolve 
heterogeneous populations of responsive and non-responsive cells, if there are at least 500 cells in 
the population.  Analysis of primary-tumor derived organoids with heterogeneous drug-response, 
identified subpopulations of cells with varied OMI index values (14).  The normalized mean 
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separation for OMI-SPA subpopulations within patient primary tumor derived organoids ranged 
from 0.4-1.4, population percentages ranged from 0.15-0.85, and the normalized standard 
deviations ranged from 0.02 to 0.36.  As indicated by the red dashed circle (Fig. 3.11b), OMI-SPA 
can resolve these subpopulations with high mean separations with as few as 100 cells, and can 
resolve the majority of these subpopulations with less than 500 cells.   
Heterogeneous tumors may contain more than two subpopulations and the characteristics 
of these subpopulations may be unknown in advance.   Furthermore, the metabolism of these 
subpopulations may change dynamically over time and in response to stimuli.  SPA, as described 
here, can be used to evaluate the presence of multiple subpopulations.  Additionally, the simulation 
experiments (Fig. 3.10 and 3.11) generalize the OMI-SPA technique and show this is a robust 
method for populations of cells with varying OMI endpoint means and standard deviations and not 
limited to the two specific cell lines used in the co-culture experiments.  Furthermore, one 
advantage of OMI is the non-invasive capabilities which enable imaging of in vitro samples over 
time to study subpopulation and individual cell dynamics.  Altogether, OMI-SPA is a robust, 
attractive platform for evaluating and monitoring subpopulation heterogeneity. 
OMI-SPA assumes that the OMI endpoints distributions for each population exhibit 
normality.  A Wilk-Shapiro test for normality revealed that the NAD(P)H and FAD mean lifetimes 
of both cell lines exhibited normality but the OMI index did not for either cell line and neither did 
the redox ratio for the SKBr3 cells.  The lack of normality of these data sets may introduce error 
when modeled as Gaussian curves.  Even with this know error, however, the errors for the mean 
OMI index modeled for both cell lines and the errors for the SKBr3 redox ratio in the co-culture 
experiments was less than 6%, suggesting OMI-SPA performs well with these distributions 
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represented as Gaussian curves. SPA can be improved to account for different data distributions 
by using additional distributions that better represent the homogenous population. 
The results of this experiment demonstrate that OMI-SPA can be used to identify cancer 
cell subpopulations based on the OMI endpoints: redox ratio, NAD(P)H mean lifetime, FAD mean 
lifetime, and OMI index.  Furthermore, these results characterize the relationships between sample 
size, standard deviation, and mean distance required for OMI-SPA to accurately describe the two 
populations.  Our previously published analyses of cellular subpopulations within in vivo tumors 
(9) and patient-derived tumor organoids (14) also indicate that OMI-SPA can accurately identify 
cell subpopulations with a sample of as few as 300 cells.  
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CHAPTER 4 
Optical Metabolic Imaging Identifies Breast Cancer Glycolytic Levels, Sub-Types, and 
Early Treatment Response 
Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC, “Optical 
metabolic imaging identifies breast cancer glycolytic levels, sub-types, and early treatment 
response,” Cancer Research. 2013; 73(20):6164-74. 
4.1 Abstract 
Abnormal cellular metabolism is a hallmark of cancer, yet there is an absence of 
quantitative methods to dynamically image this powerful cellular function.  Optical metabolic 
imaging (OMI) is a non-invasive, high-resolution, quantitative tool for monitoring cellular 
metabolism.  OMI probes the fluorescence intensities and lifetimes of the autofluorescent 
metabolic co-enzymes reduced nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FAD).  We confirm that OMI correlates with cellular glycolytic levels across a panel 
of human breast cell lines, using standard assays of cellular rates of glucose uptake and lactate 
secretion (p<0.05, r=0.89).   Additionally, OMI resolves differences in the basal metabolic activity 
of untransformed from malignant breast cells (p<0.05), and between breast cancer sub-types 
(p<0.05), defined by estrogen receptor (ER) and/or HER2 expression or absence.  In vivo OMI is 
sensitive to metabolic changes induced by inhibition of HER2 with the antibody trastuzumab 
(Herceptin) in HER2-overexpressing human breast cancer xenografts in mice.  This response was 
confirmed with tumor growth curves and stains for Ki67 and cleaved caspase-3.  OMI resolved 
trastuzumab-induced changes in cellular metabolism in vivo as early as 48 hours post-treatment 
(p<0.05), while FDG-PET did not resolve any changes with trastuzumab up to 12-days post-
treatment (p>0.05).  In addition, OMI resolved cellular sub-populations of differing response in 
vivo that are critical for investigating drug resistance mechanisms.  Importantly, OMI endpoints 
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remained unchanged with trastuzumab-treatment in trastuzumab-resistant xenografts (p>0.05).  
OMI has significant implications for rapid cellular-level assessment of metabolic response to 
molecular expression and drug action, which would greatly accelerate drug development studies. 
4.2 Introduction 
Cellular metabolism produces energy and macromolecules necessary for cell survival.  
Abnormal metabolism is involved in many of the diseases that cause the greatest burden of 
morbidity and mortality in the developed world.  Many malignant cancer cells maintain high rates 
of glycolysis in the presence of oxygen (1) and oncogenic transformation is linked with changes 
in metabolic rates. For example, the HER2 receptor tyrosine kinase, which is amplified in about 
20% of invasive breast cancer, potently activates the phosphatidylinositol-3 kinase 
(PI3K)/Akt/mTOR pathway, a master regulator of glucose metabolism (2, 3).  Patients with HER2 
gene-amplified breast cancers present with more aggressive disease and generally have a poor 
prognosis (4). HER2 inhibitors, such as the antibody trastuzumab (Herceptin), provide substantial 
clinical benefits. However, the action of HER2 inhibitors is limited due to innate and acquired 
drug resistance (5).    
Clinically and in preclinical drug development, there is a need for high-resolution, non-
invasive, functional imaging tools to monitor and predict drug efficacy vs. lack of efficacy. In 
cancer research, the primary endpoint of drug efficacy is tumor regression.  However, cellular and 
molecular changes precede changes in tumor size. If these molecular endpoints could be identified 
and measured, they would provide biomarkers predictive of drug response or drug resistance. 
Cellular metabolism is particularly sensitive to upstream molecular interventions, and therefore 
may be a powerful biomarker of early drug response. The HER2 inhibitor trastuzumab, for 
example, inhibits PI3K-mediated glucose metabolism (6-8).  Current preclinical and clinical 
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methodologies to assess metabolic state in tumors in situ include fluorodeoxyglucose-positron 
emission tomography (FDG-PET), immunohistochemical (IHC) assessment of levels of metabolic 
regulators, and metabolic flux analyses (7, 9-13).  Yet each of these techniques fails to capture 
dynamic changes in metabolic state and poorly reflect sensitivity to drug efficacy (7, 9, 14-18).   
Optical metabolic imaging (OMI) exploits the autofluorescent properties of reduced 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD), two metabolic 
co-enzymes.  We use multi-photon fluorescence and time-correlated single photon counting to 
measure the optical redox ratio and fluorescence lifetimes of NADH and FAD in living cells and 
tissues.  The optical redox ratio is the ratio of NADH fluorescence intensity divided by FAD 
fluorescence intensity (19), and provides a dynamic measure of cellular metabolism (8, 19-21).  
The fluorescence lifetime, the time a molecule remains in the excited state, is independent of inter- 
or intra- instrument variability, resolves free and bound protein configurations, and is influenced 
by preferred protein-binding of the molecules and proximity to quenchers (e.g. oxygen) (22).    
NADH and FAD each have two-component fluorescence decays.   For NADH, the short lifetime 
(1) corresponds to NADH free in solution, while the long lifetime (2) corresponds to protein-
bound NADH (23).  Conversely, protein-bound FAD corresponds to the short lifetime, while free 
FAD corresponds with the long lifetime (24). The shorter fluorescence lifetimes of both protein-
bound FAD and free NADH are due to dynamic quenching by the adenine moiety (22, 25).  The 
mean fluorescence lifetime (m) is the weighted average of the short and long lifetime components, 
m = 11+22, where 1 and 2 are the fractional contributions of the short and long lifetimes, 
respectively.  
The images acquired by OMI provide sufficient resolution and contrast to distinguish the 
cellular and extracellular tissue compartments, as the collagen-enriched extracellular matrix 
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generates a strong second harmonic signal that has a lifetime and spectral emission distinct from 
cellular NADH and FAD (26).  Resolution is adequately high to isolate single cells, allowing 
identification of inflammatory infiltrates in the stroma and tumor epithelia.  This single cell-level 
resolution may be useful for identifying resistant sub-populations of cells that pre-exist in the 
tumor and are responsible for cancer relapse.   
Because OMI is inexpensive, fast, and directly measures dynamic changes in cellular 
metabolism that reflect glycolysis, oxidative phosphorylation, and metabolic enzyme 
microenvironment interactions, we investigated the potential of OMI as a tool for monitoring 
metabolic response to targeted therapies in human breast cancer cells and xenografts.  OMI was 
validated by measuring metabolic inhibition by cyanide, and by comparison with standard assays 
of glycolytic metabolism.  The sensitivity of OMI to breast cancer sub-types was confirmed. 
Finally, the OMI-measured response of mouse xenograft models treated with trastuzumab was 
compared with FDG-PET, IHC, and tumor size measurements.  This work represents a significant 
advancement in the tools available to study cellular metabolism and tumor response to treatment 
in living systems. 
4.3 Materials and Methods 
4.3.1 Fluorescence lifetime instrumentation  
A custom built, commercial multi-photon fluorescence microscope (Prairie Technologies) 
was used to acquire fluorescence images.  A 40X water-immersion objective (1.15 NA) or a 40X 
oil-immersion objective (1.3 NA) coupled the excitation and emitted light through an inverted 
microscope (TiE, Nikon).  A titanium:sapphire laser (Coherent Inc.) was tuned to 750 nm for 
excitation of NADH and 890 nm for FAD excitation.  The average laser power was 7.5-7.8 mW 
for NADH and 8.4-8.6 mW for FAD.  A pixel dwell time of 4.8 s was used.   A GaAsP PMT 
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(H7422P-40, Hamamatsu) detected emitted photons.  A 400-480 nm bandpass filter isolated 
NADH fluorescence.  A 500 nm high pass dichroic mirror and a 500-600 nm bandpass filter 
isolated FAD fluorescence.   
Fluorescence lifetime images were acquired using time correlated single photon counting 
(TCSPC) electronics (SPC-150, Becker and Hickl).  TCSPC uses a fast detector PMT to measure 
the time between a laser pulse and fluorescence event.  Each image of 256x256 pixels was acquired 
using an integration time of 60 seconds.  No change in the photon count rate was observed, 
ensuring that photobleaching did not occur. The instrument response function (measured from the 
second harmonic generated signal of urea crystals excited at 900 nm) full width at half maximum 
was measured to be 260 ps.  The single-component fluorescence lifetime of a fluorescent bead 
(Polysciences Inc.) was measured daily.  The measured fluorescence lifetime of the bead was 2.1 
± 0.08 ns (n = 18), which is consistent with published studies (20, 27). 
4.3.2 Cell culture  
All cell lines were acquired from the ATCC except the HR6 cell line (28) which was 
provided by the Arteaga lab.  The non-cancerous mammary epithelium cell line, MCF10A, was 
cultured in MEBM (Lonza) supplemented with cholera toxin, penicillin: streptomycin, bovine 
pituitary extract, hydrocortisone, insulin, and human epidermal growth factor.  All malignant cell 
lines were grown in DMEM (Invitrogen) with 10% fetal bovine serum and 1% penicillin: 
streptomycin. The growth media for the HR6 cell line was further enhanced with 25 g/ml 
trastuzumab (Vanderbilt Pharmacy).  For fluorescence imaging, cells were plated at a density of 
106 cells per 35 mm glass-bottom imaging dish (MatTek Corp.) 48 hours before imaging.   
The MCF10A cell line was used as a daily fluorescence standard for the redox ratio, and 
imaged each day measurements were acquired.  All other cell lines were imaged on at least two 
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different days.  A total of 18 different locations were imaged for each cell line (58 for MCF10A 
cells) from six different dishes (three images were acquired from each dish, see Appendix A Table 
A.1). 
4.3.3 Cyanide experiment  
NADH and FAD fluorescence lifetime images of three locations of three dishes were 
acquired.  Media of two of the MCF10A dishes was removed and replaced with cyanide 
supplemented MCF10A growth media (4 mM NaCN, Sigma).  The cells were allowed 5 minutes 
for the cyanide to react, and post-cyanide NADH and FAD fluorescence images were acquired 
from three unique locations from each dish. 
4.3.4 Trastuzumab perturbation 
The effect of HER2 inhibition by trastuzumab was tested in HER2-overexpressing cells.  
The cells were plated at a density of 106 cells per imaging dish, 48 hours before imaging.  At 24 
hours before imaging, the growth media was exchanged for growth media containing 25 g/ml 
trastuzumab.  This dose of trastuzumab, 25 g/ml, was chosen to mimic therapeutic drug dosage 
in patients (29). 
4.3.5 Mouse xenografts  
This study was approved by the Vanderbilt University Animal Care and Use Committee 
and meets the National Institutes of Health guidelines for animal welfare.  MDA-MB-361 cells 
(106), BT474 cells (108), or HR6 cells (108) in 100µl Matrigel were injected in the inguinal 
mammary fat pads of female athymic nude mice (J:NU; Jackson Laboratories).  Tumors were 
allowed to grow to ~150mm3. Tumor-bearing mice were treated with trastuzumab (Vanderbilt 
University Medical Center pharmacy) or control human IgG 10 mg/kg twice weekly for two 
weeks.  This dose of trastuzumab was chosen to mimic therapeutic drug dosage in patients (30). 
69 
 
4.3.6 OMI xenograft imaging  
Isoflurane-anesthetized mice were used for vital imaging, by removing the skin overlying 
the tumor, overlaying the tumor with a coverslip, and placing the mouse on the microscope stage.  
NADH and FAD fluorescence lifetime images of three different tumor locations were acquired 
each day.  After imaging, mice were humanely euthanized while under anesthesia.  Each OMI 
group contained 3 mice, each with 2 tumors for a total n of 6 tumors at each time point. 
4.3.7 FDG-PET imaging  
The FDG-PET protocol follows published methods (7, 31, 32). The mice were fasted 
overnight and allowed to acclimate to the PET facility for 1hr on a warm water pad.  A single 
retroorbital injection of ~200 Ci (100l) of [18F]FDG was administered.  Following a 40-min 
distribution period, 20-min static PET scans were collected on a Concorde Microsystems 
microPET Focus 220 (Siemens) while mice were anesthetized with isoflurane.  PET images were 
reconstructed using the ordered subsets expectation maximization algorithm (33).  FDG-uptake 
values were obtained by isolating the uptake of each tumor volume and correcting for the injected 
dose.  Each FDG-PET group contained 5 mice, each with 2 tumors for a total n of 10 tumors. 
4.3.8 Quantification of the optical redox ratio  
The optical redox ratio was computed from the NADH and FAD fluorescence lifetime data.  
The photons detected at each pixel in an image were integrated over time to compute the sum of 
photons per pixel.  The total number of NADH photons was divided by the total number of FAD 
photons at each pixel to create a redox ratio image (Matlab, MathWorks).  The redox ratio image 
was thresholded to remove background and nuclear fluorescence and the average redox ratio for 
the remaining cell cytoplasms was computed.  This approach has been confirmed to be consistent 
with redox ratios obtained with steady-state detection (8, 21).   
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4.3.9 Quantification of fluorescence lifetime components 
For each image, a threshold was selected to eliminate background and nuclear fluorescence 
(SPCImage, Becker and Hickl).  A binning of nine surrounding pixels was used.  Then, the 
fluorescence lifetime components were computed for each pixel by de-convolving the measured 
system response and fitting the resulting exponential decay to a two-component model, 
CtI
tt   21 /2
/
1 expexp)(
  , where I(t) is the fluorescence intensity at time t after the laser 
excitation pulse, 1 and2 are the fractional contributions of the short and long lifetime 
components, respectively (i.e. 1 +2 = 1), 1 and2 are the fluorescence lifetimes of the short 
and long lifetime components, and C accounts for background light.  A two-component decay was 
used to represent the lifetimes of the free and bound configurations of NADH and FAD (20, 23, 
24).  The average lifetime component values and a mean fluorescence lifetime  
( 2211  m ) for each image were computed in Matlab.   
4.3.10 Statistical analysis  
A rank sum test of means was used to test for significant differences due to cyanide.  A 
Bonferroni correction for multiple-comparisons was used on rank sum tests of means of the 
metabolic values from the panel of cell lines.  A rank sum test of means was used to identify 
significant differences when cell lines were treated with trastuzumab and to find differences in the 
in vivo xenograft experiments.  A student's t-test of means tested for significantly different FDG 
uptake values between control and trastuzumab-treated xenografts.  For all statistical tests, an alpha 
significance level of 0.05 was used and the test was assumed to be two-way. 
Spearman's rank correlation coefficient was used to identify correlations.  Both a 
correlation coefficient (r) and a P-value were computed.  An alpha level of less than 0.05 signified 
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significance.  Scatterplots of the significant correlations confirmed that the correlation was due to 
data trends and not a single outlier. 
4.3.11 Computation of intra- and inter- cellular variation  
Inter-cellular variation was visualized by histogram representation of the mean metabolic 
measure (optical redox ratio, NADH m, or FAD m) for all cells.  The histogram was fit to one, 
two, and three component Gaussian curves to determine the number of modes within the data.  The 
fit with the lowest Akaike information criterion (AIC) was selected to represent the probability 
density function of the histogram (34).  Intra-cellular variation was computed as the average 
coefficient of variation (standard deviation divided by mean) for each cell and averaged over all 
cells. 
4.3.12 Percentage of mitotic cells  
The percentage of proliferating cells was measured by flow cytometry.  Cells were plated 
at a density of 106 cells per 35 mm dish.  After 48 hours, the cells were labeled with  Phospho-
Histone H3 (Ser10) antibody (Cell Signaling Technology) and a secondary antibody, Alexa Fluor 
488 goat anti-rabbit IgG (Invitrogen) enabled detection of labeled cells by flow cytometry. 
4.3.13 Glycolytic Index  
Media glucose and lactate concentrations were measured using standard assay kits 
(Amplex® Red Glucose/Glucose Oxidase Assay Kit (Invitrogen) and L-Lactate Assay Kit (Eton 
Bioscience Inc.)). Concentrations of glucose and lactate in the cell growth media were determined 
at the time of plating (0hr) and at the time of imaging (48hr).  The “glycolytic index” was computed 
as the moles of glucose consumed within 48hr divided by the moles of lactate produced in 48hr.     
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4.3.14 Histological analysis   
Tumors were collected and placed in buffered formalin, paraffin embedded, sliced, and 
stained with H&E.  Additional slides were stained for Ki-67 and cleaved caspase-3.  Staining 
protocols were verified in positive control samples.  The percentage of positively stained cells was 
quantified from 5 fields of view from 3 tumors in each group. 
4.4 Results 
 
Figure 4.1 Cyanide validation experiment. Graphical representation (a) of the 
relationship between HER2, NADH and FAD.  HER2 activation drives an increase in 
glycolysis, which produces NADH.  The pyruvate generated in glycolysis can enter the 
mitochondria as a reactant in oxidative phosphorylation.  Oxidative phosphorylation 
consumes NADH and produces FAD.  A net gain of NADH relative to FAD is observed 
with HER2 activation due to a relative increase in glycolysis.  Inhibition of HER2 by 
trastuzumab reduces cellular glycolysis rates resulting in a decrease of cellular NADH 
relative to FAD.  NADH and FAD are highlighted as the fluorescent molecules in this 
diagram, and molecules in bold indicate the net direction of the reaction.  Optical redox 
ratio (b), NADH m (c), and FAD m (d) of MCF10A (non-malignant) cells before (n=9) 
and after (n=6) treatment with 4 mM NaCN. m is the mean lifetime (m = 1*α1 + 2*α2).  
*P <0.05. 
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Figure 4.1a demonstrates the relationship between HER2 and the fluorescent molecules 
NADH and FAD.  HER2 activation drives an increase in glycolysis, which generates NADH.  The 
pyruvate produced in glycolysis can enter the mitochondria as a reactant in oxidative 
phosphorylation.  Oxidative phosphorylation consumes NADH and produces FAD.  A net gain of 
NADH relative to FAD is observed with HER2 activation due to a relative increase in glycolysis.    
4.4.1 Validation 
Chemical inhibition of oxidative phosphorylation affects the relative fluorescence 
intensities of NADH and FAD in a cell (35), so this perturbation was used to validate the optical 
imaging approach (Fig. 4.1b-d, Appendix A Fig. A.1). Cyanide (which disrupts the electron 
transport chain) induced the predicted trends23, 27: an increase in the optical redox ratio and a 
decrease in NADH m.  Unreported until now, FAD m increased with cyanide treatment.   
4.4.2 Metabolic profiling of breast cancer cells 
 
Figure 4.2 Representative OMI images. Representative images of the optical redox ratio 
(NADH/FAD; first row), NADH m (second row), and FAD m (third row) of MCF10A (non-
malignant) and malignant breast cells.  Scale bar represents 30 μm.  The redox ratio is normalized 
to the mean daily MCF10A mean redox ratio as a daily fluorescence standard. m is the mean 
lifetime (m = 1*α1 + 2*α2). The ER and HER2 status of each cell line is provided under its name. 
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High resolution images (Fig. 4.2) allowed visualization of cellular morphology and cell-
to-cell variability of the optical redox ratio and NADH and FAD fluorescence lifetimes for human 
breast cell lines (Appendix A Table A.1). Cellular fluorescence localized to the cytoplasm of cells.   
ER+/HER2- cells displayed increased redox ratios over that seen in triple-negative cells (P<0.001; 
Fig. 3a), and the greatest redox ratios were measured in HER2 gene-amplified cells (P<0.001).  To 
account for any differences in cellular proliferation rates among the cell lines and demonstrate that 
the redox ratio is not a reporter of cellular proliferation (Appendix A Fig. A.2a), we normalized 
the redox ratio to the % mitotic cells (Appendix A Fig. A.2b) and found similar trends, increased 
redox ratio/% mitotic cells in ER+ cells and the greatest redox ratio/% mitotic cells in HER2+ 
cells.  
 
Figure 4.3 In vitro OMI results. (a) The optical redox ratio (mean +/- SE), (b) NADH m, and (c) 
FAD m for a panel of breast cancer cell lines.  (d) A scatterplot of NADH m versus redox ratio/% 
mitotic cells [non-malignant (NM), triple negative (TNBC)]. (h) Correlation between redox 
ratio/% mitotic cells and glycolytic index.  Unless indicated with a line, stars (*) indicate 
statistically significant differences with the MCF10A (non-malignant) cells and bullets (•) indicate 
statistically significant differences with the HER2+ cells grouped together.   ** P <0.001,  •• P < 
0.001.  n = 18 for all malignant cell lines and n = 58 for MCF10A. 
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NADH m of HER2+ and ER+ cells were increased over that measured in non-malignant 
cells (P<0.001; Fig. 4.3b), but were statistically similar to each other (P=0.5).  Triple negative 
cells exhibited the shortest NADH m.  Reduced free and protein-bound NADH lifetimes (1 and 
2) were observed in the triple negative and ER+ cells (Appendix A Fig. A.3a-b).  The portion of 
free NADH (1) was decreased in the HER2+ cells compared to the non-malignant cells (Appendix 
A Fig. A.3c). Compared to non-malignant cells, FAD m was increased in all malignant cells 
(P<0.001), with the longest FAD m observed in ER+/HER2- cells (P<0.001; Fig. 3.3c).  Increased 
FAD 1 and 2 values, as well as a reduced 1 (contribution of bound FAD) contributed to the 
increased FAD m observed in the malignant cells (Appendix A Fig. A.3d-f).  A scatterplot of 
NADH m vs. redox ratio/% mitotic cells (Fig. 4.3d) allowed accurate clustering of data-points of 
non-malignant, triple-negative, ER+, and HER2+ cells.  Scatterplots of FAD m vs redox ratio and 
NADH m vs FAD m allow separation of triple negative and non-malignant cells (Appendix A 
Fig. A.4). 
We compared OMI to cellular rates of glucose uptake and lactate secretion, or the 
“glycolytic index”.  A Spearman's rank correlation coefficient (r) of 0.89 (P<0.05) defined a 
positive correlation between the optical redox ratio/% mitotic cells and the glycolytic index (Fig. 
4.3e).  Neither NADH m nor FAD m correlated with the glycolytic index or the redox ratio 
(Appendix A Table A.2).   
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4.4.3 Trastuzumab response in vitro 
 
Figure 4.4 In vitro trastuzumab response. (a) The redox ratio (mean +/- SE) decreases with 
trastuzumab-treatment in responsive (BT474) and partially responsive (MDA-MB-361) cells but 
remains unchanged in cells with acquired resistance to trastuzumab (HR6). (b) NADH m (mean 
+/- SE; m = 1*α1 + 2*α2) is shorter in trastuzumab-treated responsive cells (BT474) and cells 
with acquired resistance (HR6), but unchanged in cells with poor response (MDA-MB-361).  (c) 
FAD m (mean +/- SE) is shorter in trastuzumab-treated BT474 but unchanged MDA-MB-361 and 
HR6 cells. * indicates significance between control and treated, unless otherwise indicated. (d) 
Distribution density modeling (black line represents fit of untreated cell histogram, gray line 
represents fit of trastuzumab treated cells) of the redox ratio on a cell-by-cell basis reveals two 
distinct populations of MDA-MB-361 cells for the redox ratio, with 70% and 30% of cells in the 
majority and minority populations, respectively, for both control and treated cells.  There is a 
significant decrease (P<0.05) in the mean of the minority population of treated cells (but not in the 
majority population), suggesting trastuzumab response in a sub-population of cells. ** P <0.001, 
* P <0.05.  n = 18 images for control and treated for all cell lines. 
 
 The effect of trastuzumab on cellular metabolism was investigated in three HER2-
overexpressing cell lines:  BT474 cells which are responsive to trastuzumab, MDA-MB-361 cells 
which partially respond to trastuzumab, and HR6 cells, which were derived from a BT474 
xenograft that acquired resistance to trastuzumab in vivo (28). The redox ratio (P<0.05), NADH 
m (P<0.05), and FAD m (P<0.001) of BT474 cells decreased upon trastuzumab treatment for 24 
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hours (Fig. 4.4a-c).  Lifetime component analysis demonstrated significant increases in the 
portions of free NADH (1) and bound FAD (1) of BT474 cells treated with trastuzumab 
(Appendix A Fig. A.5). Similarly, the redox ratio of the MDA-MB-361 cells decreased (P<0.05) 
with trastuzumab treatment (Fig. 4.4a). The high resolution OMI enabled analysis of cellular 
heterogeneity in response to trastuzumab (Fig. 4.4d, Appendix A Fig. A.6). Distribution modeling 
of cellular redox ratios of MDA-MB-361 cells revealed two sub-populations characterized by 
differing redox ratios (Fig. 4.4d).  The mean redox ratio of the first population, representing 70% 
of cells, showed no change (1.34 to 1.31) upon trastuzumab treatment (P=0.07), suggesting that 
trastuzumab did not affect metabolic processes in the majority of MDA-MB-361 cells.   However, 
30% of the cells responded to trastuzumab with a mean redox ratio that decreased from 1.89 to 
1.65 (P<0.001).   
HR6 cells are a trastuzumab-resistant BT474-derived sub-line that retains HER2 
overexpression. Previous studies have shown maintenance of HER2 overexpression and PI3K/Akt 
signaling in trastuzumab-treated HR6 cells (28). Consistent with this observation, the redox ratio 
remained unchanged upon treatment with trastuzumab, as was FAD m.  NADH m decreased in 
HR6 cells upon treatment with the antibody (P<0.05; Fig. 4.4a-c).   An increased portion of free 
NADH (1) contributed to the decreased NADH m observed in the HR6 cells (Appendix A Fig. 
A.5).   
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4.4.4 In Vivo Xenografts  
 
Figure 4.5 BT474 Xenograft OMI and FDG-PET. (a) BT474 tumors treated with trastuzumab 
(10 mg/kg, 2 x weekly) decrease in size (mean +/- SE) compared to control IgG treated tumors. 
Trastuzumab vs. control at each time point. (b) Ki67 staining demonstrates reduced proliferation 
in trastuzumab-treated tumors. (c) Cleaved caspase 3 staining demonstrates increased apoptosis in 
trastuzumab-treated tumors at day 5. (d) Representative FDG-PET image (T=tumor).  (e) FDG 
uptake increases in control tumors at day 12 compared to control tumors at day 2.  No significant 
difference in FDG uptake between trastuzumab-treated and control tumors is observed.  n = 10. (f) 
Representative OMI images. Scale bar is 50 m.  (g) Decreased redox ratio, (h) NADH m, and (i) 
FAD m are observed in trastuzumab-treated tumors at 2 days post trastuzumab-treatment. * 
P<0.05, ** P<0.01; *** P < 0.001; n = 6 tumors. 
 
To verify the OMI response observed in cultured cells, we performed OMI on HER2-
overexpressing xenografts and compared these findings with tumor size, IHC, and FDG-PET 
measurements.  Established BT474 xenografts treated with control IgG continued to grow 
throughout the course of the experiment while the trastuzumab-treated tumors decreased in size 
(Fig. 4.5a).  IHC staining confirmed lower rates of proliferation and higher rates of apoptosis in 
the trastuzumab-treated group (Fig. 4.5b,c). A representative FDG-PET image displays the 
location of the tumors in the mammary fat near the hind limbs and demonstrates increased FDG-
uptake in the tumors compared to the surrounding tissue (Fig. 4.5d).  FDG-uptake increased in the 
control mice between days 2 and 12 post-treatment; however, no difference was observed between 
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control and trastuzumab treated tumors at any time point (day 2, 5, or 12 post-treatment; Fig. 4.5e).  
OMI imaging of an identical cohort of tumors allowed cellular-level visualization of metabolism 
(Fig. 4.5f) and resolved metabolic differences in the redox ratio (Fig. 4.5g), NADH m (Fig. 4.5h, 
Appendix A Fig. A.7a-c), and FAD m (Fig. 4.5i, Appendix A Fig. A.7) between control and 
trastuzumab-responding tumors as early as 2 days after the first dose of trastuzumab.    
 
Figure 4.6 HR6 Xenograft OMI and FDG-PET. (a) HR6 tumor size (mean +/- SE)  treated with 
trastuzumab (10 mg/kg, 2 x weekly) compared to control IgG treated tumors. (b) Ki67 staining of 
HR6 control IgG and trastuzumab-treated tumors. (c) Cleaved Caspase 3 staining of HR6 control 
IgG and trastuzumab-treated tumors. (d) Representative FDG-PET image (T=tumor).  (e) FDG 
uptake increases in control tumors at day 12 compared to control tumors at day 2, * P<0.05.  No 
significant difference in FDG uptake between trastuzumab-treated and control tumors is observed 
at any time.  n = 10. (f) Representative OMI images, scale bar is 50 m..  (g) Redox ratio, (h) 
NADH m, and (i) FAD m of control and trastuzumab-treated tumors. * P<0.05; n = 6 tumors. 
Tumor size measurements of the HR6 xenografts showed similar growth of both control 
and trastuzumab-treated HR6 tumors (Fig. 4.6a).  IHC confirmed that the trastuzumab-treated HR6 
tumors retain proliferative capabilities and express similar rates of apoptosis compared to control 
treated tumors (Fig. 4.6b,c). A representative FDG-PET image of the HR6 tumors shows increased 
FDG-uptake by the tumor compared to the surrounding tissue (Fig. 4.6d).  No change in FDG-
PET was observed between control and trastuzumab-treated tumors at any time point; however, 
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the FDG-uptake was increased in the control mice at 12 days compared to 2 days (Fig. 4.6e).   No 
difference was observed in the redox ratio between control and treated HR6 tumors at any time 
point (Fig. 4.6f,g).  NADH m decreased in the HR6 treated tumors relative to controls at 2 days 
post treatment, but was similar to controls at days 5 and 14 (Fig. 4.6h, Appendix A Fig. A.8).  No 
change in FAD m was observed at any time point (Fig. 4.6i, Appendix A Fig. A.8). 
 
Figure 4.7 MDA-MB-231 Xenograft OMI. (a) Representative images of the optical redox ratio 
(first row), NADH m (second row), and FAD m (third row) of control and trastuzumab-treated 
(10 μg/kg; 48 hours) MDA-MB-361 mouse xenograft tumors.  Scale bar is 50 μm. (b) Redox ratio, 
(c) NADH m and (d) FAD m  mean +/- SE for control and trastuzumab-treated tumors evaluated 
on a per-image basis. (e) Redox ratio, (f) NADH m and (g) FAD m  distribution density modeling 
of single-cell analysis in control and trastuzumab-treated tumors.  (e-g)  Distribution density 
modeling reveals two distinct populations of trastuzumab-treated cells for the redox ratio (e, 
maroon line) and FAD m (g, maroon line) measurements, indicating heterogeneous cellular 
metabolic response to treatment.  All control populations (e-g; blue lines) and the trastuzumab-
treated NADH m population (f, maroon line) are uni-modal. (h) The increased coefficient of 
variation in the redox ratio and FAD m of the trastuzumab treated xenografts indicates increased 
intra-cellular variation in metabolism. * P <0.05 
 
The redox ratio (P<0.05), NADH m (P<0.05), and FAD m (P<0.05) decreased in 
trastuzumab-treated MDA-MB-361 xenografts as compared to IgG-treated controls (Fig. 4.7a-d; 
81 
 
Appendix A Fig. A.9) 2 days after treatment.  Modeling of the optical redox ratio and FAD m 
values on a cell-by-cell basis (inter-cell variability) identified two sup-populations of tumor cells 
in trastuzumab-treated animals, while an uni-modal cellular distribution was identified for NADH 
m (Fig. 4.7e-g).  High resolution analysis revealed that intra-cellular variability in redox ratios and 
FAD m increased (P<0.05) in trastuzumab-treated samples (Fig. 4.7h). These results fully 
characterize OMI and demonstrate its potential for monitoring early drug response in cell culture 
and mouse xenografts on a single-cell level. 
4.5 Discussion 
OMI is advantageous for live cell and animal imaging due to several features, including 
direct and dynamic assessment of cellular metabolism in vivo, cellular and sub-cellular resolution 
imaging capabilities, rapid acquisition, low-cost, use of intrinsic signals (no contrast agents, no 
radioactivity), and high sensitivity to metabolic changes.  Our results have significant implications 
for rapid assessment of drug action in pre-clinical models, which would greatly accelerate drug 
development studies.  
These results are the first to correlate OMI with a standard assay of metabolic behavior. 
While the optical redox ratio is inferred from theory as the relative rates of glycolysis and oxidative 
phosphorylation within cells, we confirm a strong positive correlation (r = 0.89, P=0.03) with a 
standard measure of cellular glycolytic levels (Fig. 4.3). In contrast, NADH m and FAD m are not 
correlated with the glycolytic index (Appendix A Table A.2).  The proportion of free NADH (1) 
has been interpreted as an analog to the optical redox ratio (27); however, we did not find a 
correlation between the optical redox ratio and NADH 1 (Appendix A Table A.2). Given the 
physical nature of these fluorescence lifetime measurements, which are sensitive to protein-
binding, relative fractions of free and bound components, and proximity to quenchers, it is not 
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surprising that they are sensitive to more cellular processes than just glycolysis. For example, 
changes in the distribution of NADH and FAD enzyme binding sites associated with preferred 
metabolic pathways in breast cancer sub-types may be responsible for the changes in protein-
bound lifetimes between cell lines (36). The changes in the lifetimes of the free components of 
NADH and FAD may reflect changes in dynamic quenching (22). Taken together, the data (Fig. 
4.3, Appendix A Table A.2) indicate that the redox ratio, NADH and FAD lifetimes provide 
independent measures of cellular metabolism and the molecular microenvironment. The varied 
dynamics of these endpoints due to HER2 inhibition suggest that all three OMI endpoints provide 
added value when measured together.  
We used these tools to differentiate breast cancer cells by sub-type, defined by ER and/or 
HER2 expression or absence (Fig. 4.3).  OMI is sensitive to metabolic behaviors caused by ER 
and HER2 (Fig. 4.3), known oncogenic drivers of glycolytic metabolism in breast cancer cells (3, 
8, 37, 38).  ER regulates gene expression of glucose transporter proteins and proteins involved in 
oxidative phosphorylation and the citric acid cycle such as isocitrate dehydrogenase which actively 
reduces NAD+ to NADH (37, 39-41).  HER2 mediates metabolism through signaling of the 
PI3K/Akt/mTOR pathway which directs transcription of glycolytic enzymes (2, 3).  When 
combined, the redox ratio and NADH lifetime fully separate the distinct sub-types of breast cancer 
(Fig. 4.3d), indicating that the complementary measures of the redox ratio and fluorescence 
lifetime allow robust characterization of cellular metabolism and molecular microenvironments 
associated with breast cancer sub-types.   
We further show that the OMI endpoints optical redox ratio, NADH m, and FAD m, reflect 
impaired metabolic activity in trastuzumab-responsive BT474 cells (Fig. 4.4) in vitro, suggesting 
a large metabolic response of HER2-amplified cells to trastuzumab. Only one of the OMI 
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endpoints, NADH m, decreased in the trastuzumab-resistant HR6 cells (Fig. 4.4).  While HR6 
cells maintain HER2-overexpression and PTEN and P-Akt protein levels in the presence of 
trastuzumab, blockage of HER2 with trastuzumab may affect internal signaling (28).  Due to its 
highly sensitive nature, NADH m may be reporting such minute metabolism differences.   
A subset of variables also resolved metabolic changes induced by trastuzumab in poorly 
responsive HER2-amplified cells (MDA-MB-361) in vitro (Fig. 4.4).   Behavioral heterogeneity 
inherent to the MDA-MB-361 cell line suggests that 25% of the overall population would be 
growth inhibited by trastuzumab in vitro (42).   Our data detected a 30% sub-population within 
MDA-MB-361 cells that responded to trastuzumab through decreased redox ratios (Fig. 4.4d), 
suggesting correlative evidence that high resolution optical imaging is capable of detecting 
responders and non-responders at the single cell level in the context of a heterogeneous tumor cell 
population with a mixed response. The complementary metabolic information gained from the 
OMI endpoints allowed identification of a large metabolic response to trastuzumab (BT474) but 
also resolved negative (HR6) and partial (MDA-MB-361) responses, demonstrating high 
sensitivity and resolution of OMI.    
Finally, we measured the in vivo metabolic response to trastuzumab in HER2-
overexpressing mouse xenografts. Trastuzumab-induced metabolic repression in BT474 and 
MDA-MB-361 tumors was detected by 48hrs post-treatment (Fig. 4.5, 4.7).   The redox ratio and 
FAD m did not change in trastuzumab-resistant HR6 tumors treated with the antibody (Fig. 4.6).  
However, NADH m decreased in trastuzumab-treated HR6 tumors compared to controls at 48hrs 
(Fig. 4.6), which was consistent with the in vitro results (Fig. 4.4).  Modeling of the inter-cellular 
variation of MDA-MB-361 xenograft tumors identified two sub-populations in response to 
trastuzumab for the optical redox ratio and FAD m (Fig. 4.7), suggesting in vivo cell-to-cell 
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heterogeneity. This heterogeneous in vivo response is consistent with the in vitro results (in Fig. 
4.4).  We attempted to include only tumor cells in our image analysis, by evaluation of the cell 
morphology with respect to histology, but acknowledge that non-tumor cell populations could have 
been included in this analysis.  We speculate the greater intra-cellular variation of both the redox 
ratio and FAD m  observed in the MDA-MB-361 tumors treated with trastuzumab (Fig. 4.7h) is 
due to heterogeneous responses of individual mitochondria (43).  Elucidation of this possibility 
will require additional research. 
The tumor size measurements and IHC analysis of cellular proliferation and apoptosis were 
consistent with an antitumor effect of trastuzumab against BT474 tumors and a lack of an effect 
against HR6 tumors (Fig. 4.5, 4.6). Tumor size measurements first identified a difference in control 
versus trastuzumab-treated BT474 tumor size at 8 days after treatment was initiated (Fig. 4.5a), 6 
days later than the first significant change in OMI endpoints between control and trastuzumab-
treated tumors (day 2, Fig. 4.5g).  While Ki67 staining of BT474 tumors identified reduced 
proliferation in BT474 tumors treated with trastuzumab at 2 and 5 days post-treatment, OMI is 
advantageous over IHC as a measure of tumor response because OMI provides a dynamic measure 
of cellular metabolism and can be performed in vivo and over time within the same animal. While 
in vivo OMI data is presented here, OMI endpoints remain robust measures of metabolism in 
freshly excised tissues (21) allowing implementation of this metabolic imaging technique in 
situations when in vivo measurements are not feasible.   
FDG-PET has also been explored as a potential tool for assessing response to therapeutic 
agents.  Consistent with a prior study (7), in this study, FDG-PET failed to identify a metabolic 
difference between control and trastuzumab-treated BT474 tumors (Fig. 4.5).  FDG uptake did 
increase over time as the control tumors continued to grow.  Unlike OMI, PET cannot resolve 
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cellular sub-populations of differing response that are critical for investigating drug resistance 
mechanisms (7, 13-17, 44).  Furthermore, PET requires large upfront and continued costs due to 
radiolabeled tracers, while OMI can be implemented in low-cost, wide-field or confocal 
microscopes without the need for external dyes (45-47).  In addition, OMI allows for fast, accurate, 
dynamic in vivo monitoring of early therapeutic response, potentially reducing time and animals 
required for drug development.  Our studies have focused on breast cancer and HER2 inhibition, 
but the methods developed are also applicable to the array of diseases that are treated with 
metabolism-modulating drugs (48-50).    
The results of this study validate OMI as a powerful tool for quantifying cellular 
metabolism, which is an active area of investigation across multiple diseases. As we demonstrate 
using human breast cancer cells and xenografts, optical metabolic measurements are sensitive to 
distinct tumor cell sub-types.  Additionally, we present significant findings suggesting that OMI 
can be used as an early indicator of metabolic response to treatment with a targeted therapy, both 
in cell culture and in vivo.  These results represent the culmination of multiple imaging 
technologies, analysis tools, and their validation with standard assays and FDG-PET.  The results 
in breast cancer cells and xenografts provide the first direct measurements relating cellular 
metabolism, HER2 expression, HER2 inhibition, and resistance to HER2 inhibitors in live cells 
and tissues.  Additionally, these methodologies are potentially broadly applicable outside the 
cancer and imaging communities, including those in drug development and metabolism research 
across multiple diseases.  While we see OMI as an immediately powerful tool in preclinical 
models, it also may directly impact patient care as an adjunct to current practice, either on freshly 
excised tissue (21) or through in vivo endoscopes adapted for fluorescence imaging.  
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CHAPTER 5 
Ex Vivo Optical Metabolic Measurements from Cultured Tissue  
Reflect in Vivo Tissue Status 
Walsh AJ, Poole KM, Duvall CL, Skala, MC.  “Ex vivo optical metabolic measurements from 
culture tissue reflect in vivo tissue status.”  J Biomed Optics. 2012;17(11):116015. 
 
5.1 Abstract 
Optical measurements of metabolism are ideally acquired in vivo; however, intravital 
measurements are often impractical. Accurate ex vivo assessments would greatly broaden the 
applicability of optical measurements of metabolism.  In this study, we investigate the use of live 
tissue culture experiments to serve as a surrogate for in vivo metabolic measurements.  To validate 
this approach, NADH and FAD fluorescence intensity and lifetime images were acquired with a 
two-photon microscope from  hamster cheek pouch epithelia in vivo, from biopsies maintained in 
live tissue culture up to 48 hours, and from flash frozen and thawed biopsies.  We found that the 
optical redox ratio (fluorescence intensity of NADH / FAD) of the cultured biopsy was statistically 
identical to the in vivo measurement until 24h, while the redox ratio of the frozen-thawed samples 
decreased by 15% (p<0.01).  The NADH mean fluorescence lifetime (m) remained unchanged 
(p>0.05) during the first 8h of tissue culture, while the NADH m of frozen-thawed samples 
increased by 13% (p<0.001).  Cellular morphology did not significantly change between in vivo, 
cultured, and frozen-thawed tissues (p>0.05).  All results were consistent across multiple depth 
layers in this stratified squamous epithelial tissue.  Histological markers for proliferation and 
apoptosis also confirm the viability of tissues maintained in culture.  This study suggests that short-
term ex vivo tissue culture may be more appropriate than frozen-thawed tissue for optical metabolic 
and morphologic measurements that approximate in vivo status. 
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5.2 Introduction 
Optical imaging is a powerful tool for monitoring the metabolic status of cells and tissues 
due to the auto-fluorescence properties of the metabolic co-enzymes NADH and FAD.  NADH is 
the principal electron acceptor in glycolysis and electron donor in oxidative phosphorylation while 
FAD is the primary electron acceptor in oxidative phosphorylation.  The optical "redox ratio" 
(fluorescence intensity of NADH divided by that of FAD) is widely used to monitor cellular 
metabolism in cells, ex vivo tissues, and in vivo tissues in order to diagnose disease (1, 2) , monitor 
cellular differentiation (3), and characterize other metabolic perturbations (4, 5).   
Recently, the fluorescence lifetimes of NADH and FAD have also been evaluated as optical 
metabolic biomarkers (2, 6-10).  The fluorescence lifetime is the time a fluorophore remains in the 
excited state before returning to the ground state and emitting a fluorescent photon.  Fluorescence 
lifetimes are self-referenced and more robust than fluorescence intensity measurements in regard 
to inter-system and intra-system variability (7).  Additionally, fluorescence lifetimes are sensitive 
to changes in pH, temperature, and proximity to quenchers (7, 11).  Often, the fluorescence lifetime 
decay curves for NADH and FAD are each fit to a two-component exponential decay (2, 6, 12).  
The two lifetime components represent the two most probable configurations of NADH and FAD, 
which are free in solution or bound to a protein (12, 13).  The short lifetimes and long lifetimes of 
NADH represent the free and protein-bound components, respectively.  Conversely, the short and 
long lifetimes of FAD represent the protein-bound and free components, respectively.  For these 
reasons, the fluorescence lifetimes of NADH and FAD are robust reporters for metabolic 
differences between tissues.  Auto-fluorescence lifetime imaging has been used for monitoring 
pre-cancers and cancers in oral cancer models and breast cancer models (2, 6, 10, 14-18).  
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Ideally, optical metabolic measurements should be performed in vivo.  Thus, these 
techniques have been predominantly used in easily accessible tissues, such as the skin and oral 
cancer models (2, 8, 19, 20).  The growing development of endoscopes capable of confocal 
fluorescence microscopy is enabling measurements of previously inaccessible tissue (21, 22).  Yet, 
fluorescence endoscopes are still somewhat specialized, cumbersome, and represent a significant 
technical and regulatory burden for feasibility studies, especially in tissue sites that are difficult to 
access (i.e. outside of the gastrointestinal tract).  As a result, many feasibility studies in this field 
are performed on fixed tissue slides, immortalized cell lines, or excised tissue (6, 15, 23), which 
may not accurately represent the metabolic state of live, intact tissue.  Furthermore, the use of 
optical metabolic techniques would be greatly expanded by the development of an effective tissue 
handling protocol that allowed for ex vivo tissue interrogation that accurately reflects the in vivo 
metabolic state.  However, the effect of ex vivo sample preparation on optical metabolic 
measurements has not been explored.   
The goal of this study is to investigate live tissue culture as an alternative sample 
preparation for optical metabolic imaging when in vivo measurements are not feasible.  Current 
protocols to represent in vivo metabolic activity in excised tissue require flash-freezing of the tissue 
(4), however such a procedure requires tissue submersion in liquid nitrogen and may induce 
changes in sensitive fluorescence lifetime endpoints.  Live tissue culture may address these 
limitations.  Live tissue culture maintains the tissue in tissue culture media that provides oxygen, 
glucose, and other necessary nutrients.  Furthermore, chilled tissue media has been used in 
previous optical studies (23, 24) because it contains more dissolved oxygen than media maintained 
at body temperature.  However, this chilled media procedure for maintaining tissue culture has not 
been rigorously compared to in vivo metabolic measurements.   
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We hypothesized that, for a discrete period of time following harvest, excised tissue 
maintained in chilled tissue culture media will provide metabolic measurements that are 
representative of the in vivo metabolic state.  To test this hypothesis, the NADH and FAD 
fluorescence intensity and lifetime, as well as cellular morphology, of the cheek pouch epithelium 
of 16 Golden Syrian hamsters were measured in vivo, ex vivo from biopsies maintained in live 
culture over 48 hours, and ex vivo from flash frozen and thawed tissue biopsies.  Both high and 
low time resolution protocols were followed to investigate both short-term and long-term changes 
in the cellular metabolism of the cultured biopsies.   For the high resolution protocol, optical 
metabolic measurements were obtained every 30 minutes for 4 hours from a single epithelial depth.  
For the low resolution protocol, images of two different epithelial depths were acquired at 4, 8, 12, 
24, and 48 hours.   
5.3 Materials and Methods 
5.3.1 Hamster Protocol 
For this study, sixteen male Golden Syrian hamsters were evaluated (103 ± 5 g).  This study 
was approved by the Vanderbilt University Animal Care and Use Committee and meets the 
National Institutes of Health guidelines for animal welfare.  Hamsters were anesthetized with a 
mixture of 200 mg/kg ketamine and 5 mg/kg xylazine with an intraperitoneal injection.  The 
mucosa of the cheek pouch was exposed and secured against a coverslip for imaging.  All images 
were acquired from the stratum spinosum or basal epithelial layers at depths of approximately 20 
µm or 30 µm, respectively.  In vivo measurements of the cheek pouch were obtained from the 
cheek epithelium.  Then, two 6 mm biopsies of the cheek pouch were acquired immediately after 
the in vivo measurements from the same region that was imaged in vivo.  For 10 hamsters, one 
biopsy per hamster was flash-frozen in liquid nitrogen (frozen-thawed sample).  This sample was 
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placed immediately in a -80°C freezer.  The second 6 mm biopsy (live tissue culture sample) was 
immediately placed in a glass-bottom petri dish with chilled (3° C), sterile tissue culture media 
(DMEM without phenol red, GIBCO).  The stratum spinosum layer of the epithelium was 
immediately measured and sequentially measured every 30 minutes for 4 hours after the time of 
the biopsy from the live tissue culture sample.  For this high time-resolution protocol, a single 
tissue layer was interrogated to allow for comparisons between time-points and to minimize tissue 
warming at room temperature during imaging.  This high time-resolution, short time-frame 
protocol was chosen to investigate acute changes in the metabolism of the tissue immediately after 
excision.  For the remaining six hamsters, after in vivo imaging, two biopsies were obtained and 
both were placed in chilled tissue media for the long-term (low time-resolution) imaging studies.  
This low time-resolution, long time-frame protocol investigates the maximum duration over which 
optical metabolic measurements in live culture correspond with in vivo measurements.  One of the 
biopsies was imaged after 4, 8, 12, 24, and 48 hours at two different depths corresponding to the 
spinous and basal regions.  The second biopsy was fixed in formalin for histological analysis after 
4, 8, 12, 24, or 48 hours in live culture.  Each measurement in live tissue culture over this time 
course was conducted within 5 minutes at room temperature (22°C), and the sample was 
refrigerated (3°C) between measurements.   Prior to measurement of the frozen biopsy, the 
specimen was thawed in chilled tissue culture media for 15-20 minutes (25).  Each animal was 
sacrificed after both biopsies had been obtained. 
5.3.2 Imaging Instrumentation 
All data were acquired using a custom built, commercial two-photon imaging system (Prairie 
Technologies, Middleton, WI) within the Biophotonics Laboratory at Vanderbilt University.  A 
titanium sapphire laser (Coherent Inc., Santa Clara, CA) provided the excitation source.  The 
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excitation and emission light were coupled through an inverted microscope (TiE; Nikon, Melville, 
NY) with either a 40X water-immersion objective (1.15 NA) or a 40X oil-immersion objective 
(1.3 NA).  For NADH excitation and FAD excitation, the laser was tuned to 750 nm and 890 nm, 
respectively.  The average power incident on the sample was ~7.5-7.8 mW for NADH excitation 
and ~8.4-
images.  NADH and FAD images were acquired sequentially.  A 400-480 nm bandpass filter 
isolated NADH emission onto the PMT detector.  A dichroic mirror directed wavelengths greater 
than 500 nm onto a 500—600 nm bandpass filter, thus removing collagen second harmonic 
generation (SHG) signals from the FAD image.  Fluorescence lifetime images were acquired with 
time-correlated single photon counting electronics (SPC-150, Becker and Hickl, Germany) and a 
GaAsP PMT (Hamamatsu, Japan).  Isolation of NADH and FAD collection for this system was 
confirmed by treating cells with cyanide (26) and observing an increase in NADH fluorescence 
intensity and a decrease in FAD fluorescence intensity (data not shown). 
The instrument response function was measured by imaging the SHG signal of urea crystals 
with excitation at 900 nm.  The instrument system response has a full width at half-maximum of 
260 ps.  This measured system response was used in the lifetime fit model.  The fluorescence 
lifetime of a standard, Fluoresbrite YG microspheres (20 µm, Polysciences Inc.), was measured 
daily.  Fit to a single decay curve, the fluorescence lifetime of the microspheres has a value of 
2.14± 0.05 ns (n=14), which is consistent with previous studies (2, 6, 10, 27).   
5.3.3 Fluorescence Lifetime Imaging 
For the in vivo measurement, the hamster was placed face down with the cheek pouch 
mucosa in contact with a cover slip and exposed to the objective.  The epithelium of the cheek 
pouch was identified and imaged at a depth of ~20 µm.  This depth was imaged across all samples 
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(in vivo, ex vivo, and frozen tissues), as determined by stage translation distance from the surface 
of the tissue and by visual inspection of cell size.  The six hamsters imaged for the longer live 
culture time course were also interrogated at a depth of ~30 µm, corresponding to the basal 
epithelium. One NADH lifetime measurement was acquired over an integration time of 60s.  
Sequentially, an FAD lifetime image was acquired, also for 60s, at the same location.  Imaging 
parameters such as laser power, PMT voltage, pixel integration time, and lifetime collection time 
were maintained across all animals and measurements including the ex vivo and frozen samples.  
Photon count rates (~5 x 105 photons/s) were maintained throughout all imaging sessions, ensuring 
that photobleaching did not occur.  In addition, it was assured that no quantifiable change in 
fluorescence intensity was observed between sequential images of the same location, further 
confirming that photobleaching did not occur. 
5.3.4 Quantification of Cellular Morphology 
In order to monitor any change in cellular morphology in the live tissue culture, cell size 
and nuclear-cytoplasmic ratio (NCR) were computed from the high resolution NADH fluorescence 
images.  A region of well-defined cells was identified within each image and the total number of 
cells in the region of interest (ROI) was counted.  The average cell cross sectional area was 
determined by dividing the total number of pixels within the ROI (consisting of nuclear and 
cytoplasmic pixels) by 2.  
Next, each image was thresholded to assign pixels within the nucleus to 0 and pixels within the 
cytoplasm to 1 for quantification of the number of nuclear pixels and cytoplasmic pixels.  The 
NCR was calculated by dividing the number of nuclear pixels by cytoplasmic pixels.  This analysis 
was done in ImageJ (NIH, http://rsbweb.nih.gov/ij/). 
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5.3.5 Quantification of the Optical Redox Ratio 
Fluorescence intensity images were constructed from the fluorescence lifetime images by 
integrating over time, summing all photons for each pixel.  Any regions of non-cellular structures, 
such as wrinkles within the tissue, were excluded from analysis.  Additionally, a threshold was 
applied to isolate fluorescence from the cytoplasm and exclude nuclear fluorescence.  The redox 
ratio was computed for each pixel by dividing the NADH fluorescence intensity by the FAD 
fluorescence intensity.  The mean redox ratio for the image was computed by averaging the redox 
ratios from all cells, excluding the nuclear region.  For each hamster, the cultured biopsy and frozen 
biopsy redox ratio measurements were normalized to the matched in vivo measurement to account 
for inter-animal and system variation.  This analysis was done in Matlab (Natick, MA).  
5.3.6 Quantification of the Fluorescence Lifetime  
A commercial software program, SPCImage (Becker and Hickl, Germany), was utilized to 
analyze the fluorescence decay data.  In SPCImage, the measured system response of the second 
harmonic generation of urea crystals was de-convolved from the data.  The resulting decay curve 
was then fit to the following model: 
𝐼(𝑡) = 𝛼1𝑒𝑥𝑝
−𝑡/𝜏1 + 𝛼2𝑒𝑥𝑝
−𝑡/𝜏2 + 𝐶 
where I(t) is the fluorescence intensity at time t after the excitation pulse, 1 and 2 are the 
fractional contributions of the first and second emitting species (i.e. 1 + 2 = 1), 1 and 2 are the 
fluorescence lifetimes of the first and second emitting species, and C accounts for background 
light.  Within the SPCImage software, after a threshold was set to isolate cytoplasmic fluorescence, 
the fluorescence decay for each pixel was evaluated.  Then, matrices of 1, 2, 1, and 2 were 
exported for further analysis.  The mean 1, 2, 1, and 2 for each image were averaged across all 
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pixels in Matlab (Natick, MA).  Additionally, the mean fluorescence lifetime (m) was computed 
as a weighted average of 1 and 2. 
𝜏𝑚 = 𝛼1𝜏1 + 𝛼2𝜏2 
5.3.7 Statistical Analysis 
A Wilcoxon rank sum test was used to test for differences between the in vivo mean values 
of the redox ratio, NADH and FAD1, 2, m, and 1/2 ratio and each cultured biopsy time point.  
Likewise, a Wilcoxon rank sum test was used to test for significance between optical 
measurements from in vivo and frozen-thawed tissue.  For all tests, an α level < 0.05 indicates 
significance. 
5.3.8 Histological Analysis 
Hamster cheek pouch biopsies were collected and placed in chilled tissue media and 
refrigerated for 4, 8, 12, 24, or 48 hours.  The biopsy was placed in buffered formalin, paraffin 
embedded, sliced, and stained for Ki67 (a marker of proliferation) and cleaved caspase-3 (a marker 
of apoptotic cells).  Traditional H&E staining was also performed to help visualize the epithelial 
layer.  Ki67 and cleaved caspase-3 staining protocols were verified in positive control samples of 
the mouse small intestine and mouse thymus, respectively (data not shown). 
5.4 Results  
Optical redox ratio values and NADH and FAD fluorescence lifetime values were acquired 
from the cheek pouch epithelium of sixteen hamsters in vivo, from a cultured biopsy, and from a 
frozen-thawed biopsy.  Fig. 5.1 shows representative images of the normalized redox ratio, mean 
NADH lifetime, and mean FAD lifetime from the spinosum and basal layers of the epithelium in 
vivo, cultured tissue at 4, 12, 24, and 48 hours post excision, and frozen-thawed tissue for the 
normal hamster epithelium.  The redox ratio of the in vivo tissue appears to be similar to the 
cultured biopsy at 4 hours and less than the cultured biopsy at 24 hours.  The frozen-thawed tissue 
100 
 
appears to have a lower redox ratio than the in vivo tissue (Fig. 5.1).  For the mean lifetimes of 
both NADH and FAD, the cultured tissue appears to have a similar lifetime to the in vivo tissue 
after 4 hours; however, the frozen tissue shows an increased mean NADH lifetime relative to in 
vivo values (Fig. 5.1).  No significant changes in cellular morphology are observed in the cultured 
or frozen tissue relative to the in vivo tissue measurements.   
 
Figure 5.1. Representative OMI images of live cultured tissues. Representative redox ratio (first 
row), NADH m (second row), and FAD m (third row) images from in vivo  hamster epithelium at 
the basal (first column) and spinosum (second column) regions, tissue maintained in live culture 
4, 12, 24, and 48 hours after excision (third-sixth columns), and frozen-thawed tissue (last column).  
Each image is 100x100 μm. m is the mean lifetime (1*α1 + 2*α2). 
 
To compare deviations from the in vivo optical redox ratio in the cultured and frozen-
thawed tissue samples, the optical redox ratio was normalized to the in vivo measurement.  The 
variance in the redox ratio among in vivo measurements from the same hamster is 0.053, 
corresponding to a coefficient of variation (COV) of 8%.  Fig. 5.2 shows the normalized redox  
ratio of the in vivo tissue, cultured tissue over 4h, and frozen-thawed tissue.  No significant changes 
(p > 0.05) in the redox ratio are observed at any time point for the 4 hours the cultured biopsy was 
imaged (Fig. 5.2A).  The mean redox ratio of the cultured biopsy up to 4 hours after excision is 
within 8% of the in vivo value.  The redox ratio of the frozen-thawed sample, however, is 85% of 
the in vivo tissue measurement and this difference is significant (p < 0.01).   
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Figure 5.2. Redox ratio of live cultured tissues and frozen thawed tissues. A.  The redox ratio 
value of frozen-thawed (F) hamster epithelium is significantly reduced from the in vivo (IV) value, 
while live tissue culture maintains redox ratio values similar to in vivo measures over the 4 hours 
of live culture measurement (mean ± SE of n=10 measurements). B.  The redox ratios of the 
spinosum and basal epithelial layers of the live-culture biopsies over 48 hours (mean ± SE of n=6).   
Asterisk denotes significant difference between in vivo and the indicated measurement (* p < 0.05; 
** p < 0.01). 
 
The metabolic activity of the stratified squamous epithelium is known to change with 
depth, with the most metabolically active cells occupying the basal layer of the epithelium (28).  
Therefore, an analysis of the metabolic change in multiple epithelial layers was evaluated over 
time.  The redox ratio of the basal region is greater than that of the spinosum region at all time-
points (p < 0.05, Fig. 5.2B).  No significant change in the redox ratio is observed with time in live 
culture until 24 hours, when the redox ratio of both the spinosum and basal cells increases (p < 
0.05, Fig. 5.2B).  By 48 hours, the redox ratio in both regions decreases (p < 0.05, Fig. 5.2B). 
 
Table 5.1.  Mean (SE) for in vivo measurements of NADH and FAD lifetime components 
(n=10). m is the mean lifetime (1*α1 + 2*α2). 
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Quantitative parameters (mean ± SE) of NADH and FAD fluorescence lifetimes (m, 1, 2, 
and 1/2) for the in vivo images are presented in Table 5.1.   The mean lifetime (m) is a weighted 
average of the short (1) and long lifetime (2) components.   Changes in hamster epithelium NADH 
fluorescence lifetime components relative to the in vivo values are shown in Fig. 5.3A.  Over the 
first four hours, all of the mean NADH m values from the live cultured biopsy are within 2.5% of 
the in vivo value (p > 0.05), while the frozen-thawed NADH m is +13% of the in vivo value which 
is a statistically significant difference (p < 0.001; Fig. 5.3A).  Similarly, for NADH 1, all cultured 
biopsy measurements from the first four hours are within 2% of the in vivo value (p > 0.05) while 
the frozen-thawed 1 is +7% (p < 0.01; Fig. 5.3A).  For NADH 2, the cultured biopsy values are 
within 1% of the in vivo NADH 2 value (p > 0.05) and the frozen-thawed mean 2 is +2% (p < 
0.05; Fig. 5.3A).  The four hour cultured biopsy NADH 1/2 measurements are within 10% of 
the in vivo 1/2 ratio (p > 0.05) while the frozen-thawed biopsy mean 1/2 is 81% of the in 
vivo value (p < 0.05; Fig. 5.3A).   
 
Figure 5.3. NADH and FAD lifetimes of live cultured and frozen thawed tissues.  Changes 
(mean ± SE of n=10 measurements) relative to in vivo (IV) values of NADH (A) and FAD (B) m 
(diamond), 1 (square), 2 (triangle), and 1/2 (cross) observed in tissues maintained in live culture 
for 4 hours, and in frozen-thawed (F) tissues. m is mean lifetime (1*1 + 2*2).  Asterisk denotes 
significant difference between in vivo and indicated measurement (* p < 0.05; ** p < 0.01; *** p 
< 0.001). 
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Similar trends are observed in the FAD lifetime values (Fig. 5.3B).  Over the first 4 hours, 
the mean FAD m of the cultured biopsy increases slightly but stays within 8% of the in vivo FAD 
m (p > 0.05; Fig. 5.3B).  The frozen-thawed FAD m is 9.5% greater than the in vivo FAD m (p < 
0.05, Fig. 5.3B).  Changes in FAD 1 are within 6% for the cultured biopsy measurement and 
frozen-thawed samples (p > 0.05; Fig. 5.3B).  Likewise, the FAD 2 values for the cultured and 
frozen-thawed samples vary less than 4% from the in vivo FAD 2 (p > 0.05; Fig. 5.3B).  While no 
significant difference is observed in the FAD 1/2 ratio between the four hour cultured biopsy 
and the in vivo FAD 1/2 (p-value > 0.05), the frozen-thawed measurement is 83% of the in vivo 
FAD 1/2 ratio (p < 0.05; Fig. 5.3B). 
 
Figure 5.4.  Relative NADH lifetime changes over 48hr. Changes (mean ± SE of n=6 
measurements) relative to in vivo (IV) values of NADH m (A), 1 (B), 2 (C), and 1/2 (D) 
observed from both the spinosum (diamond) and basal (square) epithelial layers of tissues 
maintained in live culture for 48 hours.   m is mean lifetime (1*1 + 2*2).  Asterisk denotes 
significant difference between in vivo and indicated measurement (* p < 0.05; ** p < 0.01). 
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When the cultured biopsy is assessed past four hours, significant changes in the NADH 
fluorescence lifetime components are observed (Fig. 5.4).  Both the spinosum and basal layers 
follow the same trends.  By 12 hours, NADH m significantly decreases by 10% and remains 
significantly lower than the in vivo value out to 48h in both the spinosum and basal layers (p < 
0.05, Fig. 5.4A).  Again, at 12 hours after excision, NADH 1 and 2 significantly decrease in both 
tissue layers (p < 0.05, Fig. 5.4B,C).  NADH 1/2 is increased from the in vivo measurement at 
12, 24, and 48 hours post excision (p < 0.05, Fig. 5.4D).   
 
Figure 5.5.  Relative FAD lifetime changes over 48hr. Changes (mean ± SE of n=6 
measurements) relative to in vivo (IV) values of FAD m (A), 1 (B), 2 (C), and 1/2 (D) observed 
from both the spinosum (diamond) and basal (square) epithelial layers of tissues maintained in live 
culture for 48 hours.  m is mean lifetime (1*1 + 2*2).  Asterisk denotes significant difference 
between in vivo and indicated measurement (* p < 0.05, ** p < 0.01). 
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Changes in the FAD lifetime of the spinosum layer are observed in the cultured biopsy at 
48 hours, when the FAD m is significantly increased over the in vivo value (p < 0.01, Fig. 5.5A).  
Both FAD 1 (p < 0.01) and 2 (p < 0.01) of the spinosum also increase at 48 hours (Fig. 5.5B,C).  
FAD 1/2 decreased at 48 hours in both the spinosum (p < 0.05) and basal cells (p < 0.05, Fig. 
5.5D). 
 
Figure 5.6. Cell morphology of fresh cultured and frozen-thawed tissues. Cellular 
morphology, as measured by cell cross-sectional area (A, B) and nuclear-to-cytoplasmic ratio (C, 
D) remains unchanged (p>0.05) from in vivo (IV) values within both the spinosum and basal 
epithelial layers of tissues maintained in live culture over 48 hours and in frozen-thawed (F) tissues 
(mean ± SE of n=10 [n=6 for B,D] measurements of a minimum of 20 cells per image). 
 
Cellular morphology is maintained across the tissues regardless of preservation method 
(Fig. 5.6).  No significant change (p > 0.05) is measured in the average cellular cross sectional area 
between the in vivo tissue, cultured biopsy, and frozen biopsy (Fig. 5.6A, B).  Likewise, the NCR 
remains unchanged (p > 0.05) among the in vivo tissue, cultured biopsy, and frozen biopsy (Fig. 
5.6C,D).   
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Figure 5.7.  Representative histology of the hamster epithelium.  H&E staining demonstrates 
an intact epithelium (first row).  Nuclear Ki67 staining (brown) of the basal cells suggests cellular 
proliferation at each time point (middle row).  An absence of staining by anti-cleaved caspase-3 
suggests no apoptosis (third row).   Images were acquired using a 40X air objective. 
 
 
Histological analysis further confirms that the live tissue culture method maintains tissue 
viability.  Hematoxylin and eosin stains reveal similar structure in the epithelial layer of the tissue 
at 4, 12, 24, and 48 hours post excision (Fig. 5.7).  Positive staining with antibodies against Ki67 
reveals proliferating cells in the basal layer at all time points (Fig. 5.7).  Furthermore, no apoptotic 
cells are observed in cleaved-caspase 3 stains of the epithelium at any time point (Fig. 5.7).  
Together, the histological analysis suggests that the cells of the hamster epithelium remain alive 
in tissue culture for 48 hours post-excision. 
5.5 Discussion 
The goal of this study is to determine whether optical metabolic imaging of ex vivo tissues 
maintained in live culture reflects in vivo measurements.  Optical endpoints include the optical 
redox ratio, NADH fluorescence lifetimes, and FAD fluorescence lifetimes, which are measured 
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from in vivo tissue, a biopsy maintained in chilled tissue media, and a flash-frozen and thawed 
biopsy.  Minimal changes, within 10% for the redox ratio and within 8% for the lifetime values, 
were observed between the in vivo hamster epithelium and the cultured tissue through 8 hours 
post-excision.  However, statistically significant changes were observed in the frozen-thawed 
tissue.  These results suggest that optical metabolism measurements from cultured tissue within 8 
hours post excision represent the in vivo metabolic state of the tissue, especially when compared 
to frozen-thawed tissue.   
 Live tissue culture is used in many applications, including optical metabolic imaging and 
biochemical metabolic studies, to maintain viability of excised tissue (23, 29-31).  However, the 
temporal impact of ex vivo culture on the metabolic state of tissues has not been quantitatively 
assessed previously.  Often, studies use the tissue for several days (30) rather than the few hours 
investigated here.  Cell viability studies have shown that for epithelial tissue, less than 2% cell 
death occurs over the first 5 days (30).  However, no previous studies have confirmed that this live 
tissue culture approach provides optical metabolic measurements that are consistent with in vivo 
values, as we have shown in the current study.  This live tissue culture approach is particularly 
attractive for optical imaging because these methods interrogate superficial layers of tissue (~200 
m for two-photon microscopy, depending on tissue type), so that oxygen and nutrients can diffuse 
into the tissue and maintain viability (32, 33).  These superficial interrogation volumes also avoid 
the necrotic and hypoxic cores that are found in some live tissue culture preparations (34).  
The optical redox ratio has been previously used to quantify metabolic differences among 
normal tissue, pre-cancerous tissue, and cancerous tumors (1, 2, 26, 35, 36).  In the current study, 
two epithelial depth layers were interrogated because stratified squamous epithelial tissues are 
known to have a gradient of cellular metabolic activity, with the basal cells being most active and 
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the superficial cells being least active (2, 28).  As shown in Fig. 5.2B, the redox ratio of the basal 
region is greater (p<0.05) than the spinous region in vivo and at every time point during the live 
culture experiment, as expected.  Additionally, Fig. 5.2A suggests that the optical redox ratio of 
frozen-thawed tissue does not completely describe the in vivo metabolic state.  While the optical 
redox ratio is significantly reduced in frozen-thawed samples (p < 0.01), no significant difference 
is observed in the cultured tissue until 24 hours after biopsy (Fig. 5.2B).  The change in redox ratio 
in the frozen-thawed tissue is due to both a decrease in the NADH fluorescence intensity and an 
increase in FAD fluorescence intensity (data not shown), which is consistent with decreased 
NADH fluorescence intensity observed between fresh and frozen-thawed hamster and cervical 
tissues (25, 31).  The NADH and FAD fluorescence intensities did not change significantly in the 
live tissue culture over 4 hours (p > 0.05).   
The mean NADH lifetime of the hamster cheek epithelium is 1.149 ns (Table 5.1), which 
is consistent with previously reported NADH lifetime values (2, 6, 10, 37, 38).  The mean NADH 
fluorescence lifetime is the averaged effect of the free and protein-bound lifetime components (2, 
11).  While only minimal changes are observed in the NADH lifetime components of the cultured 
tissue until 12 hours post-biopsy, the frozen-thawed tissue has an increased m, 1, and 2 and a 
decreased 1/2 ratio (Fig. 5.3, 5.4).  These results indicate that the fluorescence lifetimes of both 
the bound and free NADH are increased in the frozen-thawed tissue and that a greater portion of 
NADH exists in the bound conformation.  Cells undergoing stress, such as apoptosis, have also 
shown increased mean NADH fluorescence lifetimes and increased proportions of bound NADH, 
suggesting that the freeze-thaw process exerts more stress than the live culture technique (37).  
Likewise, the observed FAD mean lifetime of 0.829 ns (Table 5.1) is similar to reported 
FAD lifetime measurements (2, 39).  For the FAD lifetime components, the frozen-thawed tissue 
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has an increased m and a decreased 1/2 (Fig. 5.3).  The decreased 1/2 ratio indicates an 
increase in the relative amount of free (long-lifetime) FAD.  This shift in relative amounts of the 
free and bound lifetime contributions explains the increased FAD m.  No significant change is 
observed in the FAD 1 and 2, so the FAD fluorescence lifetime may be less sensitive to the 
cellular stress involved in the freeze-thaw process than the NADH fluorescence lifetime. 
Consistent cellular morphology across the in vivo, cultured, and frozen-thawed tissue 
indicates maintenance of tissue structure.  The average cell cross sectional areas observed in the 
hamster epithelial spinosum and basal layers are 530 m2 and 200 m2, respectively (Fig. 5.6A, 
B), which is consistent with published cell cross sectional areas of hamster epithelium (40).  
Likewise, the observed NCR of the spinosum and basal layers of 0.2 and 0.4, respectively, (Fig. 
5.6C,D) is consistent with previous reports (40, 41).  The current study is also consistent with 
previous studies reporting that cell size and NCR do not change in frozen-thawed cells/tissues or 
in live tissue culture relative to in vivo values (41, 42). 
While the optical metabolic measurements varied from the in vivo values after 8 hours in 
live culture, cellular morphology and histological analysis revealed no changes in cellular 
morphology, proliferation, or cell death over the 48h time-course (Fig. 5.6, 5.7).  Therefore, optical 
metabolic imaging endpoints may be more sensitive to sub-cellular molecular changes than the 
histological or morphological analyses.  Previous studies of the live tissue culture method have 
used histology to verify cell viability (30, 33); however, our results suggest that molecular 
metabolic changes occur before changes in cellular proliferation or cell death.  Thus, optical 
metabolic imaging may be a more sensitive endpoint than histology for detecting changes in cell 
status.   
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To validate live tissue culture as an effective protocol for maintaining in vivo metabolic 
characteristics in excised tissue, the optical redox ratio, NADH fluorescence lifetime, and FAD 
fluorescence lifetime were quantified from hamster cheek epithelia in vivo, in live cultured 
biopsies followed for 48 hours, and in frozen-thawed samples.  The live tissue culture approach 
resulted in no significant change in any optical endpoint relative to in vivo measures until 12 hours, 
when a decreased NADH m was observed.  Several significant differences, including a reduced 
redox ratio, increased NADH m, and increased FAD m were observed in the frozen-thawed 
samples.  These results indicate that the live tissue culture method represents the in vivo state more 
accurately than the frozen-thawed procedure.  Therefore, when in vivo optical measurements are 
not feasible, excised tissue may be maintained in chilled tissue media up to 12 hours for close 
representation of in vivo metabolic states. 
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CHAPTER 6 
Quantitative Optical Imaging of Primary Tumor Organoid Metabolism  
Predicts Drug Response in Breast Cancer 
Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC, "Quantitative optical imaging of 
primary tumor organoid metabolism predicts drug response in breast cancer" Cancer Research, 
2014; 74(18): 5184-94. 
 
6.1 Abstract 
 
There is a need for technologies that predict the efficacy of cancer treatment in individual 
patients. We demonstrate that optical metabolic imaging of organoids derived from primary tumors 
can predict therapeutic response of xenografts and measure anti-tumor drug responses in human-
tumor derived organoids. Optical metabolic imaging quantifies the fluorescence intensity and 
lifetime of NADH and FAD, co-enzymes of metabolism. As early as 24 hours after treatment with 
clinically relevant anti-cancer drugs, the optical metabolic imaging index of responsive organoids 
decreased (p<0.001) and was further reduced when effective therapies were combined (p<5x10-6), 
with no change in drug-resistant organoids.  Drug response in xenograft-derived organoids was 
validated with tumor growth measurements in vivo and stains for proliferation and apoptosis. 
Heterogeneous cellular responses to drug treatment were also resolved in organoids. Optical 
metabolic imaging shows potential as a high-throughput screen to test the efficacy of a panel of 
drugs to select optimal drug combinations. 
6.2 Introduction 
With the ever-increasing number of drugs approved to treat cancers, selection of the 
optimal treatment regimen for an individual patient is challenging. Physicians weigh the potential 
benefits of the drugs against the side-effects to the patient.  Currently, drug regimens for breast 
cancer are chosen based on tumor expression of several proteins, including estrogen receptor (ER), 
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progesterone receptor (PR), and high levels of human epidermal growth factor receptor 2 (HER2), 
assessed in the diagnostic biopsy, and drug effectiveness is determined after weeks of treatment 
from tumor size measurements. A personalized medicine approach would identify the optimal 
treatment regimen for an individual patient and reduce morbidity from overtreatment. 
Current methods to assess therapy response include tumor size, measured by 
mammography, MRI, or ultrasound.  These methods evaluate the regimen that the patient received.  
Molecular changes induced by anti-tumor drugs precede changes in tumor size and may provide 
proximal endpoints of drug response.  Cellular metabolism may provide biomarkers of early 
treatment response, because oncogenic drivers typically affect metabolic signaling (1, 2).  Indeed 
FDG-PET has been explored as a predictor of response but lacks the resolution and sensitivity to 
accurately predict therapy response on a cellular level (3, 4).   
Optical metabolic imaging (OMI) provides unique sensitivity to detect metabolic changes 
that occur with cellular transformation (5-10) and upon treatment with anti-cancer drugs (11). OMI 
utilizes the intrinsic fluorescence properties of NADH and FAD, co-enzymes of metabolic 
reactions.  OMI endpoints include the optical redox ratio (the fluorescence intensity of NADH 
divided by the fluorescence intensity of FAD), the NADH and FAD fluorescence lifetimes, and 
the "OMI index" (a linear combination of these three endpoints).  The optical redox ratio provides 
a dynamic readout of cellular metabolism (12), with increased redox ratio (NADH/FAD) (8) 
observed in malignant cells exhibiting the Warburg effect (increased glycolysis despite the 
presence of oxygen (13)).  Fluorescence lifetime values report differences in fluorophore 
conformation, binding, and microenvironment, such as pH, temperature, and proximity to 
quenchers such as free oxygen (14).  OMI endpoints report early, molecular changes due to anti-
cancer drug treatment (11) and are powerful biomarkers of drug response.  
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Primary tumors can be cultured ex vivo as organoids, which contain the malignant tumor 
cells and the supporting cells from the tumor environment, such as fibroblasts, leukocytes, 
endothelial cells, and hematopoietic cells (15). Interactions between cancer cells and stromal cells 
have been shown to mediate therapeutic resistance in tumors (16). Therefore, organoid cultures 
provide an attractive platform to test cancer cell response to drugs in a relevant, "body-like" 
environment. Furthermore, multiple organoids can be generated from one biopsy, enabling high-
throughput tests of multiple drug combinations with a small amount of tissue. 
OMI of primary tumor organoids enables high-throughput screening of potential drugs and 
drug combinations to identify the most effective treatment for an individual patient.   Here, we 
validate OMI in primary tumor organoid cultures as an accurate, early predictor of in vivo tumor 
drug response in mouse xenografts, and present the feasibility of this approach on primary human 
tissues. The cellular-resolution of this technique also allows for subpopulations of cells to be 
tracked over time with treatment, to identify therapies that affect all cells in a heterogeneous 
population. 
6.3 Materials and Methods 
6.3.1 Mouse xenografts  
This study was approved by the Vanderbilt University Animal Care and Use Committee 
and meets the National Institutes of Health guidelines for animal welfare.  BT474 cells or HR6 
cells (108) in 100µl Matrigel were injected in the inguinal mammary fat pads of female athymic 
nude mice (J:NU; Jackson Laboratories). Tumors grew to ≥200mm3. Tumor-bearing mice were 
treated twice weekly with the following drugs: control human IgG (10 mg/kg, IP; R&D Systems), 
trastuzumab (10 mg/kg, IP; Vanderbilt Pharmacy), paclitaxel (2.5 mg/kg, IP; Vanderbilt 
Pharmacy), XL147 (10 mg/kg, oral gavage; Selleckchem), trastuzumab + XL147, trastuzumab + 
117 
 
paclitaxel, trastuzumab + paclitaxel + XL147. Tumor volume was calculated from caliper 
measurements of tumor length (L) and width (W), (L*W2)/2 twice a week. 
6.3.2 Primary human tissue collection  
This study was approved by the Vanderbilt University Institutional Review Board and 
informed consent was obtained from all subjects. A primary tumor biopsy, removed from the 
tumor mass after surgical resection, was provided by an expert breast pathologist (M.E.S.).  The 
tumor was placed immediately in sterile DMEM, transported on ice to the laboratory (~5 minute 
walk), and generated into organoids within 3 hours of tissue resection.  Pathology and receptor 
status of the tissue were obtained from the patient's medical chart.  
6.3.3 Organoid generation and culture  
Breast tumors (xenografts and primary) were washed three times with PBS.  Tumors were 
mechanically dissociated into 100-300 m macro-suspensions in 0.5 ml PMEC media 
(DMEM:F12 + EGF (10 ng/ml) + hydrocortisone (5 g/ml) + insulin (5 g/ml) + 1% penicillin: 
streptomycin) by cutting the tissues with a scalpel or by spinning in a C-tube (Miltenyi Biotec). 
Macro-suspension solutions were combined with Matrigel in a 1:2 ratio, and 100 l of the solution 
was placed on cover slips.  The gels solidified at room temperature for 30 minutes and then for 1 
hour in the incubator.  The gels were over-lain with PMEC media supplemented with drugs.  The 
following in vitro drug dosages were used to replicate in vivo doses (17-19): control (control 
human IgG + DMSO), trastuzumab (25 g/ml), paclitaxel (0.5 M), XL147 (25 nM), tamoxifen 
(2 M), fulvestrant (1 µM), and A4 (10 µg/ml, Takis, Inc.). 
6.3.4 Fluorescence lifetime instrumentation  
Fluorescence lifetime imaging was performed on a custom built multi-photon microscope 
(Prairie Technologies), as described previously (11, 20).  Excitation and emission light were 
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coupled through a 40X oil immersion objective (1.3 NA) within an inverted microscope (Nikon, 
TiE).  A titanium:sapphire laser (Coherent Inc.) was tuned to 750 nm for NADH excitation 
(average power 7.5-7.9 mW) and 890 nm for FAD excitation (average power 8.4-6 mW).  
Bandpass filters, 440/80 nm for NADH and 550/100 nm for FAD, isolated emission light. A pixel 
dwell time of 4.8 s was used to acquire 256x256 pixel images.  Each fluorescence lifetime image 
was collected using time correlated single photon counting electronics (SPC-150, Becker and 
Hickl) and a GaAsP PMT (H7422P-40, Hamamatsu).  Photon count rates were maintained above 
5x105 for the entire 60s image acquisition time, ensuring no photobleaching occurred.  The 
instrument response full width at half maximum was 260 ps as measured from the second harmonic 
generation of a urea crystal. Daily fluorescence lifetime validation was confirmed by imaging of a 
fluorescent bead (Polysciences Inc).  The measured lifetime of the bead (2.1 ± 0.06 ns) concurs 
with published values (10, 20, 21). 
6.3.5 Organoid imaging   
Fluorescence lifetime images of organoids were acquired at 24, 48, and 72 hours post-drug 
treatment.  Organoids were grown in 35-mm glass-bottom petri dishes (MatTek Corp) and imaged 
directly through the coverslip on the bottom of the petri dish. Six representative organoids from 
each treatment group were imaged.  The 6 organoids imaged contained collectively approximately 
60-300 cells per treatment group for statistical and subpopulation analyses.    First, an NADH 
image was acquired and a subsequent FAD image was acquired of the exact same field of view.   
6.3.6 Immunofluorescence   
A previously reported protocol (22) was adapted for immunofluorescent staining of 
organoids. Briefly, gels were washed with PBS and fixed with 2 ml 4% paraformaldehyde in PBS.  
Gels were washed with PBS, and then 0.15M glycine in PBS was added for 10 minutes.  Gels were 
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washed in PBS, and then added to 0.02% Triton X-100 in PBS.   Gels were washed with PBS then 
overlain with 1% fatty acid-free BSA, 1% donkey serum in PBS.  The next day, the solution was 
removed and 100 l of antibody solution (diluted antibody in PBS with 1% donkey serum) was 
added to each gel.  The gels were incubated for 30 minutes at room temperature, washed in PBS 3 
times, and then incubated in 100 l of secondary antibody solution for 30 minutes at room 
temperature.  The gels were washed in PBS 3 times, washed in water 2 times, and then mounted 
to slides using 30 l of ProLong Antifade Solution (Molecular Probes).   
The primary antibodies used were anti-cleaved caspase 3 (Life Technologies) and anti-
Ki67 (Life Technologies).  Both were diluted at 1:100. A goat anti-rabbit IgG FITC secondary 
antibody was used (Life Technologies).  FITC fluorescence was obtained by excitation at 980 nm 
on the multiphoton microscope described above, and a minimum of 6 organoids were imaged.  
Positive staining of cleaved caspase 3 and Ki67 was confirmed by staining mouse thymus and 
mouse small intestine, respectively.  Immunofluorescence images were quantified by manual 
counting of the total number of cells and the number of positively stained cells in each field of 
view.  Immunofluorescence results were presented as percentage of positively stained cells, 
quantified from six organoids, approximately 200 cells. 
6.3.7 Generation of OMI endpoint images   
Photon counts for 9 surrounding pixels were binned (SPCImage).  Fluorescence lifetime 
components were extracted from the photon decay curves by deconvolving the measured system 
response and fitting the decay to a two component model, CtI
tt   21 /2
/
1 expexp)(
  , 
where I(t) is the fluorescence intensity at time t after the laser pulse, 1 and2 are the fractional 
contributions of the short and long lifetime components, (i.e. 1 +2 = 1), 1 and2 are the 
fluorescence lifetimes of the short and long lifetime components, and C accounts for background 
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light.  A two-component decay was used to represent the lifetimes of the free and bound 
configurations of NADH and FAD (10, 23, 24) and yielded the lowest Chi2 values (0.99-1.1), 
indicative of optimal fit.  Matrices of the lifetime components were exported as ascii files for 
further processing in Matlab. 
6.3.8 Automated image analysis software  
To streamline cellular-level processing of organoid images, an automated image analysis 
routine, as previously described (25), was used in Cell Profiler in Matlab.  Briefly, a customized 
threshold code identified pixels belonging to nuclear regions that were brighter than background 
but not as bright as cell cytoplasms.  These nuclear pixels were smoothed and the resulting round 
objects between 6 and 25 pixels in diameter were segmented and saved as the nuclei within the 
image.  , Cells were identified by propagating out from the nuclei.  An Otsu Global threshold was 
used to improve propagation and prevent propagation into background pixels.  Cell cytoplasms 
were defined as the cells minus the nuclei.  Cytoplasm values were measured from each OMI 
image (redox ratio, NADH m, NADH 1, NADH 2, NADH 1, FAD m, FAD 1, FAD 2 , FAD 
1).   
6.3.9 Computation of OMI index  
The redox ratio, NADH m, and FAD m were norm-centered across cell values from all 
treatment groups within a sample, resulting in unit-less parameters with a mean of 1.  The OMI 
index is the linear combination of the norm-centered redox ratio, NADH m, and FAD m with the 
coefficients (1, 1, -1), respectively, computed for each cell. . The three endpoints, redox ratio, 
NADH m, and FAD m are independent variables (11) and are thus weighted equally. The signs 
of the coefficients were chosen to maximize difference between control and drug-responding cells.   
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6.3.10 Subpopulation analysis   
Subpopulation analysis was performed by generating histograms of all cell values within a 
group as previously reported (11).  Each histogram was fit to a 1, 2, and 3 component Gaussian 
curves.  The lowest Akaike information criterion (AIC) signified the best fitting probability density 
function for the histogram (26). Probability density functions were normalized to have an area 
under the curve equal to 1. 
6.3.11 Statistical tests   
Differences in OMI endpoints between treatment groups were tested using a student's t-test 
with a Bonferroni correction.  An  significance level less than 0.05 was used for all statistical 
tests.   
6.4 Results 
6.4.1 Response of BT474 organoids to a panel of anti-cancer drugs 
Validation of an organoid-OMI screen for drug response was first tested in two isogenic 
HER2-amplified breast cancer xenografts. BT474 xenografts are sensitive to the HER2 antibody 
trastuzumab, while HR6 xenografts, derived as a sub-line of BT474, are trastuzumab-resistant. 
The following single drugs and drug combinations were tested: paclitaxel (P, chemotherapy), 
trastuzumab (H, anti-HER2 antibody), XL147 [X, phosphatidylinositol-3 kinase (PI3K) small 
molecule inhibitor] (27), H+P, H+X, and H+P+X. Paclitaxel and trastuzumab are standard-of-care 
drugs, and XL147 is in clinical trials and preclinical studies support combination therapy of XL147 
with trastuzumab for patients who have developed a resistance to trastuzumab (27, 28). 
Representative redox ratio, NADH m, and FAD m images of BT474 xenograft-derived 
organoids demonstrate mixed multicellular morphology and highlight the sub-cellular resolution 
of this technique (Fig. 6.1A-F).  A longitudinal study of tumor growth demonstrated that the 
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BT474 xenografts responded to each treatment arm (Fig. 6.1G), with significant reduction in tumor 
volume, as determined from caliper measurements, on day 7 for all treatment groups except 
trastuzumab, which had significant reduction on day 11 (Fig. 6.1H).   
 
 
Figure 6.1. OMI of organoids derived from trastuzumab-responsive xenografts.  A. Redox 
ratio image of a control BT474 (ER+/HER2+) organoid at 72hr. Scale bar is 100 m.  B. NADH 
m image of a control BT474 organoid at 72hr. C. FAD m image of a control BT474 organoid at 
72hr.  D. Redox ratio image of a trastuzumab (anti-HER2) plus paclitaxel (chemotherapy) plus 
XL147 (anti-PI3K) (H+P+X) treated BT474 organoid at 72hr. E. NADH m image of a 
trastuzumab plus paclitaxel plus XL147 (H+P+X) treated BT474 organoid at 72hr. F. FAD m 
image of a trastuzumab plus paclitaxel plus XL147 (H+P+X) treated BT474 organoid at 72hr. G. 
Tumor growth response of BT474 tumors grown in athymic nude mice and treated with single and 
combination treatments.  H. Table of earliest detectable (p<0.05) reduction in tumor size for 
control vs. treated mice.  I. OMI index decreases in BT474 organoids treated with single and 
combination therapies at 24 hr.  J. OMI index of BT474 organoids treated for 72hr.  Red bars 
denote p<0.05 for treated organoids vs. control.  K.  Population density modeling of the mean OMI 
index per cell in control, paclitaxel, trastuzumab, and H+P+X treated organoids at 24 hr.  L.  
Population density modeling of the OMI index for control, paclitaxel, trastuzumab, and H+P+X 
BT474 organoids treated for 72hr.   M.  Immunofluorescence staining of cleaved caspase 3 in 
control and treated BT474 organoids at 72hr.  N.  Immunofluorescence staining of Ki67 in control 
and treated BT474 organoids at 72hr.  *p<0.05. 
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A composite endpoint, the OMI index, was computed as a linear combination of the mean-
normalized optical redox ratio, NADH m, and FAD m for each cell.  After 24 hr of treatment, the 
OMI index was significantly reduced in all treated BT474 organoids, compared to the control 
(p<0.05, Fig. 6.1I).  By 72 hr, the OMI index decreased further in all treatment groups (p<5x10-7, 
Fig. 6.41J).  The redox ratio, NADH m, and FAD m values showed similar trends (Appendix B, 
Fig. B.1).  Changes in short and long lifetime values and in the portion of free NADH or FAD 
contributed to the changes in m (Appendix B Table B.1).   
The high resolution capabilities of OMI allowed single cell analysis and population 
modeling for quantification of cellular subpopulations with varying OMI indices.  Visual 
inspection of cell morphology suggested that the majority of cells are tumor epithelial cells; 
stromal cells with obvious morphological differences were eliminated from the analysis.  
Population density modeling of cellular distributions of the OMI index revealed two populations 
with high and low OMI index values in all of the BT474 treated organoids at 24 hr (Fig. 6.1K, 
Appendix B Fig. B.2).  By 72 hr, the XL147, H+P, H+X, and H+P+X treated organoids have a 
single population with narrower peaks (Fig. 6.1L, Appendix B Fig. B.2). The trastuzumab treated 
organoids have two populations at 72 hr, both lower than the mean OMI index of the control 
organoids (Fig. 1L).  Immunofluorescent staining of cleaved caspase-3 and Ki67 of BT474 
organoids treated for 72 hr confirmed increased apoptosis and decreased proliferation in drug 
treated organoids, with the greatest increases in cell death with combined treatments (Fig. 6.1M-
N). 
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6.4.2 Response of HR6 organoids to a panel of anti-cancer drugs 
 
 
 
Figure 6.2. OMI of organoids derived from trastuzumab-resistant xenografts.    A. Redox 
ratio image of a control HR6 (ER+/HER2+) organoid at 72hr. Scale bar is 100 m.  B. NADH m 
image of a control HR6 organoid at 72hr. C. FAD m image of a control HR6 organoid at 72hr.  D. 
Redox ratio image of a trastuzumab (anti-HER2) plus paclitaxel (chemotherapy) plus XL147 (anti-
PI3K) (H+P+X) treated HR6 organoid at 72hr. E. NADHm image of an H+P+X treated HR6 
organoid at 72hr. F. FAD m image of an H+P+X treated HR6 organoid at 72hr. G. Tumor growth 
response of HR6 tumors grown in athymic nude mice and treated with single and combination 
treatments.  H. Table of earliest detectable (p<0.05) reduction in tumor size for control vs. treated 
mice. * Denotes tumors that initially shrank and then grew.  NS, not significant. I. OMI index 
initially decreases in HR6 organoids treated with paclitaxel, XL147, and combination therapies at 
24 hr.  J. OMI index of HR6 organoids treated for 72hr.  Red bars indicate significant reductions 
in OMI index, p<0.05, for treated organoids vs. control.  Blue bars indicate significant increases 
in OMI index, p<0.05, for treated organoids vs. control.  K.  Population density modeling of the 
mean OMI index per cell in control, paclitaxel, trastuzumab, and H+P+X organoids at 24 hr.  L.  
Population density modeling of the OMI index for HR6 control, paclitaxel, trastuzumab, and 
H+P+X organoids treated for 72 hr.   M.  Immunofluorescence staining of cleaved caspase 3 in 
control and treated HR6 organoids at 72hr.  N.  Immunofluorescence staining of Ki67 in control 
and treated HR6 organoids at 72hr. * p<0.05 
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Next, the OMI-organoid screen was tested on trastuzumab-resistant HR6 xenografts (29).  
Representative images show HR6 organoid morphology and spatial distributions of OMI 
endpoints (Fig. 6.2A-F).  These HER2 overexpressing tumors had continued growth with 
trastuzumab treatment (Fig. 6.2G).  Treatment with paclitaxel and XL147 initially caused HR6 
tumor regression (p<0.05 on day 10 for XL147 and on day 14 for paclitaxel) but then resumed 
growth (Fig. 6.2G-H). Mice treated with the H+P, H+X, and H+P+X combination therapies 
exhibited sustained HR6 tumor reduction (Fig. 6.2G-H).    
After 24 hr of treatment, significant reductions in the OMI index were detected in HR6 
organoids treated with paclitaxel, XL147, H+P, H+X, and H+P+X (p<0.05, Fig. 6.2I).  At 72 hr, 
the OMI index of the paclitaxel and XL147 treated organoids was significantly greater than that 
of the control organoids (p<0.05, Fig. 6.2J), consistent with the recovery of HR6 tumor growth 
after prolonged therapy (Fig. 6.2G).  The organoids treated with drug combinations (H+P, H+X, 
H+P+X) continued to have significantly lower OMI index values (p<10-6) at 72 hr, compared to 
untreated controls. Individual OMI endpoints showed similar trends (Appendix B Fig. B.3, 
Appendix B Table B.2).   Subpopulation analysis revealed two subpopulations in the OMI index 
for all treated groups except for trastuzumab at 24 hr (Fig. 6.2K, Appendix B Fig. B.4). By 72 hr, 
the paclitaxel and XL147 treated organoids had a single population (Fig. 6.2L, Appendix B Fig. 
B.4). Immunofluorescent staining of cleaved caspase 3 of organoids treated for 72 hr revealed 
increased cell death in HR6 organoids treated with H+P, H+X and H+P+X (p<0.05, Fig. 6.2M). 
The percentage of Ki67 positive cells at 72 hr decreased with paclitaxel, H+P, H+X, and H+P+X 
treatment (p<0.005, Fig. 6.2N). 
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6.4.3. OMI endpoints identify breast cancer subtypes 
 
 
Figure 6.3.  Representative redox ratio, NADH m, and FAD m images of organoids derived 
from primary, human breast tumors.  Redox ratio (NADH/FAD; first row), NADH m (second 
row), and FAD m (third row) images of organoids generated from primary human breast tissue 
obtained from resection surgeries.  TBNC = Triple negative breast cancer.  Scale bar is 100 m. 
 
We tested these methods on primary breast cancer biopsies obtained from surgical 
resection.  Tumors were obtained fresh from de-identified mastectomy specimens not required for 
further diagnostic purposes, and dissociated into organoids within 1-3 hr post-resection. Cancer 
drugs were added and organoids were imaged with OMI.  Representative redox ratio, NADH m, 
and FAD m images (Fig. 6.3) demonstrate the varying morphology of organoids derived from 
ER+, HER2+ and triple negative breast cancers.   
When quantified, the OMI endpoints differed between cancer subtypes.  In immortalized 
cell lines, the redox ratio was elevated in ER+/HER2- cells and was greatest in HER2+/ER- cells 
(p<5x10-5, Fig. 6.4A).  Similarly, NADH m was increased in immortalized ER+/HER2- and 
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HER2+/ER- breast cancer cells as compared to triple negative breast cancer (TNBC) cells 
(p<5x10-8, Fig. 6.4B).  FAD m was greatest in ER+/HER2- cells (p<0.05, Fig. 6.4C).  Overall, the 
OMI index was lowest in TNBC and greatest in HER2+/ER- cells (p<5x10-8, Fig. 6.4D), 
suggesting that HER2 and ER expression influence cellular metabolism. 
 
Figure 6.4. OMI endpoints differ among breast cancer subtypes.  A.  Redox ratio 
(NADH/FAD) of TNBC cells (MDA-MB-231), ER+ (HER2-negative) cells (MCF7), and HER2+ 
(ER-negative) cells (SKBr3, BT474, MDA-MB-361).  B.  NADH m of TNBC, ER+, and HER2+ 
immortalized cell lines.  C.  FAD m of TNBC, ER+, and HER2+ immortalized cell lines.  D.  OMI 
index increases in ER+ and HER2+ immortalized cell lines.  E.  Redox ratio (NADH/FAD) of 
organoids derived from triple negative, ER+ (HER2-negative), and HER2+ (ER-negative) primary 
human tumors. F.  NADH m of organoids derived from triple negative, ER+, and HER2+ primary 
human tumors. G.  FAD m of organoids derived from triple negative, ER+, and HER2+ primary 
human tumors.  H.  OMI index of organoids derived from triple negative, ER+, and HER2+ 
primary human tumors. * p<0.05 
Similar trends were observed for the OMI endpoints in organoids derived from primary 
breast tumor specimens cultured under basal conditions. The redox ratio was increased in 
organoids from ER+/HER2- tumors and was greatest in HER2+/ER- organoids (p<5x10-12, Fig. 
6.4E, Appendix B Table B.3).  Likewise, NADH m increased with ER and HER2 expression 
(p<5x10-8, Fig. 6.4F).  FAD m was increased in ER+ organoids and reduced in HER2+ organoids 
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(p<0.05, Fig. 6.4G).  The OMI index was lowest for TNBC, and greatest for HER2+ organoids 
(p<5x10-3, Fig. 6.4H).   
6.4.4 Organoid response of ER+ primary human tumors 
 
 
Figure 6.5. OMI index measures drug response and heterogeneous populations in ER+ 
primary tumor derived organoids.  A.  OMI index of organoids derived from an ER+ (HER2-
negative) primary human tumor decreases with paclitaxel (chemotherapy), tamoxifen (ER 
antagonist), XL147 (anti-PI3K) and combined therapies at 72hr.  Light gray bars indicate 
significant (p<0.05) reductions in OMI index with treatment, versus control organoids.  B.  
Quantification of immunofluorescence staining of cleaved caspase 3 for organoids derived from 
the same tumor sample as in (A) and treated for 72hr.  C.  Population density modeling of the 
control, H+X, and H+P+T+X treated organoids presented in (A).  D.  OMI index is reduced with 
paclitaxel, tamoxifen, and combined treatments in organoids derived from a different ER+ patient 
at 72hr.  E.  Population density modeling of the control, tamoxifen, and H+P+T treated organoids 
presented in (D).  F.  OMI index is reduced in organoids from a third ER+ patient treated with 
tamoxifen, XL147, H+X, and H+P+T+X at 24hr.  G.  Population density modeling of the control, 
XL147, and H+P+T+X treated organoids presented in F.  H.  Organoids derived from a fourth ER+ 
patient have significant reductions in OMI index when treated with XL147 and combination 
therapies at 72hr.  I.  Population density modeling of the control, tamoxifen, and H+P+X treated 
organoids in (H) reveals multiple populations with tamoxifen treatment.  * p<0.05. 
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Organoids were generated from four ER positive (HER2-negative) primary human tumors 
and treated with the chemotherapeutic drug paclitaxel, the selective ER modulator tamoxifen, the 
HER2 antibody trastuzumab and the pan-PI3K inhibitor XL147.  Organoids derived from the first 
ER+ tumor had significantly reduced OMI index values upon treatment with paclitaxel, tamoxifen, 
XL147, H+X, H+P+T, H+P+X and H+P+T+X for 72 hr (p<5x10-5, Fig. 6.5A). 
Immunofluorescence of cleaved caspase-3 showed increased cell death in parallel organoids 
treated for 72 hr with paclitaxel, tamoxifen, XL147,  H+X, H+P+T, H+P+X, and H+P+T+X (Fig. 
6.5B). Subpopulation analysis revealed less variability (narrower histogram peaks) within 
responsive treatment groups compared to the cells of control and trastuzumab-treated organoids 
(Fig. 6.5C, Appendix B Fig. B.5).   Corresponding OMI endpoints showed similar trends 
(Appendix B Fig. B.6, Appendix B Table B.4).  
Organoids derived from a second ER+ tumor responded similarly. The OMI index 
decreased upon treatment with paclitaxel, tamoxifen, H+P, P+T and H+P+T at 72 hr (p<5x10-5, 
Fig. 6.5D). Subpopulation analysis revealed a single population of control cells that shifted to 
lower OMI indexes with paclitaxel, tamoxifen, H+P, P+T, and H+P+T treatments (Fig. 6.5E, 
Appendix B Fig. B.7).  Corresponding OMI endpoints showed similar trends (Appendix B Fig. 
B.8, Appendix B Table B.5). 
The third and fourth ER+ clinical samples yielded organoids with variable responses to 
treatment. Organoids derived from the third patient had significant reductions in OMI index after 
24 hr treatment with tamoxifen, XL147, H+X, and H+P+T+X treatments (p<0.005, Fig. 6.5F). 
Subpopulation analysis revealed two populations with high and low OMI index values for the H+P 
and paclitaxel-treated organoids (Fig. 6.5G; Appendix B Fig. B.9). Two populations, both with 
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mean OMI index values less than that of the control organoids, were apparent in the organoids 
treated with XL147 and with H+P+T+X (Fig. 6.5G, Appendix B Fig. B.9).  Organoids from the 
fourth ER+ patient had reduced OMI indices following treatment with XL147, H+P, H+X, 
H+P+X, H+P+T and H+P+T+X for 72 hr (p<0.01, Fig. 6.5H).  Subpopulation analysis of cells 
from these organoids revealed single populations with shifted mean OMI indices for all treatments 
except tamoxifen, H+P, and H+X, which had two populations (Fig. 6.5I, Appendix B Fig. B.10). 
Corresponding OMI endpoints showed similar trends (Appendix B Fig. B.11-12, Appendix B 
Tables B.6-7).  
6.4.5 Organoid Response of HER+ and TNBC primary human tumors 
 
Figure 6.6. OMI index detects response of HER2+ organoids to trastuzumab and resolves no 
response in TNBC.   A.  Organoids derived from a HER2+(ER-negative) clinical tumor have 
reduced OMI indices with trastuzumab (anti-HER2) and A4 (anti-ErbB3) treatment, and no change 
with fulvestrant treatment (ER antagonist) at 24hr.  Light gray bars signify significant reductions 
in OMI index due to drug treatment compared to control organoids (*p<0.05).  (B).  Population 
density modeling of the organoids derived from a HER2+ tumor reveals single populations.  C.  
Organoids derived from a TNBC tumor have no significant changes (p>0.3) in OMI index with 
treatment of targeted therapies, tamoxifen (ER antagonist) and trastuzumab at 48hr.  D.  Population 
density modeling reveals single populations within the TNBC organoids. 
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OMI was also performed on organoids derived from HER2+ (ER negative) and TNBC 
specimens. Organoids derived from the HER2+ primary tumor were treated with the ER down-
regulator fulvestrant, the HER2 antibody trastuzumab, and the anti-ErbB3 antibody A4 (30). The 
OMI index was significantly decreased in the organoids treated for 24 hr with trastuzumab and A4 
(p<0.005, Fig. 6.6A).  Subpopulation analysis revealed shifts in the mean OMI index values with 
these treatments within a single population of cells (Fig. 6.6B).  Organoids derived from the TNBC 
specimen were treated with tamoxifen, the HER2 antibody trastuzumab, and the combination of 
trastuzumab plus tamoxifen (H+T).  No significant changes were observed with these treatments 
in TNBC organoids after 24 hr (p>0.3, Fig. 6.6C).  Subpopulation analysis revealed a single 
population of cells from TNBC organoids (Fig. 6.6D). Corresponding OMI endpoints showed 
similar trends (Appendix B Fig. B.7-8, Appendix B Tables B.8-9).  
6.5 Discussion 
 Primary tumor organoids are an attractive platform for drug screening because they are 
grown from intact biopsies, thus maintaining the tumor cells within the same tumor 
microenvironment (15). OMI is sensitive to early metabolic changes, achieves high resolution to 
allow analysis of tumor cell heterogeneity, and uses endogenous contrast in living cells for 
repeated measurements and longitudinal studies (11). The OMI index is a holistic reporter of 
cellular metabolism because the redox ratio and NADH and FAD lifetimes are independent 
measurements (11).  The mean lifetime captures not only changes in free-to-bound protein ratios 
but also preferred protein binding and relative concentrations of NADH to NADPH (31).  Cancer 
drugs have been shown to down-regulate certain metabolism enzymes; for example, trastuzumab 
down-regulates lactate dehydrogenase in breast cancer and paclitaxel resistant cells have been 
shown to have more lactate dehydrogenase expression and activity (32). The OMI index captures 
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these drug-induced changes in metabolism enzyme activity.  Organoids remain viable with stable 
OMI endpoints in controlled culture conditions (33), thus making them an attractive system to 
evaluate tumor response to drugs. We used OMI to assess the response of primary breast tumor 
organoids to a panel of clinically relevant anti-cancer agents used singly or in combination.  Early 
OMI-measured response in organoids (24-72 hr post-treatment) corroborated with standard tumor 
growth curves in xenografts, and the feasibility of this approach was confirmed in organoids 
derived from primary human breast tumors. 
 The OMI index was first evaluated as a reporter of tumor response in organoids derived 
from BT474 (ER+/HER2+) xenografts. Significant reductions in OMI index upon treatment with 
paclitaxel, trastuzumab, XL147 and combinations thereof, at both 24 and 72 hr, correlated with 
reduction of tumor growth (Fig. 6.1). Biochemically, cellular rates of glycolysis, and NADH and 
FAD protein-binding decrease with drug treatment in responsive cells (32), resulting in decreased 
redox ratios and NADH τm, and increased FAD τm in agreement with the decreased OMI index 
observed in drug-treated BT474 organoids. Significant reductions in tumor growth occurred 7-11 
days post-treatment initiation whereas the OMI index detected response at 24-72 hr post-treatment. 
Cellular analysis revealed an initial heterogeneous response among cells within organoids treated 
with paclitaxel and H+P at 24 hr, which, by 72 hr, became a uniform response. The heterogeneity 
of trastuzumab treated BT474 organoids persisted over 72 hr, suggesting an intrinsic subpopulation 
more susceptible to acquire drug resistance. This heterogeneity was not seen in the combination 
treatments, suggesting the combination treatments trump this drug resistance-prone subpopulation.  
OMI measured response corroborated with increased cell death and decreased proliferation due to 
single and combination drug treated organoids, measured with destructive post-mortem 
techniques.  The XL147-treated BT474 organoids have a much lower OMI index at 72 hr, but only 
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a modest increase in cleaved caspase 3 activity. The same decrease was not observed in the HR6 
cells that have alternative metabolism pathways activated due to their acquired resistance to 
trastuzumab.  The OMI index detects changes in cellular metabolism that predict drug efficacy, 
but do not necessarily correlate with IHC. 
 In the current standard of care, patients with innate drug resistance are not identified a 
priori. We tested the capabilities of OMI to predict drug resistance using trastuzumab-resistant 
HR6 (ER+/HER2+) tumors (29).  XL147 is a novel PI3K inhibitor under investigation for 
combined therapy with trastuzumab to improve response of resistant tumors (27). Significant 
reductions in the OMI index of HR6 organoids treated for 72 hr identified drug combinations 
(H+X, H+P, and H+P+X) that induced a sustained reduction in tumor growth in vivo (Fig. 6.2). 
The reduction in tumor growth upon treatment with H+X was consistent with previous reports of 
greater anti-tumor effects of the combination over trastuzumab and XL147 alone (27).   
Subpopulation analysis revealed multiple responses within the HR6 organoids after treatment with 
single drugs and combinations, suggesting increased heterogeneity compared to the parental 
BT474 organoids.  
The OMI index of paclitaxel and XL147 treated HR6-organoids initially decreased at 24 
hr, and then increased at 72 hr, mirroring the tumor growth in mice after prolonged therapy, and 
indicating that the adaptations that allow HR6 cells to survive trastuzumab treatment also affect 
response to additional drugs. This relapse of HR6 tumors treated with paclitaxel and XL147 was 
not apparent until 2-3 weeks of drug treatment; yet, the OMI index identified a resistant population 
within both paclitaxel and XL147 treated organoids at 24 hours and showed a selection of this 
population by 72hr.  Subpopulation analysis of the paclitaxel and XL147 treated HR6 organoids 
revealed heterogeneous responses at 24 hr, suggesting that OMI is capable of early detection of 
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resistant cells within a heterogeneous tumor. These results indicate that OMI of primary tumor 
organoids is able to identify heterogeneous responses within tumors on a cellular level, and 
potentially guide therapy selection early for maximal response. The ability to detect innate 
resistance at a cellular level prior to treatment may provide leads for identification of drugs that 
target such refractory subpopulations before they are selected by the primary therapy. 
 We next examined the feasibility of this approach utilizing fresh tumor biopsies obtained 
from primary tumor surgical resections. OMI measurements in vivo and corresponding 
measurements from freshly excised tissues within 8 hr of surgery are statistically identical (20), 
providing ample time for specimen acquisition and transport to the laboratory. The morphology of 
organoids differed among patients and within breast cancer subtypes (Fig. 6.3), demonstrating a 
greater heterogeneity within primary tumors compared to xenografts.   
 Previously published studies report differences in OMI endpoints due to the presence or 
absence of ER and HER2 (8, 11, 34). Both ER and HER2 signaling pathways can influence 
metabolism: ER by inducing increased glucose transport (1), and HER2 through activation of PI3K 
(2), among other signal transducers. We compared OMI endpoints from immortalized cells and 
human tissue-derived organoids of three subtypes of breast cancer: ER+, HER2-overexpressing, 
and triple negative breast cancer (TNBC). The OMI index of immortalized cell lines increased 
with ER expression and was highest in HER2 overexpressing cells (consistent with prior studies 
(11)), and these trends were replicated in organoids derived from primary human tumors.  Notably, 
NADH m was significantly increased (p<0.05) in the HER2+ organoids compared to ER+ 
organoids, but this trend was not observed in the immortalized cell lines. This difference could be 
due to molecular changes induced by the immortalization process, media components, primary 
tumor heterogeneity, and/or the heterogeneity within a primary breast tumor.  Regardless, the 
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results shown (Fig. 6.4) suggest breast cancer subtypes, ER+, HER2+ and TNBC, have different 
OMI profiles.   
 Organoids derived from human breast tumors were treated with a panel of breast cancer 
drugs (Fig. 6.5-6). Differences in the drug response of these organoids suggest heterogeneity 
across ER+/HER- tumors. Organoids from one of the four ER+ tumors did not exhibit reduced 
OMI indices after treatment with tamoxifen.  Organoids derived from two of the four ER+ samples 
did not have reduced OMI indices after paclitaxel treatment. These variable responses are 
consistent with variable responses seen with these drugs in the clinic (35-38).  None of the 
organoids had reduced OMI indices with trastuzumab, which is expected because the organoids 
were derived from HER2 negative tumors. Generally, the OMI index was reduced further upon 
treatment with drug combinations, supporting the use of drug combinations clinically.  
Subpopulation analysis revealed cells within organoid treatment groups that exhibit 
different OMI indices after treatment, suggesting that subpopulations of cells with different drug 
sensitivities preexist and develop within primary tumors. Some of these cells may represent the 
cancer stem-like population with increased renewal capacity, metastatic potential, and drug 
resistance (39). The populations of organoids derived from human tumors have more variability 
(broader population curves) than those derived from xenografts, reflecting an inherent greater 
heterogeneity within primary tumors. This corroborates previous reports (40) of greater intra-
tumoral heterogeneity in primary tumors than in xenografts derived from clonal cell lines. Thus, 
OMI imaging allows identification of heterogeneous cellular response to drug treatment in a 
dynamic population, which potentially enables drug selection to maximize therapeutic efficacy. 
Organoids derived from HER2+/ER- and TNBC primary tumors have OMI responses 
consistent with their clinical characteristics: reduced OMI index with trastuzumab treatment and 
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no change with fulvestrant (ER antagonist) treatment in the HER2+/ER- organoids (41), and no 
OMI index reductions after treatment with  trastuzumab or tamoxifen in the TNBC organoids (42, 
43) (Fig. 6.6a,c).  HER3 is an emerging target for breast cancer (30, 44) and the anti-HER3 
antibody A4 reduced the OMI index of HER2+/ER- organoids. 
 The results of this study support the validity of OMI for monitoring organoid response to 
anti-cancer drugs.  We demonstrate high selectivity of the OMI index to directly measure drug 
response of organoids derived from breast cancer xenografts to single anti-cancer drugs and their 
combinations, and validated OMI measured response with gold standard tumor growth in two 
xenograft models.  We have shown that the OMI index measured in primary tumor organoids 
resolves response and non-response within 72 hours, compared to the 3 weeks required to resolve 
this response with tumor size measurements.  Further, we extend this approach and generate drug 
response information from organoids derived from three subtypes of primary human tumors, 
TNBC, ER+, and HER2+.  The high resolution of OMI allows subpopulation analysis for 
identification of heterogeneous tumor response to drugs in dynamic tumor cell populations.  
Altogether, these results suggest that OMI of primary tumor organoids may be a powerful test to 
predict the action of anti-cancer drugs and tailor treatment decisions accordingly. 
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CHAPTER 7 
Conclusions and Future Directions 
7.1 Summary and Conclusions 
 The primary goal of this dissertation is to characterize and develop optical metabolic imaging 
endpoints as biomarkers for drug response in breast cancer.  Clinically, therapy selection remains 
difficult due to the large number of patients that present de novo and acquired drug resistance.  
Currently, there are no technologies to predict which patients will not respond to traditional therapies.  
While optical techniques, such as diffuse optical tomography, have been used to monitor therapy 
response (1-4), optical metabolic imaging is more sensitive to early drug-induced changes and 
achieves higher spatial resolution, which allows analysis of tumor heterogeneity.  Furthermore, while 
similar optical metabolic imaging techniques have been used for optical diagnosis (5, 6), this is the 
first application of these technologies for dynamic imaging of drug response.   
 The objective of Chapter 2 is to provide relevant background information and a framework 
for the work reported in the rest of the Dissertation.  Chapter 2 contains a discussion on the current 
standard of care and therapy treatment regimens for breast cancer patients.  Furthermore, cellular 
metabolism is defined and motivated as a source of contrast for drug efficacy.  Chapter 2 concludes 
with an introduction to fluorescence lifetime imaging which is utilized in optical metabolic imaging 
and a brief introduction to organoid culture which enables clinical translation of optical metabolic 
imaging.   
 The primary objective of Chapter 3 is to develop an analysis method to evaluate and quantify 
cellular heterogeneity within optical metabolic imaging data sets.  Solid tumors are highly 
heterogeneous and heterogeneity contributes to tumor aggression, invasion, metastases, and therapy 
resistance (7-11).  Therefore, single-cell resolution and tumor heterogeneity analysis is important for 
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a drug-response monitoring technology.  Chapter 3 develops and characterizes optical metabolic 
imaging subpopulation analysis (OMI-SPA). OMI-SPA uses mixed Gaussian distributions to model 
cellular populations to identify the number and parameters of cellular subpopulations.  This chapter 
presents the theoretical limitations of SPA and demonstrates utility in co-cultures of two breast cancer 
cell lines.  The main conclusions of this work are that OMI-SPA can identify cancer cell 
subpopulations based on OMI endpoints.  Furthermore, this work quantified the relationships between 
sample size, standard deviation, and mean separation distance for SPA to robustly characterize two 
populations with minimal error.  These results are presented graphically, and may act as a look up 
table for future experiments when the means and standard deviations of populations are unknown or 
estimated.  Chapter 3 addresses the first Aim, “characterize subpopulation analysis of OMI data to 
quantify heterogeneous cell populations.” 
 Chapter 4 addresses Aim 2 outlined in Chapter 1, “determine the sensitivity of OMI to breast 
cancer subtypes and therapeutic response in vitro and validate OMI measures of response in human 
breast cancer xenografts in vivo.”  In this chapter, an in vitro experiment was performed to 
determine the basal and post-therapy metabolism, as measured by OMI, in a panel of breast cancers 
with varying receptor expressions.  In addition, an in vivo xenograft experiment was performed on 
three different xenografts to determine the sensitivity of OMI endpoints to drug-induced changes 
in metabolism.  These studies demonstrated that OMI is highly sensitive to drug-induced 
metabolism changes, with significant reductions in all endpoints as early as 24 hr post-treatment 
in cells and 48hr in xenografts.  To our knowledge, this is the earliest detected response to 
trastuzumab in vivo.  Furthermore, OMI endpoints of trastuzumab-resistant cells and tumors were 
not significantly affected by trastuzumab treatment, proving specificity of OMI.  Additionally, 
OMI-measured response was directly compared with a clinically used technology FDG-PET.  FDG 
143 
 
uptake did not significantly change with trastuzumab treatment in either responsive or resistant 
tumors over the entire time course, highlighting the advantages of OMI.  Finally, Chapter 4 also 
demonstrates the application of advanced imaging analysis protocols which are able to identify 
heterogeneous cell populations in cell cultures and tumors imaged in vivo.   The main conclusion 
of Chapter 4 is that OMI is highly sensitive to drug-induced changes in cellular metabolism in 
responding cells and in vivo tumors. 
 Chapter 5 addresses Aim 3, “characterize OMI endpoints in excised tissues.”  Due to 
challenges and limitations with clinical in vivo OMI imaging of deep tissue sites such as the breast, 
OMI was performed on in vivo hamster cheek pouch tissue and compared with OMI of freshly 
excised, live cultured tissues, and frozen biopsy samples.  The results of this study demonstrate 
that OMI endpoints remain unchanged up to 8 hours post excision in live culture conditions.  
Frozen tissue samples however, expressed differences up to 15% compared to in vivo.  These 
results demonstrate that meaningful OMI data can be obtained from freshly excised, live cultured 
samples.  This study defined the time-window for OMI measurements on excised tissues and 
characterizes the metabolic changes that occur in frozen-thawed tissues.   
 The main goal of Chapter 6 was to validate that OMI-measured drug response in organoids 
correlated with in vivo drug response in xenograft models and prove feasibility of an organoid-
OMI screen for clinical use.  This chapter addressed Aim 4, “validate organoid-OMI measured 
tumor response with in vivo OMI in human breast cancer xenografts and compare organoid-OMI 
measured tumor response with measures of response in human breast cancers.”  To expedite 
clinical utility of OMI measured drug response, an OMI-organoid drug screen was developed and 
validated.  Organoids are 3D cultures of primary tumor sections and contain all the cells and 
microenvironment of the original tumor, including malignant cells, fibroblasts, leukocytes, and 
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endothelial cells (12).  Organoids are an attractive platform for an OMI-based drug screen because 
they recapitulate in vivo tumor environments and cell signaling networks which have been shown 
to mediate drug resistance (13).  Furthermore, organoids are inexpensive and easy to image.  
The work in Chapter 6 is the first to demonstrate that OMI-measured organoid drug 
response agrees with in vivo drug response, as measured by changes in tumor size.  Furthermore, 
the drug response of organoids over 72 hours predicted for drug response of in vivo tumors treated 
for three weeks.  Heterogeneity analysis revealed subpopulations with different OMI profiles 
following drug response and these subpopulations could be tracked over the 72-hr time course.  
Additionally, Chapter 6 defines the OMI index, a combination of the redox ratio, NADH mean 
lifetime, and FAD mean lifetime, as a composite variable which enables direct correlation between 
cellular metabolism and drug response.  Finally, Chapter 6 proved feasibility of an organoid-OMI 
approach to measuring drug response in 6 clinical samples.  Altogether, this Chapter validates the 
organoid-OMI drug screen approach in two xenograft models and demonstrates feasibility in 
human breast tumors. 
This dissertation characterizes OMI for monitoring and predicting drug response.  OMI is 
an attractive platform because it is high-resolution, non-invasive, uses non-ionizing radiation, and 
is highly sensitive to changes in cellular metabolism.  When combined with image processing 
techniques and cellular-level analysis, OMI is capable of resolving cellular heterogeneity, which 
is increasing important for identifying cancer stem cells and non-responding subpopulations.  
Furthermore, this dissertation has defined time windows for robust OMI measurements of excised 
tissues and developed an organoid-drug screen for universality and clinical application of OMI. 
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7.2 Future Directions 
Test Organoid-OMI Screen in Immune-Competent Mice 
 Chapter 6 validated OMI-measured drug response of organoids with in vivo tumor growth 
curves of two xenograft mouse models, one responsive to trastuzumab and one resistant to 
trastuzumab.  These experiments demonstrated corroboration between organoid-OMI detected 
response and in vivo response.  However, xenograft tumors must be grown in immune-
compromised mice and these models of breast cancer and tumor response may not fully 
recapitulate clinical disease and response (14).  Many drugs, including trastuzumab, modulate 
immune function and the full effects may not be well represented in xenograft studies.  Genetically 
engineered mouse models of breast cancer are grown in immune-competent mice and may reveal 
interactions between tumor, drugs, and the immune system.  Future experiments in immune-
competent mice are warranted to ensure an organoid-OMI screen retains its prognostic capability. 
Validate Organoid-OMI Screen in Clinical Neoadjuvant Study 
 Validation of the organoid-OMI screen in patients is challenging due to the long follow-up 
time, variety of treatments, and lack of robust clinical measures of response.  However, the 
neoadjuvant therapy setting in breast cancer provides an opportunity to test organoid-OMI 
predicted response with actual patient outcomes.  Neoadjuvant therapy is systemic chemotherapy 
or targeted therapy given to a cancer patient before surgical removal of the primary tumor.  
Neoadjuvant therapy is used to improve surgical outcomes, obtain information on tumor response, 
and obtain long-term disease-free survival (15).  Studies have shown that patients that achieve 
pathological response to neoadjuvant chemotherapy have better survival (16).  Response to 
neoadjuvant therapy is determined pathologically at the time of surgical resection of the primary 
tumor.  Therefore, the neoadjuvant setting provides a window for validating organoid-OMI drug 
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response.  In this study, pre-treatment tissue would be obtained by core needle biopsy prior to 
chemotherapy.  Organoids would be generated from the tissue and treated with the same drug 
cocktail received by the patient.  Organoid-OMI drug response would be compared with 
pathological response determined at the time of surgery.   
Investigate Biochemical Source of OMI Contrast 
 OMI probes the fluorescence intensities and lifetimes of NADH and FAD.  Assuming 
constant imaging parameters and sample optical properties, changes in the fluorescence intensity 
of NADH and FAD are most likely due to changes in the concentration of the fluorophore (17).  
However, the physiological source of changes in the fluorescence lifetime of NADH and FAD are 
less defined.  NADH and FAD can exist in free and bound states and changes in the mean lifetime 
may be due to changes in the proportion of free and bound fluorophore which would manifest as 
changes in 1 and 2.  Changes in the bound lifetime may be due to different conformations of the 
fluorophore and binding to different enzyme complexes.  Future experiments in solutions and cell 
culture will elucidate the physiological basis for significant changes in fluorescence lifetimes of 
NADH and FAD. 
Investigate Organoid-OMI Screen for Additional Diseases  
 Abnormal cellular metabolism is a hallmark of many additional cancers and diseases.  An 
organoid-OMI screen has the potential to guide therapy selection for additional diseases, and not 
be limited to breast cancer.  Future studies will explore the validity and usefulness of OMI 
technology for additional diseases and cancers. 
Automate Imaging Acquisition and Increase Speed for High Throughput Measurements 
 For widespread clinical adoption of an organoid-OMI screen, OMI needs to be faster, less 
expensive, and automated.  Recent advances in time correlated single photon counting electronics 
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and computing power have allowed faster FLIM.  For clinical use, OMI should be incorporated 
into an automated plate reader which could automatically identify and image organoids.  A 
sophisticated system would include an environmental chamber.  Furthermore, with faster FLIM 
capabilities, image stacks throughout the organoid could be imaged to improve sampling.   
Optimize Organoid Growth Conditions 
 The organoid generation and growth protocol could be optimized.  The organoid generation 
protocol presented in Chapter 6 uses mechanical dissociation to generate organoids and the 
organoids grow in matrigel.  Additional protocols could be tested, such as addition of extracellular 
matrix degredation enzymes, collagenases, to optimize organoid generation (18).  Furthermore, 
organoids could be grown in a variety of gels.  While matrigel facilitates organoid growth, gel 
mechanical properties could be controlled by growing organoids on collagen gels.  Organoid 
growth on gels of varying stiffness could be investigated as well as organoid invasion (18, 19).   
7.3 Contribution to the Field and Societal Impact 
Innovation in Biophotonics 
 The studies in this dissertation have led to several innovations within the field of 
biophotonics.  First, these studies are the first to characterize OMI endpoints in regards to other 
measures of cellular metabolism.  In Chapter 4, OMI endpoints, the redox ratio, NADH mean 
lifetime, and FAD mean lifetime, are robustly compared with measurements of glucose-uptake 
and lactate secretion by cells, and FDG-PET in xenograft tumors.  This characterization of OMI 
endpoints provides insights on the physiological source of contract.   
Additionally, this work is the first to develop OMI for monitoring anti-cancer therapy.  
Outside of these studies, no OMI endpoint has been exploited for predicting the outcome of any 
therapy in animal models or clinical settings.  Traditionally, the field of biophotonics has largely 
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focused its efforts on diagnostics, such as optical biopsy, and breast cancer margin assessment (20-
23).  This work presents a novel application of optical technologies, using OMI endpoints as 
measures of drug response.  While diffuse optical tomography has also been used to detect 
response (2-4), diffuse optical tomography is low resolution and limited to the treatment received 
by the patient.  The novelty of the research presented in this dissertation is the combined organoid-
OMI screen which shifts from a focus of measuring response and reacting to non-response to being 
able to directly test all drugs and drug combinations to guide initial therapy decisions.  In vivo 
functional imaging methods are inherently low-throughput, because they are limited to assessing 
only the drugs that the patient has already received.  The combination of functional measures 
(OMI) of live tumors (organoids) in a high-throughput screening format is completely 
unprecedented in the research literature. The organoid-OMI approach also provides a potentially 
powerful system to test an individual’s response to multiple treatment schemes, rather than infer a 
possible response from biomarkers.   This combination of optical imaging of metabolism, organoid 
drug screens, and single cell analysis is highly innovative and opens up additional research 
avenues. 
The fluorescence lifetimes of NADH and FAD are significantly under-studied, with only a 
handful of labs around the world that investigate any of these endpoints alone in any context.  The 
work in this dissertation has characterized the fluorescence lifetimes of NADH and FAD in vivo, 
in live cultured, freshly excised tissues, frozen tissues, and organoids.  Traditionally, metabolism 
endpoints are thought to significantly change upon removal from the body and thus metabolic 
imaging studies have been limited to in vivo studies.  However, the results of Chapter 5 suggest 
that optical metabolic endpoints, particularly the fluorescence lifetime of NADH and FAD remain 
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stable up to 8 hr post removal.  These findings enable optical metabolic imaging in an array of 
experiments and situations when in vivo imaging is not practical. 
Additionally, this dissertation presents novel image analysis techniques that are applicable 
and translatable to microscopy research, and not limited to optical metabolic imaging data.  An 
automated image segmentation algorithm was developed in CellProfiler to segment 
autofluorescence images of clumped cells and organoids into cells, nuclei, and cytoplasms 
(Appendix D).  To our knowledge, this is the first published code for segmentation of clumped 
cells in auto-fluorescence images.  Additionally, image analysis techniques were developed to 
analyze images and data sets on a single cell level to quantify cellular heterogeneity and identify 
cell subpopulations (Chapter 3).  Both of these techniques can be used in future optical metabolic 
imaging studies and applied to additional microscopy techniques and applications. 
Contributions to Cancer Biology 
Cancer cells are known to exhibit abnormal cellular metabolism (24). Furthermore, 
oncogenic signaling often regulates cellular metabolism processes.  For example, in breast cancer, 
the estrogen receptor regulates gene expression of glucose transporter proteins and proteins 
involved in oxidative phosphorylation and the citric acid cycle (25-27).  Additionally, HER2 
mediates metabolism through signaling of the PI3K pathway (28, 29).  Therefore, oncogenic 
inhibition by anti-cancer drugs may affect cellular metabolism and as demonstrated in this 
dissertation, cellular metabolism provides a robust indicator of drug response.  This dissertation 
contributes research and evidence on the relationships between metabolism, cancer, and drug 
response.   
Furthermore, cellular metabolism is difficult to quantify.  Cellular metabolism can be 
investigated by measuring quantities of fuel sources, metabolic products, flux of metabolic 
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enzymes, or by imaging methods such as histology, diffuse optical tomography or FDG-PET; 
however, each of these methods is sensitive to only a small subset of the cellular metabolism 
process.  Fluorescence imaging of NADH and FAD provides a global measure of cellular 
metabolism because the source of contrast, NADH and FAD, are coenzymes used throughout 
metabolism.  The studies and experiments reported in this dissertation fully characterize NADH 
and FAD fluorescence and fluorescence lifetimes as biomarkers of cellular metabolism for use in 
future studies of cancer biology. 
There is a growing body of evidence that interactions between cancer cells and surrounding 
cells in the tumor microenvironment may mediate resistance to cancer drugs (30).  Therefore, 
organoid cultures provide an attractive platform for drug response studies because organoids retain 
the malignant tumor cells and the native tumor microenvironment.  To date, primary tumor 
organoid cultures are understudied and underutilized.  Chapter 6 and Appendix E present novel 
methods for the generation and culture of primary xenograft and human tumor-derived organoids.  
This work is innovative and applicable for future organoid studies.  Furthermore, the work in 
Appendix E demonstrates feasibility of growth of organoids from frozen-thawed tissues. This will 
enable broad adoption of organoid techniques, even where fresh tissues are not available. 
Bridging the Gap Between Preclinical and Clinical Research 
 Currently, the costs to develop a new drug are astronomical and many new drugs that show 
potential in preclinical experiments fail to show efficacy in expensive clinical trials (31).  More 
relevant disease models are needed to bridge the gap between preclinical and clinical research.  In 
oncology, preclinical models include immortalized cell lines, human xenografts grown in mice 
from immortalized cell lines, and genetically engineered mouse cancers.  Recently, patient-derived 
xenograft models have also been proposed as a relevant cancer model (32, 33), however, patient 
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derived xenografts are expensive, difficult to grow, and require lengthy growth periods and 
multiple passages.  Primary tumor-derived organoids present an attractive platform for preclinical 
studies and may help bridge the gap between preclinical and clinical studies.  Organoid generation 
and culture is inexpensive, fast, and highly reproducible with nearly 100% of tumors able to grow 
organoids.  Organoids contain all the innate cells of the tumor and maintain tumor-stroma 
interactions.  Therefore, organoids may better represent cancer physiology than immortalized cells 
or 2D culture.  For these reasons, organoids may provide a missing link for preclinical trials. 
Potential Impact on Preclinical Drug Trials 
Development of OMI to measure therapeutic response would have a revolutionary effect 
on pre-clinical studies of drug development and efficacy.  Currently, the gold standard of drug 
efficacy is tumor regression or growth.  Early identification of responding tumors requires IHC 
staining of drug targets, apoptotic cells, and proliferating cells.  IHC can only be performed on 
excised tissue and thus, requires the sacrifice of cohorts of mice at each time point in a longitudinal 
study.  Long-term drug efficacy trials can require hundreds of mice to obtain the statistical power 
for conclusive results.  OMI can be performed in vivo, through a coverslip, or window chamber 
(34).  In such manner, OMI data from the same animal and tumor can be acquired over time, 
reducing the need for parallel cohorts.  This reduction in animal burden would reduce the cost and 
greatly accelerate preclinical studies. 
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Figure 7.1 Clinical impact of OMI-organoid drug screen. The potential impact 
of the live tumor (organoid) and optical metabolic imaging (OMI) system on breast 
cancer care.  A small breast tumor biopsy is broken up and grown in multiple 
organoid macro-suspensions.  Each organoid is treated with a different drug or drug 
combination, and subsequently imaged with OMI.  Changes in cellular metabolism 
are used to assess the efficacy of each drug and drug combination.  The 
individually-tailored optimal treatment regimen is then applied to the patient, 
increasing the chances of remission-free survival. 
 
Implications of an Organoid-OMI Drug Screen for Breast Cancer Care 
Development of a live-culture tissue technique combined with OMI will enable a high-
throughput screen of potential drugs and drug combinations to identify the most effective treatment 
for each breast cancer patient.  In such a system, a tumor sample is removed via a routine biopsy, 
organoids are generated from the tissue biopsy and treated with potential drugs and drug 
combinations, OMI is performed to measure metabolic response of the organoids, and the ideal 
drug or drug combination is identified and administered to the patient (Fig. 7.1). This technology 
will revolutionize patient care by predicting response to multiple treatment regimens, rather than 
reacting to a prescribed treatment.  Optimal matching of a patient to a drug regimen will result in 
earlier effective treatment for the ~300,000 breast cancer patients diagnosed each year, resulting 
in increased survival.  Also, this screen will save patients from the emotional, temporal, and 
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financial cost of ineffective therapies and spare patients the increased toxicities of exposure to 
ineffective drugs.  
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APPENDIX A 
Supplementary Figures and Tables for Chapter 4 
 
Figure A.1: NADH (a-c) and FAD (d-f) fluorescence lifetime components in MCF10A cells before and 
after exposure to 4 mM NaCN. NADH 1 and 2 correspond to the free and protein-bound components of 
the lifetime, respectively.  FAD 1 and 2 correspond to the protein-bound and free components of the 
lifetime, respectively. 1 corresponds to the relative contribution of 1 to the overall decay, such that 
1+2=1.** P <0.001, * P <0.05 
 
Table A.1: Breast cancer cell lines and receptor expression. Eight cell lines were investigated in this 
study, with ER and HER2 status provided.  The last three columns provide the number of images (in vitro) 
or tumors (in vivo) collected to compile the results in Fig. 2-6. 
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Figure A.2: Relationship between redox ratio and cell proliferation. (a) Redox ratio results normalized 
to % mitotic cells. The optical redox ratio increases with ER (MCF7, green) and HER2 (MDA-MB-361, 
BT474, and SKBr3, blue) expression relative to non-malignant (MCF10A, black) cells.  The redox ratio is 
also increased in HER2+ cells relative to triple negative (MDA-MB-231, red) and ER+ cells, and in ER+ 
cells relative to triple negative cells.  Unless indicated with a line, stars (*) indicate statistically significant 
differences with the MCF10A (non-malignant) cells and bullets (•) indicate statistically significant 
differences with the HER2+ cells grouped together.   ** P<0.001 , •• P<0.001, • P<0.05. (b) Percentage of 
mitotic cells measured for each cell line.   
 
Figure A.3: Fluoresccence lifetime components for a panel of breast cancer cells. NADH (a-c) and 
FAD (d-f) lifetime components (1, short lifetime; 2, long lifetime; and 1, relative contribution of the short 
lifetime) for a non-malignant (MCF10A, black), a triple-negative breast cancer (MDA-MB-361; red), an 
ER+ (MCF7, green), and three HER2+ (MDA-MB-361, BT474, and SKBr3; blue) cell lines. Stars (*) 
indicate statistically significant differences with the MCF10A (non-malignant) cells and bullets (•) indicate 
statistically significant differences with the HER2+ cells grouped together.   ** P <0.001 , •• P < 0.001, • 
P <0.05 
a 
b 
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Figure A.4: Scatterplots of OMI endpoints. (a) A scatterplot of FAD m versus redox ratio/proliferation 
provides visual separation of the different molecular sub-types of breast cancer [non-malignant (NM), 
ER+, HER2+, and triple negative (TNBC)]. (b) A scatterplot of FAD m versus NADH m provides visual 
separation of the different molecular sub-types of breast cancer [non-malignant (NM), ER+, HER2+, and 
triple negative (TNBC)].  
 
Table A.2:  Spearman’s rank correlation coefficients (P-value) for comparisons of metabolic 
measures.  NADH and FAD m are computed from 1, 2, and 1 (m = 1*α1 + 2*α2). Shaded boxes 
highlight significant (P<0.05) correlations. 
 
  
a b 
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Figure A.5:  Fluorescence lifetime components for in vitro trastuzumab experiment. NADH (a-c) and 
FAD (d-f) lifetime components (1, short lifetime; 2, long lifetime; and 1, relative contribution of the short 
lifetime) for trastuzumab perturbation of BT474, MDA-MB-361, and HR6 cells. ** P <0.001; * P <0.05 
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Figure A.6: Distribution density modeling of OMI endpoints for in vitro trastuzumab experiment.  (a, 
c) Distribution density modeling reveals one population of cells in BT474 (a) and HR6 (c) in control (blue) 
and trastuzumab (red) treated cultures. (b) Distribution density modeling reveals two distinct populations 
of MDA-MB-361 cells for the redox ratio with a significant decrease in the mean of the minority peak (30% 
of cells) with trastuzumab treatment, suggesting trastuzumab response in a sub-population of cells. (d-i) 
Distribution density modeling of cellular NADH m (d-f) and FAD m (g-i) reveals one population of cells 
for control (blue) and trastuzumab (red) treated BT474 (d,g), MDA-MB-361 (e,h) and HR6 (f, i) cells. m 
is the mean lifetime (1*α1 + 2*α2).  * P<0.05 
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Figure A.7 Fluorescence lifetime components for BT474 xenografts. NADH (a-c) and FAD (d-f) 
lifetime components (1, short lifetime; 2, long lifetime; and 1, relative contribution of the short lifetime) 
for control IgG-treated and trastuzumab-treated (10 μg/kg, 2x weekly) BT474 xenografts, measured at 2, 
5, and 14 days after treatment was initiated. *P<0.05 
 
 
Figure A.8 Fluorescence lifetime components for HR6 xenografts. NADH (a-c) and FAD (d-f) lifetime 
components (1, short lifetime; 2, long lifetime; and 1, relative contribution of the short lifetime) for 
control IgG-treated and trastuzumab-treated (10 μg/kg, 2x weekly) HR6 xenografts, measured at 2, 5, and 
14 days after treatment was initiated.  
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Figure A.9 Fluorescence lifetime components for MDA-MB-231 xenografts.   NADH (a-c) and FAD 
(d-f) lifetime components (1, short lifetime; 2, long lifetime; and 1, relative contribution of the short 
lifetime) for control IgG-treated and trastuzumab-treated (10 μg/kg, 48 hours) MDA-MB-361 xenografts, 
measured 48h after treatment. * P <0.05 
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APPENDIX B 
Supplementary Figures and Tables for Chapter 6 
 
Figure B.1: OMI endpoints of organoids derived from a trastuzumab-responsive xenograft 
tumor. A. Redox ratio of BT474 xenograft-derived organoids treated with paclitaxel (P), 
trastuzumab (H), XL147 (X), and the combined drug treatments H+P, H+X, H+P+X at 24 (blue), 
48 (red), and 72hr (green).  B. NADH m  of BT474 xenograft-derived drug treated organoids at 
24 (blue), 48 (red), and 72hr (green).  C. FAD m  of BT474 xenograft-derived drug treated 
organoids at 24 (blue), 48 (red), and 72hr (green).  D. OMI index (composite endpoint of weighted 
redox ratio, NADH m, and FAD m) of BT474 xenograft-derived drug treated organoids at 24 
(blue), 48 (red), and 72hr (green).  *p<0.05, for treated vs. control within a time point. 
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Table B.1: NADH and FAD lifetime component values of BT474-xenograft derived 
organoids (mean, standard deviation) from a two-component exponential fit of the fluorescence 
decay, ( CtI
tt   21 /2
/
1 expexp)(
  ). Boxes shaded pink represent a significant decrease in 
mean value vs. control.  Boxes shaded blue represent a significant increase in mean value vs. 
control. NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound NADH. FAD 
1/1 is attributed to bound FAD, FAD 2/2  is attributed to free FAD.  
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Figure B.2: Population modeling identifies heterogeneous drug responses of BT474 cells.  
A.  Population density modeling of the mean OMI index per cell in control and treated BT474 
organoids at 24 hr.  B.  Population density modeling of the OMI index for BT474 organoids 
treated for 72hr.  
 
Figure B.3: OMI endpoints of organoids derived from a trastuzumab-resistant xenograft 
tumor. A. Redox ratio of HR6 xenograft-derived organoids treated with paclitaxel (P), 
trastuzumab (H), XL147 (X), and the combined drug treatments H+P, H+X, H+P+X at 24 (blue), 
48 (red), and 72hr (green).  B. NADH m  of HR6 xenograft-derived drug treated organoids at 24 
(blue), 48 (red), and 72hr (green).  C. FAD m  of HR6 xenograft-derived drug treated organoids 
at 24 (blue), 48 (red), and 72hr (green).  D. OMI index (composite endpoint of weighted redox 
ratio, NADH m, and FAD m) of HR6 xenograft-derived drug treated organoids at 24 (blue), 48 
(red), and 72hr (green).  *p<0.05, for treated vs. control within a time point. 
A B 
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Table B.2: NADH and FAD lifetime component values of HR6-xenograft derived organoids 
(mean, standard deviation) from a two-component exponential fit of the fluorescence decay, (
CtI
tt   21 /2
/
1 expexp)(
  ). Boxes shaded pink represent a significant decrease in mean 
value vs. control.  Boxes shaded blue represent a significant increase in mean value vs. control. 
NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound NADH. FAD 1/1 
is attributed to bound FAD, FAD 2/2  is attributed to free FAD.  
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Figure B.4: Population modeling identifies heterogeneous drug responses of HR6 cells.  A.  
Population density modeling of the mean OMI index per cell in control and treated HR6 organoids 
at 24 hr.  B.  Population density modeling of the OMI index for HR6 organoids treated for 72hr.  
 
 
 
Table B.3: Grade, proliferation rate, estrogen receptor expression, progesterone receptor 
expression, and HER2 receptor expression of the patient samples.   
Sample Grade 
Proliferative 
rate 
ER 
intensity 
(% cells) 
PR 
intensity 
(% cells) 
Her2 
FISH 
Her2:Cep17 
ratio Figures 
1  high high 3+ (95) 3+ (95) 
Not 
Amp 1.7 
Fig. 5A-C,  
Sup. Fig. 3 
2 
Inter-
mediate Intermediate 3+ (90) 3+ (90) 
Not 
Amp 1.4 
Fig. 5D,E 
Sup. Fig. 4 
3 high high 3+ (95) 3+ (99) 
Not 
Amp 1 
Fig. 5F,G 
Sup. Fig. 5 
4 high Intermediate 3+ (95) 3+ (70) 
Not 
Amp 1.1 
Fig. 5H,I 
Sup. Fig. 6 
5 high high 0 (0) 0 (0) Amp 7.95 
Fig. 6A,B 
Sup. Fig. 7 
6 high high 2+ (3) 2+(3) 
Not 
Amp 0.9 
Fig. 6C,D 
Sup. Fig. 8 
A B 
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Figure B.5: Population modeling identifies heterogeneous drug responses of organoids from 
patient sample #1 (ER+/HER2-).  Population density modeling of the mean OMI index per cell 
in control and treated organoids derived from patient sample #1 (ER+/HER2+) at 72 hr.  
 
Figure B.6: OMI endpoints of organoids derived from a ER+ primary tumor. A. Redox ratio 
of organoids derived from an ER+ primary tumor treated with paclitaxel (P), tamoxifen (T), 
trastuzumab (H), XL147 (X), and the combined drug treatments H+X, H+P+X, H+P+T, and 
H+P+T+X at 24 (blue), 48 (red), and 72hr (green).  B. NADH m of organoids derived from an 
ER+ primary tumor at 24 (blue), 48 (red), and 72hr (green).  C. FAD m of  organoids derived from 
an ER+ primary tumor at 24 (blue), 48 (red), and 72hr (green).  D. OMI index (composite endpoint 
of weighted redox ratio, NADH m, and FAD m) of organoids derived from an ER+ primary tumor 
at 24 (blue), 48 (red), and 72hr (green).  *p<0.05, for treated vs. control within a time point. 
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Table B.4: NADH and FAD lifetime component values of organoids derived from an ER+ 
primary tumor (mean, standard deviation). Boxes shaded pink represent a significant decrease in 
mean value vs. control.  Boxes shaded blue represent a significant increase in mean value vs. 
control. NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound NADH. FAD 
1/1 is attributed to bound FAD, FAD 2/2  is attributed to free FAD.  
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Figure B.7: Population modeling identifies heterogeneous drug responses of organoids from 
patient sample #2 (ER+/HER2-).  Population density modeling of the mean OMI index per cell 
in control and treated organoids derived from patient sample #2 (ER+/HER2+) at 72 hr.  
  
Figure B.8: OMI endpoints of  organoids derived from a second ER+ primary tumor.  A. 
Redox ratio of organoids derived from a second ER+ primary tumor treated with paclitaxel (P), 
tamoxifen (T), trastuzumab (H), and the combined drug treatments H+P, H+T, P+T, and H+P+T 
at 24 (blue), 48 (red), and 72hr (green).  B. NADH m  at 24 (blue), 48 (red), and 72hr (green).  C. 
FAD m at 24 (blue), 48 (red), and 72hr (green).  D. OMI index (composite endpoint of weighted 
redox ratio, NADH m, and FAD m)  at 24 (blue), 48 (red), and 72hr (green).  *p<0.05, for treated 
vs. control within a time point. 
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Table B.5: NADH and FAD lifetime component values of organoids derived from a second 
ER+ primary tumor (mean, standard deviation). Boxes shaded pink represent a significant 
decrease in mean value vs. control.  Boxes shaded blue represent a significant increase in mean 
value vs. control. NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound 
NADH. FAD 1/1 is attributed to bound FAD, FAD 2/2  is attributed to free FAD.  
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Figure B.9: Population modeling identifies heterogeneous drug responses of organoids from 
patient sample #3 (ER+/HER2-).  Population density modeling of the mean OMI index per cell 
in control and treated organoids derived from patient sample #3 (ER+/HER2+) at 24 hr.  
 
Figure B.10: Population modeling identifies heterogeneous drug responses of organoids from 
patient sample #4 (ER+/HER2-).  Population density modeling of the mean OMI index per cell 
in control and treated organoids derived from patient sample #4 (ER+/HER2+) at 72 hr.  
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Figure B.11: OMI endpoints of  organoids derived from a third ER+ primary tumor. A. 
Redox ratio of organoids derived from a third ER+ primary tumor treated with paclitaxel (P), 
tamoxifen (T), trastuzumab (H), XL147 (X) and the combined drug treatments H+P, H+X, and 
H+P+T+X at 24hr.  B. NADH m  of these organoids at 24hr.  C. FAD m of these organoids at 
24hr.  D. OMI index (composite endpoint of weighted redox ratio, NADH m, and FAD m)  at 
24hr.  *p<0.05, for treated vs. control. 
Table B.6: NADH and FAD lifetime component values of organoids derived from a third 
ER+ primary tumor (mean, standard deviation). Boxes shaded pink represent a significant 
decrease in mean value vs. control.  Boxes shaded blue represent a significant increase in mean 
value vs. control. NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound 
NADH. FAD 1/1 is attributed to bound FAD, FAD 2/2  is attributed to free FAD.  
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Figure B.12: OMI endpoints of organoids derived from a fourth ER+ primary tumor. A. 
Redox ratio of organoids derived from a fourth ER+ primary tumor treated with paclitaxel (P), 
tamoxifen (T), trastuzumab (H), XL147 (X) and the combined drug treatments H+P, H+X, 
H+P+X, H+P+T, and H+P+T+X at 24 (blue), 48 (red), and 72hr (green).  B. NADH m of these 
organoids at 24 (blue), 48 (red), and 72hr (green).  C. FAD m at 24 (blue), 48 (red), and 72hr 
(green).  D. OMI index (composite endpoint of weighted redox ratio, NADH m, and FAD m) at 
24 (blue), 48 (red), and 72hr (green).  *p<0.05, for treated vs. control within a time point. 
 
  
175 
 
Table B.7: NADH and FAD lifetime component values of organoids derived from a fourth 
ER+ primary tumor (mean, standard deviation). Boxes shaded pink represent a significant 
decrease in mean value vs. control.  Boxes shaded blue represent a significant increase in mean 
value vs. control. NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound 
NADH. FAD 1/1 is attributed to bound FAD, FAD 2/2  is attributed to free FAD.  
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Figure B.13: OMI endpoints of organoids derived from a HER2+ primary tumor.  A. Redox 
ratio of organoids derived from a HER2+ primary tumor treated with fulvestrant, trastuzumab, and 
A4 at 24hr.  B. NADH m  of these organoids at 24hr.  C. FAD m at 24hr.  D. OMI index (composite 
endpoint of weighted redox ratio, NADH m, and FAD m)  at 24hr.  *p<0.05, for treated vs. 
control. 
Table B.8: NADH and FAD lifetime component values of organoids derived from a HER2+ 
primary tumor (mean, standard deviation). Boxes shaded pink represent a significant decrease in 
mean value vs. control.  Boxes shaded blue represent a significant increase in mean value vs. 
control. NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound NADH. FAD 
1/1 is attributed to bound FAD, FAD 2/2  is attributed to free FAD.  
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Figure B.14: OMI endpoints of organoids derived from a TNBC primary tumor. A. Redox 
ratio of organoids derived from a TNBC primary tumor treated with tamoxifen (T), trastuzumab 
(H), and the combined treatment, H+T at 48hr.  B. NADH m  of these organoids at 48hr.  C. FAD 
m at 48hr.  D. OMI index (composite endpoint of weighted redox ratio, NADH m, and FAD m)  
at 48hr.  *p<0.05, for treated vs. control. 
Table B.9: NADH and FAD lifetime component values of organoids derived from a TNBC 
primary tumor (mean, standard deviation). Boxes shaded pink represent a significant decrease in 
mean value vs. control.  Boxes shaded blue represent a significant increase in mean value vs. 
control. NADH 1/1 is attributed to free NADH, NADH 2/2 is attributed to bound NADH. FAD 
1/1 is attributed to bound FAD, FAD 2/2  is attributed to free FAD. 
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APPENDIX C 
Optical Imaging of Metabolism in HER2 Overexpressing Breast Cancer Cells 
Walsh AJ, Cook RS, Rexer B, Arteaga CL, Skala MC. “Optical imaging of metabolism in HER2 
overexpressing breast cancer cells.” Biomed Opt Express. 2012;3(1):75-85.  
 
C.1 Abstract 
The optical redox ratio (fluorescence intensity of NADH divided by that of FAD), was 
acquired for a panel of breast cancer cell lines to investigate how overexpression of human 
epidermal growth factor receptor 2 (HER2)  affects tumor cell metabolism, and how tumor 
metabolism may be altered in response to clinically used HER2-targeted therapies.  Confocal 
fluorescence microscopy was used to acquire NADH and FAD auto-fluorescent images.  The 
optical redox ratio was highest in cells overexpressing HER2 and lowest in triple negative breast 
cancer (TNBC) cells, which lack HER2, progesterone receptor, and estrogen receptor (ER).  The 
redox ratio in ER-positive/HER2-negative cells was higher than what was seen in TNBC cells, but 
lower than that in HER2 overexpressing cells. Importantly, inhibition of HER2 using trastuzumab 
significantly reduced the redox ratio in HER2 overexpressing cells. Furthermore, the combinatorial 
inhibition of HER2 and ER decreased the redox ratio in ER+/HER2+ breast cancer cells to a 
greater extent than inhibition of either receptor alone. Interestingly, trastuzumab had little impact 
upon the redox ratio in a cell line selected for acquired resistance to trastuzumab. Taken together, 
these data indicate that the optical redox ratio measures changes in tumor metabolism that reflect 
the oncogenic effects of HER2 activity within the cell, as well as the response of the cell to 
therapeutic inhibition of HER2. Therefore, optical redox imaging holds the promise of measuring 
response and resistance to receptor-targeted breast cancer therapies in real time, which could 
potentially impact clinical decisions and improve patient outcome. 
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C.2 Introduction  
The course of breast cancer treatment increasingly relies on the molecular phenotype of the 
tumor.  For example, breast cancers that overexpress the estrogen receptor (ER) are often treated 
with ER-antagonists (e.g., tamoxifen, fulvestrant), while those that overexpress human epidermal 
growth factor receptor 2 (HER2) are often treated with HER2-inhibitors (e.g., trastuzumab, 
lapatinib).  HER2 overexpressing tumors display aggressive cancer progression (1) and account 
for approximately 25% of all breast cancer patients.   Treatment with trastuzumab (a monoclonal 
antibody which binds HER2) and lapatinib (a dual tyrosine kinase inhibitor that binds both HER2 
and the epidermal growth factor receptor) has been shown to prolong survival in patients with 
HER2 overexpressing breast cancers (2-4).  Due to the importance of choosing the correct 
treatment for breast cancer patients, breast tumors are routinely screened for expression of ER and 
HER2.  Currently, ER and HER2 expression are determined by immunohistochemistry (IHC) and 
fluorescence in situ hybridization (FISH).   
Unfortunately, approximately one-third of breast tumors that overexpress HER2 do not 
respond to trastuzumab and lapatinib therapy (4).  Similarly, only 57% of patients with ER-positive 
breast cancers respond to tamoxifen therapy (5).  However, there are reasons to remain optimistic, 
as novel therapeutics are in development to overcome clinical resistance to these therapeutic 
inhibitors (6).  Early identification of those cancers that respond to targeted therapies versus those 
that are resistant will expedite clinical decisions regarding the course of treatment and will improve 
the clinical outcomes of breast cancer patients.  
Methods currently under development to determine tumor response to therapy include 
positron emission tomography (PET), x-ray computed tomography (CT) and magnetic resonance 
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imaging (MRI) (7-9). Evidence that tumor response to targeted inhibitors can be visualized was 
demonstrated with the use of fluoro-deoxyglocose (FDG)-PET, which is capable of detecting 
focused areas of high glucose uptake that are often seen in solid tumors. A preliminary clinical 
study of lapatinib-treated breast cancers showed changes in tumor metabolism after 1 month of 
lapatinib treatment (10).   Yet, these currently available technologies provide only low resolution 
images, are non-portable, and usually require the use of contrast agents. Given the high cost of 
these procedures, it is unlikely that these will be adopted as standard of care, underscoring the need 
for more efficient, accurate, and cost-effective methods of identifying receptor expression and 
therapeutic response.   
Cellular metabolism is a potentially powerful biomarker for tumor analysis. Unlike normal 
cells that rely on oxidative phosphorylation to generate ATP, or that use glycolysis under anaerobic 
conditions, cancer cells often generate ATP through aerobic glycolysis (11).  Interestingly, 
signaling through the HER2 and ER pathways in breast cancer cells is thought to promote aerobic 
glycolysis. ER increases glucose transport and glycolysis (12, 13).  Similarly, HER2 activated 
pathways may increase glucose transport into the cell and glycolysis (14, 15). HER2 signaling 
activates phosphatidyl inositol 3-kinase (PI3K) a major driver of aerobic glycolysis (16-19).  In 
mouse models of HER2 overexpressing breast cancer, trastuzumab and lapatinib inhibited PI3K 
activity and decreased glucose uptake as measured by FDG-PET imaging (20).   Conversely, breast 
tumor cells exhibiting resistance to HER2 inhibitors display aberrantly increased PI3K activity 
and active hypoxia signaling despite the presence of adequate oxygen(18). These studies suggest 
that differences in aerobic glycolysis may reflect not only oncogene-driven metabolic 
characteristics of the tumor cell, but also the effect of therapeutic inhibitors on tumor metabolism, 
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and could therefore be used to distinguish tumors that are responsive to therapeutic inhibitors from 
those that are resistant.  
During oxidative phosphorylation, NADH is oxidized to NAD+ and FAD is reduced to 
FADH2.  However, the process of glycolysis causes NAD+ to be reduced to NADH.  Therefore, 
the ratio of NADH to FAD is a measurement of the balance between glycolysis (seen in tumor 
cells) and oxidative phosphorylation (seen in untransformed cells). NADH and FAD can be 
measured in situ using autofluorescence optical imaging techniques. The optical redox ratio 
(NADH fluorescence intensity divided by FAD fluorescence intensity) is a proven method of 
probing cellular metabolism and has been used to differentiate cancerous from non-cancerous 
tissues in a variety of models including oral  and breast cancer (21-27).  Ostrander et al. showed 
the optical redox ratio is also sensitive to ER expression in breast cancer cell cultures, and that 
treatment with tamoxifen decreased the optical redox ratio of tamoxifen-sensitive cells, but not 
tamoxifen-resistant cells (27).   
The purpose of this study was to determine the effect of HER2 overexpression on the 
metabolism of breast cancer cells as measured by the optical redox ratio.  The hypothesis that 
HER2 overexpression influences cellular redox ratios independently of ER expression was tested.  
Additionally, the impact of HER2 inhibition on the redox ratio in HER2 overexpressing breast 
cancer cells was measured. Finally, we determined if therapeutic resistance to HER2 inhibitors 
reflected on redox ratio measurements as a failure to reduce redox ratios in response to HER2 
inhibition.  HER2 overexpression was found to increase the redox ratio, independently of ER 
expression.   While HER2 inhibition decreased the optical redox ratios in HER2 overexpressing 
cells, the HER2 inhibitor, trastuzumab, had no impact on redox ratios in trastuzumab resistant 
cells, despite continued overexpression of HER2.   
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C.3 Materials and methods 
C.3.1 Cell culture 
MCF10A cells were cultured in Mammary Epithelial Cell Growth Medium (MEGM, 
Lonza, Walkersville, MD) excluding the gentamycin-amphotericin B mix and supplemented with 
100 ng/ml cholera toxin and 1% penicillin:streptomycin.  The BT474, MDA-MB-231, MCF7, and 
SKBr3 cells were grown in DMEM (Invitrogen, Carlsbad, CA), supplemented with 10% fetal 
bovine serum and 1% penicillin:streptomycin, hereafter referred to as DMEM+.  The resistant cell 
lines were grown in the DMEM+ at levels of the corresponding drug to maintain resistance.  The 
lapatinib resistant cells were grown at 1 µM lapatinib (LC Laboratories, Woburn, MA) 
concentration and the trastuzumab resistant cells were grown at 25 µg/ml.   
For imaging, all cell lines were plated at a density of 1x105 cells per 35 mm plate, 48 hours 
prior to imaging.  Glass bottom dishes (MatTek Corporation, Ashland, MA) were used to allow 
live cell imaging on an inverted, confocal microscope.  The trastuzumab and lapatinib resistant 
cell redox ratio was determined from cells grown in trastuzumab and lapatinib supplemented 
media.  For the drug perturbation experiments, the responsive BT474 cells were fed the drug 
supplemented media 24 hours prior to imaging.  For the trastuzumab perturbation of the 
trastuzumab resistant cells, the cells were fed the DMEM+ media for the first 24 hours after plating 
and the DMEM+ with trastuzumab for the second 24 hours.  Drug concentrations of the media 
were selected to mimic therapeutic drug dosage in patients, 25 µg/ml for trastuzumab (VUMC 
Pharmacy, Nashville, TN) and 2 µM for tamoxifen (Sigma-Aldrich, St. Louis, MO) (20, 28).  
For the cyanide experiment to verify measurement of the redox ratio, MCF10A cells were 
plated at 1 x 105 cells per plate, 48 hours prior to imaging.  Cells were imaged before the addition 
of cyanide.  After 3 images from a plate were acquired, the cell media was exchanged for growth 
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media supplemented with 4 mM NaCN (Sigma-Aldrich, St. Louis, MO).  The cells were given one 
minute to react with the cyanide; then, three different places of each plate were imaged.   
Proliferation rates of MCF10A, MCF7, and BT474 cells were determined by antibody 
labeling of cells grown on parallel imaging plates.  Mitotic cells were first marked using a 
Phospho-Histone H3 (Ser10) antibody (Cell Signaling Technology, Danvers, MA).  Then, labeling 
of the primary antibody with Alexa Fluor 488 goat anti-rabbit IgG antibody (Invitrogen, Carlsbad, 
CA) allowed counting by flow cytometry of the highly fluorescent mitotic cells and the less-
fluorescent unlabeled cells.  The percentage of proliferating cells was determined by dividing the 
number of highly fluorescent cells into the total number of cells counted.   
C.3.2 Verification of ER and HER2 expression  
Cells were homogenized in ice-cold lysis buffer [50 mM Tris pH 7.4, 100 mM NaF, 120 
mM NaCl, 0.5% NP-40, 100 µM Na3VO4, 1X protease inhibitor cocktail (Roche)], sonicated for 
10 s at 4ºC, 13,000 x g for 5 min. Protein concentration was determined using the BCA assay 
(Pierce). Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
Membranes were blocked in 3% gelatin in TBS-T [Tris-buffered saline, 0.1% Tween-20) for 1 h, 
incubated in primary antibody in 3% gelatin for 2 h at room temperature, washed with TBS-T, 
incubated in HRP-conjugated anti-rabbit or anti-mouse IgG, washed with TBS-T, and then 
developed using ECL substrate (Pierce). The following primary antibodies were used: ErbB2 
(HER2) (Neomarkers, InVitrogen; 1:2000); ER-alpha (Santa Criz Biotechnologies; 1:1000); beta 
actin (Sigma-Aldrich; 1:5000). 
C.3.3 Confocal imaging 
Images were acquired using an Olympus FV-1000 Inverted Confocal Microscope with a 
40X/1.3 NA oil-immersion objective.   Confocal microscopy was chosen over widefield 
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fluorescence to reduce background noise for ease of NADH and FAD auto-fluorescence 
measurement.  Additionally, the redox ratio is sensitive to measurement volumes and confocal 
microscopy ensures that the NADH and FAD signals can be co-registered to the same volume.  
For NADH fluorescence, the cells were excited at 405 nm and 410-510 nm emission was collected.  
FAD was excited at 488 nm and 500-600 nm emission was collected.  The two images were 
acquired simultaneously, with NADH and FAD acquired sequentially for each pixel.  A pixel dwell 
time of 2 µs was used.    Each line was averaged 4 times to reduce noise.  A single 1024x1024 
pixel image required 39.0 s to acquire.  To ensure the cells were not photobleaching, two images 
of the same field of view were acquired consecutively with no significant change in average pixel 
intensity.  Settings for the gain, offset, and pinhole were maintained across all imaging sessions.  
To account for daily variations in laser power or instrumentation instability, the images were 
normalized to MCF10A cell measurements acquired during each imaging session.  Each plate was 
imaged at 3 different, non-overlapping locations.   
C.3.4 Image analysis 
The optical redox ratio, NADH fluorescence intensity divided by FAD fluorescence 
intensity, was computed for each cell in the image using ImageJ software (NIH).  The fluorescence 
signal of non-cellular regions, or background signal, was removed to ensure the fluorescence 
comparisons were made only for the cells.  NADH and FAD used for cellular metabolism are 
contained within the cytoplasm and mitochondria, and the fluorescence signal from the nucleus is 
not involved in cellular metabolism.  Therefore, the fluorescence signal from the nucleus was also 
removed to ensure isolation of metabolic NADH and FAD and eliminate the possibility of nuclear 
size as a confounding factor.     Next, a NADH/FAD per pixel image was computed and the redox 
ratio for each cell in the image was determined.  The average redox ratio value from all cells in 
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each image was computed and normalized to the corresponding session's MCF10A measurement.  
Standard error was computed from the mean redox ratio value across all images from each cell 
line.  A rank sum test was used for all statistical comparisons.   
C.4 Results 
The optical redox ratio of a panel of human breast-derived cell lines with varying 
expression of ER and HER2 were studied (Table C.1, Fig. C.1).  MCF10A, a non-cancerous breast 
cell line with negligible or low expression of ER and HER2 was used as a control for each analysis. 
Table C.1:  Breast cancer cell lines with corresponding ER and HER2 expression. 
Cell line Cancerous ER status HER2 
overexpression 
n 
MCF-10A Non-
cancerous 
- / low - / low 30 
MDA-MB-231 Cancer Negative Negative 15 
MCF-7 Cancer Positive Negative 15 
BT-474 Cancer Positive Positive 15 
SKBr3 Cancer Negative Positive 15 
HR6 
(Trastuzumab  
Resistant BT-474) 
Cancer Positive Positive 15 
BT-LR (Lapatinib 
Resistant BT-474) 
Cancer Positive Positive 15 
 
 
Figure C.1: Receptor expression of breast cancer cell lines. Western blot analysis demonstrates 
overexpression of HER2 in the SKBR3 and BT474 cells and expression of ER in the MCF7 and 
BT474 cells. 
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Figure C.2. Cyanide validation experiment. Addition of CN to MCF10A cells (n = 6) 
results in an increase in redox ratio and NADH fluorescence and a decrease in FAD 
fluorescence.  Bar height represents mean and error bars represent SE. 
 
To verify the use of optical imaging to measure the redox ratio, cyanide was used to disrupt 
the electron transport chain, thus preventing the conversion of NADH to NAD+ (29).  As 
predicted, MCF10A cells treated with cyanide exhibited increased NADH fluorescence (p < 0.01, 
Fig. C.2) and decreased FAD fluorescence (p < 0.05; Fig. C.2). Therefore, the redox ratio was 
increased in cyanide-treated MCF10A cells as compared to untreated cells (p < 0.005, Fig. C.2).  
These results confirm that our optical imaging methods accurately reflect the balance between 
glycolysis and oxidative phosphorylation, and can be used to assess the metabolic state of tumor 
cells.  
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Figure C.3. Representative confocal images. Representative NADH, FAD, and redox ratio 
images for MCF10A, MDA-231, MCF7, BT474 and SKBr3 cells.  Optical redox ratio increases 
with ER and HER2 expression. 
 
 
 
 
 
Figure C.4. Redox ratio of breast cancer cells. Quantitative representation (mean +/- 
SE) of the redox ratio values for the MCF10A (n=30), MDA-MB-231 (n=15), MCF7 
(n=15), BT474 (n=15), and SKBr3 cells (n=15).  Redox ratio is elevated in cells 
overexpressing HER2. 
 
We used optical imaging to capture NADH and FAD fluorescence in five breast derived 
cell lines (Fig. C.3): MCF10A (untransformed breast epithelial cells), MDA-MB-231 (ER-
/HER2), MCF-7 (ER+/HER2-), SKBR3 (ER-/HER2+), and BT474 (ER+/HER2+). The 
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fluorescence intensities were used to calculate the redox ratio per cell for each cell line (Fig. C.4).  
While ER-/HER2- MDA-MB-231 cells displayed a redox ratio that was similar to what was seen 
in untransformed MCF10A cells, redox ratios were elevated in all other breast cancer cell lines (p 
< 0.005).  ER+/HER2- breast cancer cell lines displayed elevated redox ratios (p<0.005), but not 
to the extent seen in HER2+ breast cancer cell lines (p<0.001).   
 
Figure  C.5.  Redox ratio divided by proliferation rate mean +/- SE for 
MCF10A (n=30), MCF7 (n = 15) and BT474 (n = 15) cells.   
 
Controlling for differences in rates of proliferation among the MCF10A, MCF7, and 
BT474 cells did not reduce the significance of the redox ratio results shown in Fig. 4.  In fact, 
controlling for proliferation (redox ratio divided by proliferation rate for each cell line) increases 
the differences between these three cell lines (Fig. C.5). 
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Figure C.6. Redox ratio following tamoxifen and trastuzumab treatment. (A) 
The redox ratio (mean +/-SE) of responsive BT474 cells is different from the 
trastuzumab  (HR6) and lapatinib (BT-LR) resistant cells (n=15), and there was no 
change in the redox ratio of trastuzumab-resistant HR6 cells with trastuzumab-
treatment.  (B) The redox ratio of responsive BT474 cells decreased with tamoxifen 
(2 µM), trastuzumab (25 µg/ml), and tamoxifen + trastuzumab treatment (n=15). 
 
The redox ratio of both the trastuzumab resistant cell line, HR6, and the lapatinib resistant 
cell line, BT-LR, was lower than the redox ratio for the responsive parental BT474 cells (Fig. 
C.6A). The HR6 cells are BT474-derived cells that continue to grow in the presence of trastuzumab 
(30).  Likewise, the BT-LR cells are BT474-derived cells that were selected in culture with 
increasing concentrations of lapatinib (31). To investigate the contributions of the ER and HER2 
signaling pathways to the redox ratio, BT474 cells (ER+/HER2+) were exposed to the ER 
antagonist tamoxifen and the anti-HER2 monoclonal antibody trastuzumab, (Fig. C.6B).  
Trastuzumab significantly decreased the redox ratio in ER+/HER2+ breast cancer cells (p<0.001; 
Fig. C.6B). Similarly, tamoxifen resulted in a decrease in redox ratio in the same cells (p<0.001, 
Fig. C.6B).  The combination of tamoxifen with trastuzumab decreased the redox ratio in  BT474 
cells (ER+/HER2+) to a greater extent than single agent tamoxifen (p<0.001) or trastuzumab 
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(p<0.001; Fig. C.6B).  Interestingly, treatment of HR6 cells with trastuzumab did not cause any 
alterations in the redox ratio (Fig. C.6A).  It is difficult to fully eliminate the influence of lapatinib 
on the BT-LR cells; and therefore, outside the scope of this paper to robustly perform a comparison 
of pre- and post- lapatinib treatment in these cells.   
C.5 Discussion 
The selective use of aerobic glycolysis over oxidative phosphorylation by cancer cells has 
been known for over a century. We and others have shown that this characteristic of cancer cells 
can be monitored in situ using optical imaging to measure the redox ratio, or the ratio of glycolysis 
to oxidative metabolism. Furthermore, we show that “driver” oncogenes in breast cancer cells also 
drive aerobic glycolysis in these cells. Specifically, HER2 activity was required for maximal 
aerobic glycolysis in breast cells overexpressing HER2, while ER signaling was required for 
aerobic glycolysis in ER+ breast cancer cells. These results demonstrate the effect of the HER2 
and ER signaling pathways on cancer cell metabolism, as measured by the optical redox ratio.  
These data support the conclusion that optical imaging of redox ratios can be used to measure the 
tumor cell response to therapeutic inhibitors in situ. Finally, using HER2 overexpressing breast 
cancer cells with acquired resistance to HER2 inhibitors, we demonstrated that loss of oncogene 
dependence was reflected in the optical redox ratio measurement, such that HER2 inhibitors failed 
to decrease the redox ratio in a resistant cell line. Therefore, these findings could be applied to 
future studies using optical imaging of breast cells and tumors to predict their response to HER2 
inhibitors, a development that would significantly inform clinical decisions regarding therapeutic 
strategies used to treat patients with HER2-positive breast cancers. 
While this is the first study to correlate HER2 overexpression and activity to the redox 
ratio, a previous study similarly determined that ER+ breast cells exhibited a higher optical redox 
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ratio than ER-negative cells (27).  The previous study differs from the results presented herein 
because the previous study suggested that MCF7 cells (ER+/HER2-) exhibited a similar redox 
ratio to BT474 cells (ER+/HER2+). However, our results suggest that BT474 cells have 
significantly higher redox ratios than MCF7 cells. Several experimental factors could explain the 
differing results, including different excitation wavelengths for NADH, differing emission filters, 
and different growth media.  Ostrander et al. used media supplemented with 5% FBS versus 10% 
used in our studies, which may have increased cellular proliferation in our experiments versus 
those described earlier, thus affecting tumor cell metabolism (32).   However, when controlling 
for cell proliferation, the difference in the redox ratio between MCF7 and BT474 cells increased 
in the current study (Fig. C.5).  Different emission filters capture different areas of the NADH and 
FAD emission curves, affecting absolute fluorescence intensity which may change the redox ratio.  
The results of the cyanide experiment ensure measurement of NADH and FAD fluorescence for 
this study (Fig C.2). 
The results show that redox ratios in triple-negative MDA-MB-231 cells were similar to 
what was seen in MCF10A cells, which was less than the redox ratio seen in HER2+ or ER+ breast 
cancer cells.   Triple-negative breast cancers (TNBC) lack HER2, ER, and PR, so they are difficult 
to target and no molecular targeted therapies exist for these breast cancers.   Several FDG-PET 
studies in TNBC, ER+, and HER2+ tumors report high variability in the glucose uptake of triple 
negative cells (33, 34).  Note that FDG-PET imaging illuminates different aspects of cellular 
metabolism (glucose uptake) than the optical redox ratio (relative concentrations of NADH and 
FAD, end products of metabolism).  However, these previous reports indicate that the metabolism 
of TNBC is complex and heterogeneous, so a full characterization of this tumor subtype will likely 
require a more concentrated study.      
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The highest redox ratios were measured in breast cancer cell lines with HER2 
overexpression.  The higher redox ratio of HER2 overexpressing cells suggests that the HER2 
pathway may affect cellular metabolism.  Indeed, studies have found increased concentrations of 
glucose transporters and glycolytic enzymes present in HER2 overexpressing cells versus cells 
with low expression of HER2 (14, 15). 
We found that HER2 inhibition with trastuzumab decreased the redox ratio of HER2 
overexpressing breast cancer cells (p< 0.001, Fig. C.6B).  This is consistent with several studies 
reporting reduced glucose uptake, decreased lactate secretion, and decreased glycolysis, in 
responsive HER2 overexpressing breast cancer cells treated with trastuzumab (35, 36).  Treatment 
with both trastuzumab and tamoxifen decreased the redox ratio of responsive BT474 cells to levels 
seen in the non-cancerous MCF10A cell line (Fig. C.6B).  These results suggest that both ER and 
HER2 signaling affects tumor cell metabolism in breast cancer cells.  Mechanistic studies of 
receptor expression support this result.  Cells expressing ER overexpress glucose transporters and 
have higher reported rates of glycolysis (12, 13).  Similarly, HER2 overexpression is linked with 
increased glucose transport into cells and increased glycolysis (14, 15). 
Innate and acquired resistance to HER2 inhibitors limits their current clinical success. 
Nearly all HER2-amplified breast cancers treated with trastuzumab or lapatinib will ultimately 
develop resistance to these targeted inhibitors. We examined trastuzumab-resistant cells, 
demonstrating that trastuzumab failed to reduce the redox ratio in the resistant cells (Fig. C.6A). 
These results are the first of its kind, but are consistent with an FDG-PET study of trastuzumab 
responsive and non-responsive breast cancer xenographs, demonstrating that HER2 inhibitors 
failed to reduce FDG uptake in those tumors whose growth was unaffected by trastuzumab (37).  
Interestingly, the redox ratio of the trastuzumab and lapatinib resistant cells are different from the 
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pre-treatment redox ratio value of responsive BT474 cells, p<0.001 (Fig. C.6A).  These results 
open up the possibility of screening HER2-inhibitor resistance with the optical redox ratio. 
Future in vivo studies are needed to verify the influence of ER and HER2 expression on 
cellular metabolism.  Increasing research is elucidating the importance of metabolism in cancer 
cells and its relationship with drug resistance.  Here, upon treatment with receptor targeted 
therapies, the change in metabolism of resistant cells is shown to be negligible, while the 
metabolism of responsive cells is significant.  Additionally, basal redox ratios are different in 
resistant versus responsive cells.  Therefore, cellular redox ratios may prove an invaluable tool for 
research and clinical identification of receptor expression, tumor resistance to targeted therapies, 
and for monitoring treatment efficacy. 
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APPENDIX D 
An Automated Image Processing Routine for Segmentation of Cell Cytoplasms in High-
Resolution Autofluorescence Images 
Walsh AJ, Skala MC. “An automated image processing routine for segmentation of cell 
cytoplasms in high-resolution autofluorescence images.” SPIE Proceedings. 2014; 8948.  
 
D.1 Abstract 
The heterogeneity of genotypes and phenotypes within cancers is correlated with disease 
progression and drug-resistant cellular sub-populations.  Therefore, robust techniques capable of 
probing majority and minority cell populations are important both for cancer diagnostics and 
therapy monitoring.  Herein, we present a modified CellProfiler routine to isolate cytoplasmic 
fluorescence signal on a single cell level from high resolution auto-fluorescence microscopic 
images.   
D.2 Introduction 
Solid tumors contain many cell types including the malignant cancer cells, immune cells, 
endothelial cells, and fibroblasts.  Depending on the tumor, the majority of the tumor mass may be 
immune and stromal cells.    Furthermore, within the malignant cell population, cells contain 
different genes and express different phenotypes, most likely arising due to the mutagenic nature 
of cancer (1, 2).  A stem-cell-like population of cells, capable of establishing phenotypically 
diverse xenografts, may exist in solid cancers and tumor heterogeneity is thought to contribute to 
tumor resistance (3).  Drugs selectively kill only portions of a tumor and the remaining resistant 
cells are able to proliferate and grow in the presence of the drug.  Therefore, studies of tumor 
physiology and drug treatment should be performed at high resolution to ensure data is from the 
correct malignant cells.  Further, cellular-level analysis may elucidate patterns and differences 
within cell types otherwise masked by the phenotype of the majority of cells. 
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Optical microscopy techniques, particularly fluorescence imaging of NADH and FAD, are 
high resolution, are non-invasive, and yield quantitative endpoints.  The optical redox ratio, the 
fluorescence intensity of NADH divided by the fluorescence intensity of FAD, provides a dynamic 
read-out of cellular metabolism and is often elevated in malignant cells (4, 5), breast cancer cells 
overexpressing the estrogen receptor, and breast cancer cells expressing human epidermal growth 
factor receptor 2 (HER2) (6, 7).  Further, the optical redox ratio detects drug-induced changes in 
cellular metabolism and may be an early reporter of drug efficacy (6).  Within a breast cancer 
xenograft containing both cells responsive and resistant to the HER2 inhibitor trastuzumab, in vivo 
fluorescence imaging and subsequent single cell analysis revealed a heterogeneous population of 
cells characterized by two populations, one with a lower redox ratio (responding to the drug) and 
one with a higher redox ratio (no effect by the drug) (6).   
These papers highlight the relevance of fluorescence imaging for mapping tumor 
metabolism and the potential information that can be obtained from single-cell analysis.  However, 
manual segmentation of cells and nuclei is time-consuming and not practical for large data sets, 
high-throughput experiments, or clinical translation.  Therefore, we have developed a 
computational routine for automated image segmentation.  The program presented here identifies 
and segments the cells, nuclei, and cytoplasms of a high-resolution auto-fluorescence image.   
D.3 Methods 
The automated image analysis code was created using standard and customized modules 
within Cell Profiler (Fig. D.1) and Matlab (http://www.cellprofiler.org/).  The steps of the code 
are outlined in Table D.1.  First, the images are loaded.  Next, the original images are rescaled to 
have pixel values between 0 and 1.  Then, a customized threshold code identifies pixels belonging 
to nuclear regions that are brighter than background but not as bright as cell cytoplasms (see Table 
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D.1 for custom code).  Next, several image processing steps remove the background and define 
cell edges to improve the automated nucleus and cell identification routines.  Finally, the resulting 
round objects between 6 and 25 pixels (6.12-25.5 m) in diameter in the nucleus image are 
segmented and saved as the primary objects within the image.  Secondary objects, or cells, are 
identified by propagating out from the nuclei.  An Otsu Global threshold is used to improve 
propagation.  Cell cytoplasms are defined as the secondary objects (cells) minus the primary 
objects (nuclei).  The final modules measure the pixel intensity values from the original images.   
 
 
Figure D.1.  CellProfiler graphical user interface. 
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Table D.1. Steps of CellProfiler pipeline. 
Pipeline Purpose Notes 
Load Images Load images Changes to code must be made to load .txt or .asc image files 
Rescale Intensity Rescale 
fluorescence image 
to have pixel values 
between 0 and 1 
Necessary for several image processing commands 
Apply Threshold Create an image 
with just the nuclei 
pixels using a 
multithreshold 
technique to 
determine pixel 
values of 
background, nuclei, 
and cytoplasm 
Code added to ApplyThreshold.m: 
if HighThreshold == 0 & LowThreshold ==0; 
        pix = OrigImage( : ); 
        Options = statset('MaxIter',400); 
        obj = gmdistribution.fit(pix,4,'Options',Options); 
        [mu,ind] = sort(obj.mu); 
    LowThreshold = mu(3)-sqrt(obj.Sigma(ind(3))); 
    HighThreshold = mu(3); 
end 
** A four-component fit modeled this data best, with two peaks for 
background pixels, 1 for nuclei, and 1 for cytoplasm.  The number of 
modes in the pixel distribution fit 
(gmdistribution.fit(pix,4,'Options',Options) and the Low and High 
threshold values should be optimized for a given data set. 
Smooth Keeping 
Edges 
Apply Threshold 
Image Math 
Create a mask to 
isolate the cells and 
remove the 
background 
 
Find Edges 
Invert Intensity 
Image Math 
Image Math 
Finds edges of the 
cells/cell clump and 
creates a mask 
These steps set a hard edge boundary to prevent propagation of the 
secondary objects into the background and remove artifacts from 
nuclei image at cell boundaries. 
Smooth or 
Enhance 
Smooths the result 
of the nuclei 
thresholding  
Eliminates noise pixels 
Identify Primary 
Automatic 
Identify nuclei  
Identify 
Secondary 
Identify cell 
boundaries 
Cells are found by propagating out from the primary objects (nuclei).  
This works best if the image has some pre-processing, removal of 
background and edge definition.   
Identify Tertiary 
Subregion 
Identify cytoplasms Subtracts nuclei from cells 
Measure Object 
Intensity 
Measure and report 
statistical 
information for the 
identified regions 
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D.4 Results 
The results of the image segmentation code are presented here for a representative image 
of an organoid grown from a breast cancer xenograft.  The original image is an NADH fluorescence 
image, characterized by bright cytoplasms and dark nuclei and background.  Figure D.2 shows the 
rescaled image (Fig. D.2A) and the result of the customized thresholding code to isolate the nuclei 
(Fig. D.2B). 
 
 
Figure D.2. Result of threshold. A. Original image rescaled to have all pixel values between 0 
and 1.  B. Result of thresholding code, nuclei remain, background and cytoplasms removed. 
 
 
Figure D.3. Image processing steps. A. Smoothed image allows masking of cell clumps.  B. 
Zeros (black) and ones (white) cell clump mask. C.  Resulting image of the product of the nuclei 
image and cell clump mask (Fig. shown in B).    D.  Resulting image of the product of the original 
image and cell clump mask (Fig. shown in B).   
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 The next steps include image processing to improve the automated routines that identify 
the nuclei and cells.  The background pixels are set to 0 by smoothing the cell clumps (Fig.D.3A), 
generating a cell clump mask (Fig. D.3B), and multiplying the original and nuclei images by the 
mask (Fig. D.3C-D).  Likewise, the edges of the cell clump are found using an edge detect routine 
(Fig. D.4A), a mask is created (Fig. D.4B), and these edges are subtracted from the nuclei image 
and the cell image (Fig. D.4C-D).   The removal of the edges from the nuclei image removes 
artifacts in the nuclei image at the edges of the cell clump. 
 
Figure D.4. Edge detect.  A. Edge detect to identify the edges of the cell clumps or regions of 
interest.  B. Zeros (black) and ones (white) edges mask. C.  Resulting image of the product of the 
nuclei image and edge mask (Fig. shown in B).    D.  Resulting image of the product of the original 
image and edge mask (Fig. shown in B).   
 
 After the image processing steps, the CellProfiler modules are used to find the primary 
objects (nuclei), secondary objects (cells), and tertiary objects (cytoplasms) are used to segment 
out the cell components.  First, the nuclei are identified from the post-processed nuclei image (Fig. 
D.5A).  Objects within the set diameter size are outlined in green and nuclei that exceed the size 
(25 pixels) or are too small (less than 6 pixels, in diameter) are excluded from analysis and 
identified in red.  From the primary objects identified in Fig. D.5A, the secondary objects, or cells, 
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are identified by propagating outward until a boundary is reached (as identified from a Otsu Global 
threshold) or another propagating boundary is met (Fig. D.5B).  The tertiary objects are the 
secondary minus the primary (Fig. D.5C).  An overlap of the cytoplasm outlines and the original 
image is shown in Fig. D.6. 
 
Figure D.5.  Segmented nuclei and cells. A. Primary objects (nuclei) outlined in green, objects 
with diameters outside the target range (6-25 pixels) are outlined in red.  B. Outlines of secondary 
objects. C.  Tertiary objects.   
 
   
 
Figure D.6. Cytoplasm outlines. Image of tertiary object (cytoplasms) outlines overlain on the 
original image. 
 
D.5 Discussion 
Segmentation of autofluorescence images of tissues and highly confluent cell cultures is 
challenging due to the clumping nature of cells.  This paper presents a novel method which utilizes 
a multi-level threshold to identify cell nuclei, which are typically brighter than the background and 
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darker than the cytoplasms, and propagates out from the nuclei to identify the cells.  Cell 
cytoplasms are then the cells minus the nuclei.   
This method has been used on NADH autofluorescence images of confluent cell cultures, 
organoid cultures, and tissues imaged in vivo.  Thresholding parameters are optimized for a data 
set to ensure optimal segmentation of nuclei.  Typical processing times for a single image are 
approximately 20 seconds, which is a 10-20 fold improvement over manual segmentation.  The 
segmentation code performs admirably and error with respect to manual segmentation is less than 
10%.   However, the program does have a few limitations including an inability to identify cells 
without a nuclei, increased error around the edges of the cell clumps, and thresholding problems 
in images with non-uniform illumination.  
Due to the heterogeneity of cancers and the contributions of minority populations to tumor 
drug resistance, it is important to study not only the characteristics of the majority of cells but also 
analyze single cells and sub-populations of cells.  The automated image segmentation code 
presented above demonstrates one method of isolating cells, nuclei, and cytoplasms from high-
resolution NADH auto-fluorescence images. 
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APPENDIX E 
Autofluorescence Imaging of Drug Response in Organoids Generated from Frozen 
Primary Tumor Tissues 
E.1 Abstract 
Primary tumor organoids grown in three-dimensional culture provide a robust platform for 
studying tumor progression, invasion, and drug response.  However, organoid generation protocols 
require fresh tissue, which limits the application of organoid-based experiments and drug-response 
studies to medical centers with co-localized operating rooms and research facilities.  The purpose 
of this study is to investigate tissue-freezing methods that will preserve tissues for organoid 
generation.  We tested two freezing protocols, flash-freezing in liquid nitrogen and slow-freezing 
of bulk tissue samples in DMSO-supplemented media, on primary breast cancer xenografts.  
Additionally, organoids were derived from flash frozen human breast cancer biopsies, to evaluate 
the use of banked tissue.  Our results demonstrate that organoids can be grown from flash-frozen 
or slow, DMSO frozen tissues and these organoids have similar morphologies and rates of 
proliferation and apoptosis as organoids derived from fresh tissues.  Furthermore, while the 
freezing process affects the basal metabolic rate of the cells, optical metabolic imaging can be used 
to detect drug response of organoids derived from frozen-thawed tissues.  These results validate 
the two freezing methods, which can be performed at the site of tissue extraction and do not require 
specialized tissue culture equipment, for tissue preservation and subsequent organoid generation. 
E.2 Introduction 
Primary three-dimensional organoid culture of tumors is an attractive platform for studies of 
malignant tissues.  Organoids contain all components of the original tissue.  When derived from 
tumor samples, organoids contain malignant epithelial cells, endothelial cells, leukocytes, and 
fibroblasts. Three-dimensional organoid cultures recapitulate in vitro tissue structural 
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organization, functional differentiation, chemical and mechanical signals, and therefore, may be 
more physiologically relevant than 2D cultures of primary or immortalized cells (1-3).   
Traditionally, cancer models are limited to immortalized cell lines, xenograft models, or murine 
models of cancer.  While these models are readily accessible and allow studies of cancer 
progression and drug testing, the models often fail to fully represent human cancers and therefore 
many drugs fail in initial stages of clinical trials (2, 4, 5).  Organoid culture of primary human 
tumors may help overcome these limitations of traditional cancer models. 
Organoid culture of primary tumor tissues enables dynamic studies of cancer development (3), 
invasion (6-8), and drug response (9).  Optical imaging, particularly multi-photon fluorescence 
imaging, is well suited to study organoids due to the spatial scale, depth of imaging, and functional 
fluorescence endpoints.  Recently, we have shown that optical metabolic imaging (OMI) of 
organoids generated from primary breast tumors provides a dynamic and powerful assessment of 
drug response for both individualized patient treatment planning and exploratory studies of novel 
anti-cancer drugs (9).  OMI utilizes both the fluorescence intensity and lifetime of the metabolic 
co-enzymes, NAD(P)H and FAD, to detect early metabolic shifts in response to anti-cancer 
therapy.  These metabolic shifts, detected non-invasively, correlate well with drug-induced 
inhibition of proliferation and induction of apoptosis within the organoids, as well as with in vivo 
drug response (9).  Due to its non-destructive nature and endogenous source of contrast, OMI is 
attractive for longitudinal studies of dynamic changes in cellular metabolism.  
To date, all studies of primary organoids have been performed on organoids generated from fresh 
tissues (6, 9, 10).  However, fresh primary human tissues are not always available, and limit 
organoid-based therapeutics and research to sites with co-localized operating rooms and cell 
culture facilities.  Optimizing organoid generation protocols to use preserved tissues will allow 
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research on banked tissues and enable transport of tissue from the hospital to research or testing 
facilities. Tissue is often preserved for biomedical research either as formalin-fixed paraffin 
embedded samples or flash frozen in liquid nitrogen.  Preservation of cells in cell culture utilizes 
DMSO supplemented media and a slow-freezing procedure.  This study investigates these two 
tissue freezing techniques for subsequent organoid generation.   The use of frozen tissues will 
greatly enhance the applications and clinical use of organoid-based drug screens and research.   
This study tests the hypothesis that organoids can be grown from frozen/thawed tissues and that 
organoids derived from frozen-thawed tissues will have the same drug response as organoids 
grown from fresh tissues.  To test this hypothesis, organoids were generated from primary fresh 
tumor tissue, flash frozen and thawed tumor tissue, and tissue placed in tissue culture media + 5% 
DMSO and slowly frozen (an alternative tissue banking method).  Organoid viability was assessed 
by immunofluorescence (IF) assessment of proliferation and apoptosis proteins, Ki67 and cleaved 
caspase 3, respectively.  Organoid drug response was assessed with OMI and IF.  Both freezing 
protocols were performed on two xenograft models of HER2-overexpressing breast cancers, 
BT474 and HR6 tumors, to compare the two freezing techniques for optimal organoid viability 
and drug response. The flash-frozen experiments were additionally performed on two primary 
human breast cancer biopsies to evaluate the use of frozen tissues in tissue banks. 
E.3 Methods 
 
E.3.1 Mouse Xenografts   
This study was approved by the Vanderbilt University Animal Care and Use Committee 
and meets the NIH guidelines for animal welfare.  BT474 or HR6 cells (108) in 100 l Matrigel 
were injected in the inguinal mammary fad pads of two female athymic nude mice (J:NU; The 
Jackson Laboratory).  BT474 and HR6 tumors are both estrogen receptor positive and HER2 
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overexpressing.  The HR6 tumors were extracted from a BT474 tumor that developed acquired 
resistance to the drug trastuzumab in a murine model (11).  The HR6 cells and tumors used herein 
retain HER2 overexpression but lack response to trastuzuamb (9, 11), thus the BT474 and HR6 
tumors represent trastuzumab responsive and trastuzumab-resistant tumors, respectively.   When 
tumors were ~500 mm3, mice were humanly sacrificed and the tumors removed.  Each tumor was 
cut into three approximately equal sections, ~150mm3.  One section was processed immediately 
into organoids, one section was flash frozen, and one section was slowly frozen in DMSO 
supplemented media. 
E.3.2 Clinical Breast Cancer Samples  
This study was approved by the Vanderbilt University Institutional Review Board and 
informed consent was obtained from all subjects.  Two primary tumor biopsies from separate 
patients were provided by an expert breast pathologist (ME Sanders).  Tumor biopsies were 
obtained from the tumor mass following surgical excision.  The tumor biopsies were placed in 
sterile DMEM and transported on ice to the laboratory (~5 minute walk).  The tumor biopsies were 
cut into two approximately equal sections, ~200mm2.  One section was processed into organoids 
immediately, and the second section was flash frozen. 
E.3.3 Freezing Protocols 
For flash freezing in liquid nitrogen, samples were placed in a histology cassette and 
submerged in liquid nitrogen for 30 seconds.  Then, the cassette was removed, wrapped in foil, 
and stored in a -80°C freezer.  For the slow freezing method, samples were placed in a cryotube 
with 950 l tissue culture media and 50 l DMSO.  Samples were slowly frozen by placement in 
a Styrofoam container in a -80°C freezer.  Samples were stored at -80°C until use.  All samples 
were stored at -80°C for 6-12 months. 
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E.3.4 Organoid Generation 
Frozen samples were thawed in PBS at room temperature for ten minutes.  All samples 
were washed three times with sterile PBS.  Tissue samples were placed in 0.5 ml primary 
mammary epithelial cell (PMEC) media [DMEM:F12 + EGF (10 ng/ml) + hydrocortisone (5 
g/ml) + insulin (5 g/ml) + 1% penicillin:streptomycin] and mechanically dissociated into 
macrosuspensions of tissue approximately 50-300 m in diameter by mechanical cutting of the 
tissue with a scalpel and surgical scissors.  Matrigel was added to the macrosuspension solutions 
in a 2:1 ratio and 100 l of the matrigel/macrosuspension solution was placed on coverslips.  The 
gels solidified at room temperature for 30 minutes and then in the incubator for 1 hour.  Then, gels 
were overlain with PMEC media.   
 Organoids generated from fresh tissues were treated immediately.  BT474 and HR6 
organoids were treated with the following drugs and combination: control (human control IgG + 
DMSO), trastuzumab (25 g/ml), paclitaxel (25 nmol/L), XL147 (25 nmol/ml), and trastuzumab 
+ paclitaxel + XL147.  The organoids derived from the clinical biopsies were treated with control 
(human control IgG + DMSO), trastuzumab (25 g/ml), paclitaxel (25 nmol/L), tamoxifen (2 
mol/ml), and trastuzumab + paclitaxel + tamoxifen.  Organoids derived from frozen tissues were 
grown for a recovery period of 3 or 7 days (media replaced every 2-3 days) and then treated with 
the same drugs and combination as the fresh-tissue derived organoids.   
E.3.5 Optical Metabolic Imaging  
Fluorescence lifetime imaging was performed on a multiphoton microscope (Bruker) 
modified for fluorescence lifetime imaging, as previously described (9, 12, 13).  Briefly, a 
titanium-sapphire laser, tuned to 750 nm for NAD(P)H excitation and tuned to 890 nm for FAD 
excitation, provides the excitation light.  A 40X objective (1.3 NA) couples excitation and emission 
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light.  Customized filter sets isolate NAD(P)H emission between 400-480nm and FAD emission 
between 500-600nm.  A GaAS PMT (H7422P-40; Hamamatsu) detects emitted photons and time 
correlated single photon counting electronics (SPC-150; Becker and Hickl) enable fluorescence 
lifetime imaging. Images, 256x256 pixels, were collected for 60s with a pixel dwell time of 4.8 
s.  Photon count rates were maintained above 5 x 105 to ensure adequate photon counts for 
lifetime fits and no photobleaching occurred.  The instrument response full width at half maximum 
was 260 picoseconds as measured from the second harmonic generation of a urea crystal.  Daily 
fluorescence lifetime validation was confirmed by imaging a fluorescent bead (Polysciences Inc.).  
The measured lifetime of the bead (2.1 ± 0.04 nanoseconds) agrees with published values (9, 12, 
14, 15). 
 NAD(P)H and FAD fluorescence lifetime images of the organoids were acquired at 24, 48, 
and 72 hours after drug treatment.  For each organoid, the NAD(P)H image was acquired first and 
followed immediately by the FAD image.  Organoids were imaged through glass coverslips on the 
inverted microscope.  One image from each of six representative organoids were collected per 
group (6 organoids/group; n=30-300 cells/group), at an imaging depth through the center of the 
organoid.   
 Fluorescence lifetime images were analyzed as described previously (9, 12, 16).  Briefly, 
fluorescence lifetime decay curves were deconvolved from the measured instrument response 
function and fit to a two component model, 𝐼(𝑡) =  𝛼1 exp (−
𝑡
𝜏1
) + 𝛼2 exp (−
𝑡
𝜏2
) + 𝐶, where I(t) 
is the fluorescence intensity at time t after the laser pulse,  and 2 are the fractional contributions 
of the short and long lifetime components, (i.e.  + 2 = 1),  and 2 are the fluorescence lifetimes 
of the short and long lifetime components, and C accounts for background light (SPCImage).  A 
two component model was used to fit the lifetime decays of NAD(P)H and FAD because 
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NAD(P)H and FAD exist physiologically in both free and protein-bound forms (17, 18).  The free 
and protein-bound forms have different lifetimes depending on fluorescence quenching (19).  
NAD(P)H self-quenches in the free state and thus has a short lifetime associated with free 
NAD(P)H and a long lifetime with bound NAD(P)H (17, 19).  FAD is quenched when bound and 
has a short bound lifetime and long free lifetime (18).  The mean lifetime,   is calculated as a 
weighted average of  and 2, m + 2*. 
 Using an automated cell segmentation routine in CellProfiler, the images were segmented 
into cells, nuclei, and cytoplasms (16).   The following endpoints were extracted from the 
fluorescence lifetime data sets for both the NAD(P)H and FAD image for each cell: fluorescence 
intensity, mean fluorescence lifetime,  and 2.  A redox ratio image was computed by 
dividing the NAD(P)H intensity by the FAD intensity at every pixel in the image.  The average 
redox ratio for each cell was also extracted.  As determined previously, the optical redox ratio, 
NAD(P)H mean lifetime, and FAD mean lifetime are independent measures of cellular metabolism 
(12) and a combination index, the optical metabolic imaging index, provides a robust endpoint for 
evaluating drug response (9).  The OMI index was calculated for each cell as follows, 
𝑂𝑀𝐼 𝐼𝑛𝑑𝑒𝑥 =
𝑅𝑅𝑖
⟨𝑅𝑅⟩
+
𝑁𝐴𝐷𝐻𝜏𝑚𝑖
⟨𝑁𝐴𝐷𝐻𝜏𝑚⟩
−
𝐹𝐴𝐷𝜏𝑚𝑖
⟨𝐹𝐴𝐷𝜏𝑚⟩
  (9). 
E.3.6 Immunofluorescence 
Immunofluorescence labeling of cleaved caspase 3 and Ki67 was performed as previously 
described (9, 20).  Briefly, gels were fixed with 2 mL of a 4% paraformaldehyde solution and 
neutralized with a 0.15 mol/L glycine solution.  A 0.02% Triton X-100 solution was used to 
permeabolize cellular membranes.  Gels soaked in a blocking solution (1% fatty acid-free BSA, 
1% donkey serum) over night at room temperature.  The next day, gels were incubated for 30 
minutes at room temperature with 100 l of the primary antibody solution: either anti-cleaved 
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caspase 3 (Life Technologies) or anti-Ki67 (Life Technologies) diluted 1:100 in a 1% donkey 
serum PBS solution.  Gels were washed 3X with PBS and 100 l of the secondary antibody 
solution (goat anti-rabbit IgG FITC probe diluted 1:100 in a 1% donkey serum PBS solution) was 
added to each gel.  Gels were washed 3X with PBS and 2X in water then mounted on slides with 
30 l of ProLong Antifade Solution (Molecular Probes).  Positive staining was confirmed in mouse 
small intestine for Ki67 and mouse thymus for cleaved caspase 3.  Immunofluorescence results 
are presented as the percentage of positively stained cells from 6 organoids imaged at 40X (1.3 
NA).   
E.3.7 Quantification of Cell Morphology 
Cellular morphology was assessed from the NAD(P)H fluorescence lifetime image, 
integrated over time to yield an intensity image.  Average cell size and nuclear-to-cytoplasm ratio 
(NCR) were extracted from the CellProfiler segmentation routine outputs. Average nucleus 
diameter was determined by manually measuring the longest axis through the center of each cell 
in ImageJ. 
E.3.8 Statistical Analysis 
A student’s t-test with a Bonferoni correction for multiple comparisons was used to assess 
differences in immunofluorescence results, morphology, and fluorescence lifetime endpoints 
between fresh and frozen control organoids.  Time course drug response OMI data was analyzed 
with multiple t-tests with a Bonferoni correction for multiple comparisons between control and 
drug treated organoids at each time point.  For all statistical comparisons, an alpha level of 0.05 
was used for significance. The number of cells per group varied between 30 and 300.   
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E.4 Results 
 
Figure E.1 Viability of organoids derived from frozen-thawed xenograft tumors. (A) 
Representative NAD(P)H m and FAD m images of BT474 organoids derived from fresh (I), flash-
frozen (II), and DMSO frozen tissues (III). (B)  Ki67 and (C) cleaved caspase 3 staining of control 
organoids derived from fresh, flash-frozen and DMSO frozen BT474 tumors.   (D) Representative 
NAD(P)H m and FAD m images of HR6 organoids derived from fresh (I), flash-frozen (II), and 
DMSO frozen tissues (III).  (E)  Ki67 and (F) cleaved caspase 3 staining of control organoids 
derived from fresh, flash-frozen and DMSO frozen HR6 tumors.  d3/d7 represents organoids 
grown for 3 or 7 days after generation. 
E.4.1 Viability of Organoids Derived from Frozen-thawed Xenograft Samples 
 Organoids were successfully grown from fresh, flash-frozen, and DMSO frozen samples 
of BT474 xenograft tumors (Fig. E.1 A-C).  The organoids generated from flash-frozen and DMSO 
frozen BT474 tissue samples had similar expression of Ki67 and cleaved caspase 3, markers of 
proliferation and apoptosis, respectively, as compared to organoids derived from a fresh BT474 
tumor sample (Fig. E.1B, C).  Likewise, the organoids generated from flash-frozen and DMSO 
frozen HR6 tumor samples grew (Fig. E.1D) and had similar percentages of Ki67 and cleaved 
caspase 3 positively stained cells as compared to organoids generated from fresh HR6 tissue (Fig. 
E.1E, F). 
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Figure E.2 Morphology of organoids derived from frozen/thawed xenograft tumors.  (A) Cell 
area, (B) nucleus diameter, and (C) nucleus to cytoplasm ratio for BT474 organoids derived from 
fresh and frozen/thawed tissues.  (D) Number of cells per organoid for BT474 organoids derived 
from fresh and frozen/thawed tissues. (E) Cell area, (F) nucleus diameter, and (G) nucleus to 
cytoplasm ratio for HR6 organoids derived from fresh and frozen/thawed tissues.  (H) Number of 
cells per organoid for HR6 organoids derived from fresh and frozen/thawed tissues. d3/d7 
represents organoids grown for 3 or 7 days after generation. * p<0.05; ** p<0.01, *** p<0.001, 
**** p<0.0001, versus Fresh except where indicated. 
 
E.4.2 Morphology of Organoids Derived from Frozen-thawed Xenograft Samples 
 Next, cellular morphology was quantified and compared between organoids generated 
from fresh and frozen tissues.  No change in cell area, nucleus diameter, or nucleus to cytoplasm 
ratio (NCR) was detected for the cells within organoids generated from frozen-thawed BT474 
tumor samples compared to organoids generated from fresh BT474 tumor samples (Fig. E.2A-C).  
However, there was a significant reduction in the number of cells within each organoid for the 
organoids generated from flash-frozen BT474 tumors compared to organoids generated from fresh 
tissues (Fig. E.2 D).  This reduction was significant for organoids grown for both 3 and 7 days 
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(Fig. E.2D).  A significant reduction in number of cells within each organoid was not observed for 
organoids generated from BT474 DMSO frozen tissues (Fig. E.2D).   
 In contrast to the BT474 results, the cells grown from frozen HR6 tumor samples showed 
morphological differences compared to cells grown from fresh tumor samples.  The cell area of 
HR6 cells was significantly reduced for cells within organoids generated from flash-frozen 
sections grown for 3 or 7 days, and in organoids generated from DMSO frozen tissue grown for 3 
days (Fig. E.2E).  Likewise, the nucleus diameter was significantly reduced for cells within 
organoids generated from flash-frozen tissue (Fig. E.2F).  The NCR of HR6 cells did not 
significantly change due to either freezing method or growing time (Fig. E.2G).  Also, no 
significant change in the number of HR6 cells within each organoid was detected for either 
freezing protocol or length of growing time (Fig. E.2H). 
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Figure E.3 Drug Response of BT474 Organoids Generated from Frozen Tissues (A) 
NAD(P)H m and (B) FAD m measured from BT474 organoids derived from fresh or frozen 
tissues grown for 7 days. * p<0.05 vs. Fresh, except where indicated.  (C) Drug response of BT474 
organoids derived from fresh tissue at 24, 48, and 72hr.  (D)  Drug response of BT474 organoids 
derived from flash-frozen tissues grown for 7 days and treated for 24, 48, and 72hr.  (E) Drug 
response of BT474 organoids derived from DMSO frozen tissues grown for 7 days and treated for 
24, 48, and 72hr.  (F) Cleaved caspase 3 staining of 72 hr drug-treated organoids derived from 
fresh and DMSO frozen (grown for 7 days) tissues.  (G) Ki67 staining of 72 hr drug-treated 
organoids derived from fresh and DMSO frozen (grown for 7 days) tissues.  * p<0.05; ** p<0.01, 
*** p<0.001, **** p<0.0001 versus control. 
 
E.4.3 Drug Response of BT474 Organoids Generated from Frozen Tissues 
 OMI endpoints were evaluated for metabolism differences between organoids grown from 
fresh tissues and organoids grown from frozen/thawed tissues.  For the BT474 tumors, NAD(P)H 
m was significantly decreased in cells from organoids generated with both freezing methods on 
day 7 (Fig. E.3A).  However, FAD m showed no significant differences between organoid 
generated from fresh and frozen BT474 tumors (Fig. E.3B).  The 72-hour time course for drug 
response of BT474 organoids generated from fresh tissues showed a significant reduction in the 
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OMI index with paclitaxel (P), trastuzumab (H), XL147 (X), and the combination, H+P+X at 24hr, 
48hr, and 72hr of drug treatment (Fig. E.3C).  For the BT474 organoids derived from flash-frozen 
tissues grown for 7 days prior to drug treatment, the OMI index was significantly reduced with 
only the combination treatment, H+P+X, at 24 and 48 hr of drug exposure (Fig. E.3D).  By 72 hr, 
trastuzumab, XL147, and H+P+X induced significant reductions in the OMI index (Fig. E.3D).  
Organoids derived from the BT474 tumor sample slowly frozen in DMSO supplemented media, 
showed response to anti-cancer drugs (Fig. E.3E).  By 72hr, paclitaxel, trastuzumab, XL147, and 
H+P+X treated organoids all had significant reductions in OMI index (Fig. E.3E).  
Immunofluorescence staining of Ki67 and cleaved caspase 3 of organoids derived from fresh and 
DMSO frozen BT474 tumors treated for 72hr with anti-cancer drugs, revealed increased cleaved 
caspase 3 expression in organoids treated with paclitaxel, trastuzumab, XL147, and H+P+X (Fig. 
E.3F).  Likewise, reduced expression of Ki67 was observed in organoids treated with all anti-
cancer therapies (Fig. E.3G). 
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Figure E.4 Drug Response of HR6 Organoids Generated from Frozen Tissues  (A) NAD(P)H 
m and (B) FAD m measured from HR6 organoids derived from fresh or frozen tissues grown for 
7 days. * p<0.05 vs. Fresh.    (C) Drug response of HR6 organoids derived from fresh tissue at 24, 
48, and 72hr.  (D)  Drug response of HR6 organoids derived from flash-frozen tissues grown for 
7 days and treated for 24, 48, and 72hr.  (E) Drug response of HR6 organoids derived from DMSO 
frozen tissues grown for 7 days and treated for 24, 48, and 72hr.  (F) Cleaved caspase 3 staining 
of 72 hr drug-treated organoids derived from fresh and DMSO frozen (grown for 7 days) tissues.  
(G) Ki67 staining of 72hr drug-treated organoids derived from fresh and DMSO frozen (grown for 
7 days) tissues.  * p<0.05; ** p<0.01, *** p<0.001, **** p<0.0001, versus control. 
 
E.4.4 Drug Response of HR6 Organoids Generated from Frozen Tissues 
 The effect of freezing HR6 tumors before generating organoids was also evaluated with 
OMI of organoid drug response.  No change in NAD(P)H m was observed between organoids 
generated from fresh HR6 tumors and flash frozen or DMSO frozen tumors on day 7 after organoid 
generation (Fig. E.4A).  A slight increase in FADm was observed in organoids generated from 
flash-frozen HR6 tumors compared to organoids generated from fresh HR6 tumors (p<0.05, Fig. 
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E.4B); however, no significant change in FADm was observed in the organoids generated from 
DMSO frozen HR6 tissue (p>0.05, Fig. E.4B).    
Organoids generated from fresh HR6 tumors have a significantly reduced OMI index at 24 
hr due to paclitaxel, trastuzumab, and H+P+X treatment (Fig. E.4C).  By 48 and 72hr, only H+P+X 
induces a significant reduction in the OMI index (Fig. E.4C).  For the HR6 organoids derived from 
flash-frozen HR6 tumors, at 24hr, both XL147 and H+P+X induce significant reductions in the 
OMI index (Fig. E.4D).  By 48 and 72hr, only the H+P+X treated organoids have a significant 
reduction in OMI index (Fig. E.4D).  Likewise, HR6 organoids derived from the DMSO frozen 
tumor showed significant reductions in OMI index with paclitaxel, trastuzumab, XL147, and 
H+P+X treatment at 24hr (Fig. E.4E).  By 48hr and 72hr, only the H+P+X treatment induced a 
significant reduction in the OMI index (Fig. E.4E).  At 72hr, the paclitaxel and XL147 treated HR6 
organoids induced a significant increase (p<0.05) in the OMI index in both organoids generated 
from fresh (Fig. E.4C) and DMSO frozen tumors (Fig. E.4E), but this increase was not detected in 
the organoids derived from flash-frozen tumors (Fig. E.4D).  Immunofluorescence staining of 
cleaved caspase 3 and Ki67 of organoids derived from fresh and DMSO frozen tumors treated for 
72hr revealed an increased proportion of cells stained cleaved caspase 3 positive and a reduced 
proportion of cells stained Ki67 positive in H+P+X treated HR6 organoids (Fig. E.4F, G). 
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Figure E.5 Viability of Organoids Derived from Frozen-thawed Human Breast Cancer 
Biopsies  (A) Representative NAD(P)H m and FAD m images of organoids derived from fresh 
(I) and flash frozen/thawed (II) Patient Sample 1. (B) Cleaved caspase 3 staining, (C) Ki67 
staining, (D) cell area, and (E) number of cells per organoid for organoids derived from fresh and 
flash-frozen/thawed Patient Sample 1.   (F) Representative NAD(P)H m and FAD m images of 
organoids derived from fresh (I) and flash frozen/thawed (II) Patient Sample 2.  (G) Cleaved 
caspase 3 staining, (H) Ki67 staining, (I) cell area, and (J) number of cells per organoid for 
organoids derived from fresh and flash-frozen/thawed Patient Sample 2. * p<0.05; *** p<0.001, 
versus Fresh, except as indicated. d3/d7 represents organoids grown for 3 or 7 days after 
generation. 
 
E.4.5 Viability of Organoids Derived from Frozen-thawed Human Breast Cancer Biopsies 
 To test whether organoids could be grown from flash frozen primary human breast tumors, 
two primary human breast cancer biopsies were acquired and cut into two pieces, one for fresh 
organoid generation and one which was flash-frozen, stored at -80°C for months (mimicking 
current tissue banking procedures), and then thawed and generated into organoids. For Patient 
1,organoids grew from both the fresh primary human tumor sample (Fig. E.5AI) and from the 
flash-frozen/thawed sample (Fig. E.5AII).  Immunofluorescence staining revealed similar 
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percentages of cleaved caspase 3 positive and Ki67 positive cells between organoids generated 
from fresh tumor and organoids generated from flash-frozen tumor (Fig. E.5B, C).  No differences 
were observed in Ki67 and cleaved caspase 3 staining between organoids generated from flash-
frozen tumor grown for 3 or 7 days (Fig. E.5B, C).  Likewise, there were no differences in the 
morphology of the cells, cell size, nucleus diameter or NCR ratio, between organoids generated 
from fresh tumor and organoids derived from the flash-frozen tumor (Fig. E.5D, and Fig. E.6).  
However, there was a significant reduction in the number of cells per organoid that were grown 3 
days after generating organoids from the flash-frozen and thawed tumor from Patient 1 compared 
to organoids generated from fresh tumor from the same patient (Fig. E.5E).  No significant 
difference in number of cells within each organoid was detected for the organoids derived from 
flash-frozen tumor grown for 7 days versus organoids derived from fresh tumor from the same 
patient (Fig. 5E).   
 
Figure E.6 Morphology of Organoids Derived from Frozen-thawed Human Breast Cancer 
Biopsies  (A) Nucleus diameter and (B) nuclear to cytoplasm ratio (NCR) for organoids derived 
from fresh and flash-frozen sections of Patient Sample 1. (C) Nucleus diameter and (D) nuclear to 
cytoplasm ratio (NCR) for organoids derived from fresh and flash-frozen sections of Patient 
Sample 2. d3/d7 represents organoids grown for 3 or 7 days after generation. 
 
Likewise, organoids from Patient Sample 2 grew robustly from fresh and flash-frozen 
tissues (Fig. E.5F, G-H).  No significant changes were observed in the percentage of cells that 
stained cleaved caspase positive or Ki67 positive between organoids derived from fresh tumor and 
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organoids derived from flash-frozen tumor grown for 3 or 7 days (Fig. E.5G, H).  Likewise, no 
significant differences in cell morphology (cell area, nucleus diameter, or NCR) were detected 
between organoids derived from fresh tumor versus organoids derived from flash-frozen tumor for 
Patient 2 (Fig. E.5I, and Fig. E.6).  Additionally, the number of cells within each organoid 
remained unchanged in organoids derived from flash-frozen tumor verses organoids derived from 
fresh tumor for Patient 2 (Fig. E.5J). 
 
Figure E.7 Drug Response of Organoids Generated from Flash-Frozen Human Breast 
Cancer Biopsies (A) NAD(P)H m and (B) FAD m measured from Patient Sample 1 organoids 
derived from fresh or frozen tissues (grown for 7 days).  * p<0.05, versus Fresh.  (C) Drug response 
of Patient Sample 1 organoids derived from fresh tissue at 24, 48, and 72hr.  (D)  Drug response 
of Patient Sample 1 organoids derived from flash-frozen tissues grown for 7 days and treated for 
24, 48, and 72hr.  (E) NAD(P)H m and (F) FAD m measured from Patient Sample 2 organoids 
derived from fresh or frozen tissues.  * p<0.05, versus Fresh.  (G) Drug response of Patient Sample 
2 organoids derived from fresh tissue at 24, 48, and 72hr.  (H)  Drug response of Patient Sample 2 
organoids derived from flash-frozen tissues grown for 7 days and treated for 24, 48, and 72hr.  * 
p<0.05; ** p<0.01, *** p<0.001, **** p<0.0001, versus control. 
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E.4.6 Drug Response of Organoids Generated from Flash-Frozen Human Breast Cancer Biopsies 
As with the xenograft tumors, OMI measurements of drug response were compared between 
organoids derived from fresh and flash-frozen patient tumor (frozen preparation was allowed to 
grow for 3 or 7 days before imaging and treatment).  Both samples were derived from estrogen 
receptor positive, HER2 negative tumors and the subsequent organoids were treated with  the 
clinically relevant drugs, paclitaxel (P), trastuzumab (H), tamoxifen (T), and the combination, 
H+P+T.  For Patient Sample 1, no difference in NAD(P)H m was detected between the organoids 
generated from fresh tumor and flash-frozen tumor grown for 7 days (Fig. E.7A).  However, a 
significant increase in FAD m was detected between organoids generated from fresh versus flash-
frozen tumor from Patient 1 (p<0.05, Fig. E.7B).  The OMI index was significantly decreased with 
H+P+T after 72 hr of treatment in organoids derived from fresh tumor from Patient 1 (Fig. E.7C).  
None of the treatments induced a significant reduction in the OMI index for the organoids 
generated from flash-frozen tumor, grown for 3 (Table E.1) or 7 days (Fig. E.7D).   
Finally, organoids derived from Patient Sample 2 showed significant response to the anti-
cancer drugs.  First, NAD(P)H m was significantly reduced in the organoids derived from the 
flash-frozen tumor compared to the organoids derived from fresh tumor (Fig. E.7E), but the FAD 
m showed no significant difference (Fig. E.7F).  The OMI index was significantly reduced in 
organoids derived from fresh tumor due to all drug treatments at 24hr, tamoxifen and H+P+T at 
48hr, and paclitaxel, tamoxifen, and H+P+T at 72 hr (Fig. E.7G).  Likewise, the paclitaxel, 
tamoxifen, and H+P+T treated organoids derived from the flash-frozen tumor showed significant 
reductions in OMI index at 72 hr (Fig. E.7H), while only the combination treatment, H+P+T, 
induced reductions in the OMI index at 24 and 48hr.  Altogether, these results suggest that viable 
organoids can be grown from frozen tumors and the cells remain sensitive to anti-cancer drugs. 
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Table E.1  Drug induced changes in OMI index at 72hr drug treatment for different organoid 
generation protocols. 
 
E.4.7 Comparison of Freezing Methods 
 OMI measured drug response was compared between fresh-tissue generated organoids and 
organoids generated from frozen-thawed tissues.  Both freezing methods, flash frozen and slow, 
DMSO frozen were compared for optimal drug response outcomes, as were the recovery times, 3 
or 7 days, between organoid generation and drug treatment.  The response of organoids grown for 
7 days and treated for 72 hr better reflected the response of fresh-tissue generated organoids with 
only 4/24 (16%) inconsistences versus 7/24 (30%) inconsistencies for organoids grown for 3 days 
before treatment (Table E.1). The response of the organoids derived from DMSO frozen tissues 
resembled that of the organoids derived from fresh tissues after 72hr of drug treatment with fewer 
inconsistencies than flash-frozen preparations, 3/16 (19%) vs. 9/32 (28%)  (Table E.1).   
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E.5 Discussion 
 Primary cells grown in 3D culture as organoids provide a robust and relevant model for 
investigations of cancer progression, drug development, and individualized treatment planning in 
the clinic.  Typically, organoids are generated by mechanical dissociation of fresh, primary tissue 
into small pieces that are embedded and grown in collagen or extracellular matrix gels.  Organoid 
culture of primary cells more accurately preserves cell-cell interactions and recapitulates the in 
vivo environment than 2D culture of single cell lines (1, 2, 10, 21).  However, current organoid 
generation protocols require fresh tissue (9, 22), which limits the use of primary human tumor 
organoids to labs in close proximity to hospitals, and also limits the applicability of organoid-based 
individualized drug screens to hospitals with expertise in organoid generation.  In order to ensure 
widespread use of primary tumor organoids for research and clinical treatment planning, tissue 
preservation methods must be assessed and alternative organoid generation protocols developed. 
This study tested two methods of tissue preservation by freezing, which would maintain cancer 
tissue for subsequent organoid generation and drug response studies.  Both flash-freezing tissue in 
liquid nitrogen and slow freezing in media supplemented with 5% DMSO were tested, because 
flash freezing is the current method for tissue banking yet slow freezing in DMSO is known to 
preserve tissue viability (23).  Four samples were used, two HER2 overexpressing xenografts and 
two estrogen receptor positive human breast cancer samples.   For all samples, organoids were 
generated from a piece of the fresh tissue and compared with organoids generated from a portion 
of the same tumor that was frozen and thawed. 
 Organoids grew from all fresh and frozen tissue samples, for both the xenograft tissues 
(Fig 1) and the human biopsies (Fig. E.5).  However, for two of the samples frozen by flash 
freezing in liquid nitrogen, the BT474 xenograft and one of the patient samples, there was a 
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significant decrease in the number of cells per organoid, suggesting that some cells do not survive 
the freeze/thawing process as well as others.  However, for the cells that did survive the freeze/thaw 
process, no significant differences in cellular expression of proliferation or apoptosis proteins were 
(Fig. E.1B, C, E, F; Fig. E.5B, C, G, H), suggesting the organoids generated from frozen/thawed 
tissues are viable and proliferate similarly to the organoids generated from fresh tissues.  
Furthermore, no significant differences in cellular morphology were quantified for the cells 
generated from frozen/thawed BT474 tissues or from the frozen/thawed patient samples (Fig. 
E.2A-C, E-G; Fig. E.5A, E, B, I).  The HR6 cells did show significant reductions in cell area and 
nucleus diameter (Fig. E.2E, F), which may reflect that either smaller HR6 cells were more suited 
to survive the freeze/thaw protocols or that the freeze/thaw process induces changes within the 
HR6 cells which reduced the cell size.  Prior studies of frozen/thawed cells have demonstrated that 
cells exposed to flash freezing methods have reduced volumes upon thawing compared to non-
frozen control cells and these morphological differences are reduced in slow-frozen cells (23).  
 
Figure E.8 Fluorescence lifetime components of organoids derived from frozen/thawed 
tissue. (A) NAD(P)H 1, (B) NAD(P)H 2, and (C) NAD(P)H 1 for organoids derived from fresh 
tissues and organoids derived from frozen tissues and grown for 7 days. (D) FAD 1, (E) FAD 2, 
and (F) FAD 1 for organoids derived from fresh tissues and organoids derived from frozen tissues 
and grown for 7 days. * p<0.05 vs. Fresh 
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 The fluorescence lifetime results indicate that the freeze/thaw protocols induce significant 
biochemical changes within the cells.  In 2/4 samples (BT474 Fig. E.3A; Patient 2 Fig. E.7E), the 
mean NAD(P)H lifetime decreased in organoids derived from frozen/thawed tissue compared to 
organoids derived from fresh tissues.  Likewise, in 2/4 samples (HR6 Fig. E.4B, Patient 1 Fig. 
E.7B) the mean FAD lifetime increased in organoids derived from frozen/thawed tissue compared 
to organoids derived from fresh tissue.  The changes in the free lifetime components (1 for 
NAD(P)H and 2 for FAD, Fig. E.8) suggest morphological changes to NAD(P)H and FAD, and 
changes in the microenvironment surrounding NAD(P)H and FAD (17-19).  The changes in bound 
protein fluorescence lifetimes (2 for NAD(P)H and 1 for FAD, Fig. E.8) may be indicative of 
morphological changes in the enzyme-substrate conformations, changes in preferred protein 
binding, or differences in the microenvironment of surrounding NAD(P)H and FAD enzyme 
structures (17, 19).  A previous study of in vivo, freshly excised tissue, and frozen hamster cheek 
pouch tissues also identified an increased FAD m in frozen tissues (13).   A cryopreservation study 
has previously identified freezing-induced inactivation of metabolic enzymes, such as lactate 
dehydrogenase, and suggest some intracellular molecules may have protective properties (24), 
further indicating changes in metabolism coenzyme environment after tissue freezing.   
The OMI index is a robust, dynamic endpoint of cellular metabolism and has been shown 
to accurately measure early drug response in anti-cancer drug-treated cells, tumors imaged in vivo, 
and organoids (9, 12).  We used the OMI index to test the drug-response of organoids generated 
from frozen/thawed tissues, and compared this response with that of fresh organoids.  OMI detects 
drug-induced changes in cellular metabolism and the frozen/thawed organoids had significant 
differences in basal metabolism endpoints compared with fresh organoids, so all comparisons were 
between DMSO/IgG control and drug-treated organoids within each sample, preparation protocol, 
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and time point.  The OMI index is computed per group per time point and normalizes data to the 
means of the data set.  As demonstrated previously (9), significant reductions in the OMI index 
between control and drug treated organoids indicate response. Drug induced increases in apoptosis 
and decreases in proliferation verify that a decrease in the OMI index of organoids tumors 
correlates with drug response (Fig. E.3, 4). 
 The OMI index indicated similar drug response for organoids derived from frozen/thawed 
tissues compared to the drug response from organoids derived from fresh tissues.  However, the 
frozen/thawed tissues were less sensitive to anti-cancer drugs.  Drugs induced a smaller change in 
OMI index of organoids derived from frozen/thawed tissues (Fig. E.3C-E, Fig. E.4C-E, Fig. E.7 
G-H) suggesting the dynamic range of the OMI index was dampened in the organoids generated 
from frozen/thawed tissue.  The dynamic range of the drug-induced metabolism changes may be 
reduced due to damage induced by the freezing protocols on the metabolic coenzymes, enzymes, 
and substrates (24).  Furthermore, the cells that survive the freezing protocols may be more 
resistant to anti-cancer drugs.  As indicated by 5 drug treatments that failed to induce the expected 
response by 72hr of treatment in OMI index (Table E.1) in organoids generated from flash frozen 
tissues, this freezing protocol may select for more resistant cells.  The mutations and phenotypic 
differences that enable cells to evade drug treatment may enable the cells to survive the flash-
frozen protocol.   
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Figure E.9 Mean NAD(P)H and FAD fluorescence lifetimes of organoids derived from 
frozen/thawed tissue.   NAD(P)H m of (A) BT474, (B) HR6, (C) Patient Sample 1, and (D) 
Patient Sample 2 organoids grown from fresh and frozen tissue. FAD m of (E) BT474, (F) HR6, 
(G) Patient Sample 1, and (H) Patient Sample 2 organoids grown from fresh and frozen tissue. 
d3/d7 represents organoids grown for 3 or 7 days after generation.  * p<0.05 vs. Fresh; ns = not 
significant 
 In order to investigate whether cells required a recovery growth period following 
freeze/thaw protocols, all experiments were repeated on organoids grown for 3 or 7 days.  No 
significant differences were observed in cellular morphology, rates of proliferation or apoptosis, 
NAD(P)H m, or FAD m values of control organoids for any sample between the organoids 
generated from flash frozen tissue grown for 3 versus 7 days (Fig. E.1, 2, 5, and Fig. E.9).  This 
observation held for organoids generated from DMSO frozen tissues as well, and suggests the 
effects of the freezing processes on cellular metabolism persist for at least a week of growth.  A 
slight, but significant, increase in the number of cells per organoid was observed on day 7 versus 
day 3 in the organoids derived from the flash-frozen BT747 tumor and Patient Sample 1 (Fig. 
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E.2D, Fig. E.5F). OMI drug response studies of organoids grown for either 3 or 7 days from 
frozen/thawed tissues yielded similar results; however, additional response (12.5% fewer 
inconsistencies) was detected in organoids grown for 7 days (Table E.1), suggesting a longer 
recovery time yields better response data.  The lack of response observed in organoids grown for 
only 3 days and then treated with anti-cancer drugs may suggest inherent selectivity of non-
responsive cells which are more suited to surviving the freeze/thaw process, or that the freeze/thaw 
process induces a survival response within the cells which enable them to also survive the cancer 
drugs.  
 The xenograft studies investigated the differences in organoids grown from flash-frozen 
tissues and slow, DMSO frozen tissues.  No significant differences were observed in cell 
proliferation, apoptosis, or morphology between organoids derived from tissues frozen by either 
method (Fig. E.1, 2).  A significantly greater number of cells per organoid were grown from the 
BT474 DMSO frozen tissues than the flash frozen tissues (Fig. E.2D). However, this was not 
observed in the HR6 tumors.  The mean NAD(P)H lifetime of BT474 organoids derived from 
DMSO frozen tissue and the mean FAD lifetime of HR6 organoids derived from DMSO frozen 
tissue were closer to the values of organoids derived from fresh tissue than organoids derived from 
flash frozen tissue, suggesting that slow, DMSO freezing of tissues may yield organoids with 
metabolic behaviors more similar to the metabolic behaviors of organoids derived from fresh 
tissues than flash-frozen tissues.   Furthermore, OMI-measured drug response revealed more 
consistent OMI drug response behavior of the organoids derived from DMSO frozen tissues then 
organoids derived from flash frozen tissues (Table E.1).  
 Recent studies have demonstrated the wealth of knowledge that can be gained from primary 
tumor organoid research (2, 9, 10, 22).  Furthermore, as we have demonstrated, OMI drug response 
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studies of organoids reflect in vivo drug response (9).  However, organoid generation protocols 
require immediate processing of fresh tissue into organoids.  This limits the application of 
organoid-based experiments and drug-response studies to medical centers with both operating 
rooms and research facilities.  The purpose of this study was to investigate tissue-freezing methods 
that would enable preservation of tissues for subsequent organoid generation.  This opens up the 
applicability of clinical organoid drug screens and organoid research by enabling shipment of 
tissues to centralized testing sites and research labs.  Primary tissue samples are routinely flash 
frozen for storage in tissue banks.  Therefore, this study evaluated flash-frozen primary human 
breast cancer samples, to determine if organoids could be grown from these samples. Furthermore, 
this study compared the viability and drug response of organoids derived from flash frozen tissue 
to organoids derived from DMSO freezing protocols, which is the standard method of cell 
preservation used in cell culture.  Our results show that organoids can be grown from flash-frozen 
or slow, DMSO frozen tissues and these organoids have similar morphologies and rates of 
proliferation and apoptosis as organoids derived from fresh tissues.  Furthermore, while the 
freezing process effects the basal metabolic rate of the cells, OMI can be used to detect drug 
response of organoids derived from frozen-thawed tissues.  Altogether these results suggest that 
when possible, slow freezing bulk tissues in DMSO supplemented media induces fewer changes 
in organoid cellular metabolism and yields drug-response more similar to that of organoids derived 
from fresh tissues. However, viable organoids can be grown from flash-frozen tissues and present 
an alternative tissue source if fresh or DMSO frozen tissues are not available, as in current tissue 
banks. 
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APPENDIX F 
Collagen Density and Alignment in Responsive and Resistant  
Trastuzumab-Treated Breast Cancer Xenografts  
Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC, "Collagen density and alignment of 
responsive and resistant trastuzumab-treated breast cancer xenografts" Journal of Biomedical 
Optics, 2015; 20(2):026004. 
 
F.1 Abstract 
Tumor collagen characteristics influence tumor malignancy, invasion, and metastasis.   
This study investigates the effects of trastuzumab (Tz) on the collagen of Tz-responsive (BT474), 
and Tz-resistant (HR6) breast cancer xenografts.  Collagen content was assessed by in vivo second 
harmonic generation (SHG) imaging and histological trichrome staining of tumor sections.  
Collagen SHG imaging of control BT474 and HR6 tumors demonstrated increased collagen 
density after 14 days of treatment (p<0.05). Trichrome staining revealed decreased collagen in Tz-
treated BT474 and HR6 tumors at 2, 5 and 14 days of treatment, suggesting that Tz affects the 
tumor microenvironment independent of epithelial cell response.  Additionally, collagen alignment 
analysis revealed significantly less aligned collagen in the Tz-treated BT474 tumors at day 14 
compared with control BT474 tumors.  There was no correlation between SHG endpoints (collagen 
density and alignment) and trichrome staining (p>0.05), consistent with the physically distinctive 
nature of these measurements. There was also no correlation between tumor size and collagen 
endpoints (p>0.05). These results identify changes within the collagen compartment of the tumor 
microenvironment following Tz treatment that are independent from tumor cell response to Tz, 
and demonstrate that intravital collagen SHG imaging is capable of measuring dynamic changes 
in tumor microenvironment following treatment that complement trichrome staining. 
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F.2 Introduction 
Collagen is an important protein within the extracellular matrix (ECM) of normal and 
malignant tissues.  In normal breast tissue, increased collagen is associated with increased risk of 
developing breast cancer and increased disease aggressiveness (1).  Recent studies of intra-tumoral 
collagen demonstrate that collagen fiber alignment and density associate with aggressive disease 
and increased invasion (1-3).  Furthermore, a high density of interconnected collagen fibers within 
the extracellular matrix of tumors can block the diffusion of drugs into the tumor (4). These studies 
highlight the importance of collagen within the tumor microenvironment (TME), particularly with 
respect to tumor invasion and drug response. They also demonstrate a need for studies that monitor 
dynamic changes in collagen during breast tumor progression, and elucidate how intra-tumoral 
collagen may change in response to anti-cancer treatments.  
 Breast cancers are divided into three clinical subtypes: estrogen receptor (ER) positive, 
human epidermal growth factor receptor 2 (HER2) positive, and triple negative breast cancer 
(TNBC, lacking expression of ER, HER2, and progesterone receptor, or PR).  HER2 is 
overexpressed in approximately 20% of breast cancers, correlating with poor clinical outcome and 
increased tumor malignancy (5).  Fortunately, several drugs are approved for direct targeting of 
HER2, including trastuzumab (a monoclonal antibody) and lapatinib (a tyrosine kinase inhibitor). 
HER2 inhibitors increase the survival of patients when used alone and in combination with 
standard chemotherapies (6-9).  Unfortunately, many patients do not initially respond to HER2 
inhibitors, or develop acquired resistance to these targeted agents (9).   
 Trastuzumab (Tz) specifically binds to the extracellular domain of HER2 and prevents 
activation of the intracellular HER2 tyrosine kinase.  Tz has other mechanisms of action, including 
blockade of HER2 dimerization, increased HER2 endocytosis and degradation, and induction of 
antibody-dependent cellular cytotoxicity (ADCC) (10, 11). Tz induces cytostatic effects by 
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arresting the cell cycle in the G1 phase and inhibits signaling involved in cell survival (12, 13).  
Additionally, Tz has been shown to inhibit angiogenesis and reduce the expression of growth 
factors such as VEGF and TGF-.  However, additional changes that occur in the TME, 
particularly changes in collagen content and organization, following Tz treatment are poorly 
understood. 
 Images of collagen within the TME can be obtained from second harmonic generation 
(SHG) microscopy.  SHG is a non-linear optical phenomenon in which two photons of the same 
wavelength are combined through a material to yield one photon with twice the energy (one-half 
the wavelength) of the incident photon.  Collagen SHG imaging probes the fibrillar collagen 
content of tissues and generates photon intensity images of collagen fibers within the tissue,  which 
can be analyzed to assess collagen density and alignment (14-18).  Collagen fibers, such as type I, 
II, III, V, and XI, exhibit a strong SHG signal.   In particular, increased amounts of collagen types 
I, III, and V have been found within breast cancers (19, 20).  SHG imaging of breast cancer samples 
has revealed distinct collagen alignment configurations that correlate with increased tumor 
aggressiveness and invasion (1-3, 21).  SHG images can be assessed for collagen density and 
relative alignment of collagen fibers. Additionally, tumor collagen can be assessed by trichrome 
staining of histological slides.  Trichrome stains all types of collagen non-discriminately and 
provides information complementary to that quantified from SHG images of fibrillar collagen. In 
contrast to trichrome stains, SHG microscopy can be performed in vivo.   
 Few studies have characterized changes in the TME following chemotherapy or targeted 
therapy.  Therefore, this study investigates changes in collagen content of HER2+ tumors 
following treatment with Tz.  Two isogenic HER2+ breast cancer cell lines, one Tz-responsive 
(BT474) and the other selected for Tz resistance (HR6), were established as xenografts in athymic 
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mice. Tumor-bearing mice treated with Tz or with a control IgG were used to assess collagen 
content from SHG images in vivo at three time points (2, 5, and 14 days of treatment) and in 
histological trichrome-stained tumor sections harvested at days 2, 5, and 14. These studies tested 
the hypothesis that Tz treatment affects collagen in the TME, independent of the effect of Tz on 
the tumor cells themselves.   
F.3   Materials and Methods 
F.3.1 Xenograft Model 
 This study was approved by the Vanderbilt University Animal Care and Use Committee 
and meets the NIH guidelines for animal welfare.  A total of 36 mice were used. BT474 (108; 
ATCC) and HR6 cells (108; (22)) in 100 L Matrigel (Corning) were injected in the inguinal 
mammary fat pads of 6 week old female athymic nude mice (J:NU; Jackson Laboratories).  Each 
mouse was injected in two locations, on the right and left of the lower portion of the mammary fat 
pad and two tumors grew in all mice except three, which only had one tumor (tumor take rate of 
96%).   BT474 and HR6 cells are ER+/HER2+ isogenic cell lines.  The HR6 cell line was derived 
from a BT474 tumor that developed resistance to Tz treatment (22). These two cell lines were 
chosen because both overexpress HER2, the target protein of Tz, but only the BT474 tumors shrink 
in response to Tz treatment.  Tumors were allowed to grow to approximately 150 mm3; then the 
mice were randomized into control or trastuzumab treatment groups, with nine mice in each group. 
Tumor-bearing mice were treated intraperitoneal with control human immunoglobulin, 10 mg/kg 
(IgG; R&D Systems) or Tz, 10 mg/kg (Genentech), twice weekly for two weeks (on days 0, 3, 7, 
and 10).  This dose of Tz was chosen to mimic the therapeutic dose in patients (23).    To minimize 
tumor variance, age-matched mice were used, a single batch of cells for each tumor type was 
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generated and injected, the same number of cells per tumor was injected, and treatment was 
initiated when the tumors were approximately the same size (~150 mm3). 
 For intravital imaging, the mice were anesthetized with isofluorane and the skin overlaying 
the tumor was removed.  The tumor was covered with a coverslip and the mouse was positioned 
on the microscope stage.  Three locations of each tumor were imaged.  Each tumor type (BT474, 
HR6) and group (control, Tz) at each time point (2, 5, and 14 days of treatment) consisted of 3 
mice (6 tumors).  One mouse from the control and Tz-treated BT474 groups on day 2 and the Tz-
treated HR6 day 2 group only grew 1 tumor and therefore, those groups consisted of 5 tumors.   
Mice were humanly euthanized after imaging while under anesthesia.  Tumors were collected post-
mortem for tissue fixation.  The time points (2, 5, and 14 days) were chosen based on previous 
studies of these mouse tumors, which found metabolic and vascular changes within 2 and 5 days, 
respectively of Tz treatment, and significant changes in tumor volume within 14 days of Tz 
treatment (24, 25). 
F.3.2 Collagen SHG Imaging 
 Collagen SHG imaging was performed on a custom built, commercial multiphoton 
microscope (Bruker).  A 40X oil-immersion objective (1.3 NA) coupled the illumination and 
emission light through an inverted microscope (TiE, Nikon).  A titanium:sapphire laser (Coherent 
Inc.) tuned to 890 nm, with an average power of 8.4 to 8.6 mW, provided the illumination light.  
The incident light was attenuated by a Pockel cell to vary the power of the illumination light which 
results in an elliptically polarized beam.  A PMT (Hamamatsu) detected the emitted photons 
through a 450/35 nm notch filter.  A pixel dwell time of 4.8 s was used to collect 256x256 pixel 
images.  Single frame images for three different locations for each tumor were acquired. Each 
image frame was averaged 8 times to reduce noise.  Sequential images were separated laterally by 
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at least one field of view, 270 m.  Images were acquired of tumor tissue approximately 20-60 m 
in depth into the tumor. 
F.3.3 Collagen SHG Image Analysis 
 Collagen alignment was quantified from the SHG images using the curvelet-based 
alignment analysis software, CurveAlign (http://loci.wisc.edu/software/).  CurveAlign uses a fast 
discrete curvelet transform to find the location and edges of collagen fibers and returns orientation 
data and descriptive statistics.  For our images, collagen alignment was assessed relative to the 
horizontal plane of the image.  An alignment coefficient of 1 indicates parallel fibers while 0 
indicates perpendicular fibers. Collagen density was quantified by image thresholding.  The 
histogram of pixel intensities for most images was bimodal, with one mode representing the 
background pixels and one mode representing the collagen fibers.  Each pixel was assigned a value 
of 0 or 1, depending on if the intensity value of that pixel was above (value = 1) or below (value 
= 0) the optimal threshold value computed for the image using Otsu’s method (Matlab).  Collagen 
density was quantified as the sum of the thresholded image, which represents the portion of 
collagen positive pixels.  The collagen alignment and density outputs from the three fields of view 
interrogated for each tumor were averaged for a single collagen profile of each tumor.  
F.3.4 Trichrome Staining and Analysis 
 Tumors were collected and placed in buffered formalin, paraffin embedded, sliced, and 
stained with trichrome.  Trichrome stains multiple cellular structures including collagen, cell 
cytoplasms, and cell nuclei.  All types of collagen are stained with trichrome, and the resulting 
sections can be qualitatively analyzed. Collagen staining was quantified from 3 tumors per group 
by expert (RSC) analysis of intra- and extra- tumoral collagen content.  Tumor collagen content 
was scored based on presence and intensity of staining, with an increased score indicative of 
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increased collagen staining.  The trichrome score represents the sum of four measures, selected 
between 0-2 for each field of view analyzed: intra dense strands, intra diffuse strands, extra dense 
strands, and extra diffuse strands.  
F.3.5 Statistics 
 Independence of observations between tumors was confirmed using logistic regression.  
Differences in collagen alignment, density, and trichrome staining were assessed between control 
and Tz-treated tumors within each time point and within control or Tz-treated tumors over time 
using non-parametric rank sum tests. We used an alpha significance level of 0.05.  Correlation 
analysis was performed using Spearman’s Rank Correlation Coefficient.  
F.4   Results 
 
Figure F.1. Collagen SHG images and representative trichrome images. (a) Original collagen 
SHG image.  (b) Overlay image of identified collagen fiber angles (green arrows).  (c) Collagen 
density is obtained from a thresholded image. (d-f) Representative trichrome images obtained at 
400X to demonstrate a low (d; score of 2), medium (e; score of 5), and high (f, score of 8) score.   
Scale bars are 100 m.  
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 The collagen content of Tz-responsive (BT474) and Tz-resistant (HR6) tumors was 
examined by in vivo collagen SHG imaging and trichrome staining over a 14 day time course of 
control-IgG or Tz treatment.  BT474 tumors respond to Tz with increased cell death and decreased 
tumor volume, while Tz does not induce cell death or decrease growth in HR6 tumors (22, 24, 25).  
Collagen SHG images were analyzed using CurveAlign to extract relative fiber alignment and 
density of collagen positive pixels (Fig. F.1).  Figure F.1c shows the thresholded intensity mask 
image of collagen density, where all collagen positive pixels have a value of 1 and all negative 
pixels have a value of 0.  Trichrome stained tumor sections were scored from 0-8 based on the 
presence and intensity of the intra- and extra-tumor collagen.  Representative images of trichrome 
stained tumor sections demonstrate trichrome scoring heterogeneity (Fig. F.1d-f). 
 
Figure F.2. Collagen changes in BT474 tumors treated with trastuzumab. (a) Representative 
collagen SHG images from BT474 tumors.  Scale bar is 100 m. (b) Collagen density of SHG 
images for control and Tz-treated BT474 tumors.  (c)  Coefficient of alignment of SHG images for 
control and Tz-treated BT474 tumors.  (d) Trichrome staining score for control and Tz-treated 
BT474 tumors.  † (p<0.05) vs. day 2. * (p<0.05) vs. control. 
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 Collagen analysis revealed significant differences as a result of tumor growth and treatment 
with Tz in BT474 xenografts.  Representative collagen SHG images demonstrate the typical size, 
density, and alignment of collagen fibers within control and Tz-treated BT474 tumors over the 
time course (Fig. F.2a).   Collagen density was obtained from collagen SHG images as the portion 
of collagen positive pixels.  Control BT474 tumors initially had a collagen density of 0.38 on day 
2, which significantly (p<0.05) increased to 0.47 on day 5 and was maintained at 0.49 on day 14 
(Fig. F.2b).  No significant differences in collagen density were detected between control and Tz-
treated BT474 tumors.  Likewise, no differences in collagen alignment were detected in BT474 
tumors treated with Tz for 2 or 5 days.  On day 14, however, there was a significant reduction in 
the collagen alignment of Tz-treated BT474 tumors compared with control BT474 tumors (p<0.05; 
Fig. F.2c).  The intra-tumor variance for the density of the BT474 tumors was 0.002 while the 
inter-group variance was 0.004, suggesting greater differences between tumors within a time point 
and treatment group, than within individual tumors.  The intra-tumor variance for the coefficient 
of alignment of collagen fibers within BT474 tumors was 0.008 while the inter-group variance was 
0.02 (p<0.05), again indicating greater heterogeneity between individual tumors rather than within 
a tumor.  
Trichrome staining of collagen revealed significant differences in collagen between control 
and Tz-treated BT474 tumors.  A trichrome staining score was assigned to each histology section 
based on visual analysis of the intra- and extra- tumoral collagen, both dense and diffuse.  An 
increased score indicates increased collagen content.  Significant reductions in collagen trichrome 
scores were detected on 2, 5, and 14 days (p<0.05) of treatment in the BT474 tumors (Fig. F.2d). 
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Figure F.3. Collagen changes in HR6 tumors treated with trastuzumab.  (a) Representative 
collagen SHG images from HR6 tumors, scale bar is 100 m.  (b) Collagen density of SHG images 
for control and Tz-treated HR6 tumors.  (c)  Coefficient of alignment of SHG images for control 
and Tz-treated HR6 tumors. (d) Trichrome staining score for control and Tz-treated HR6 tumors.  
† (p<0.05) vs. day 2. * (p<0.05) vs. control. 
 
Representative collagen SHG images from control and Tz-treated HR6 tumors are shown 
in Fig. 3a.  Control HR6 tumors showed an increase in collagen density over time, from 0.38 on 
day 2 to 0.55 on day 14 (p<0.05; Fig. F.3b), similar to the increase in collagen density observed in 
the control BT474 tumors over time (Fig. F.2b).  Tz resulted in stable collagen SHG density in 
both the BT474 and HR6 tumors across all time points (Fig. F.2b, F.3b).  No significant differences 
in collagen density between the Tz-responsive and Tz-resistant tumors (within control and Tz-
treated groups) were observed at any time point (p>0.05).  The intra-tumor variance for the 
collagen density of the HR6 tumors was less than the variance between HR6 tumor groups (0.003 
and 0.007, respectively; p<0.05).  Likewise, the intra-tumor variance for the collagen coefficient 
247 
 
of alignment of the HR6 tumors was less than the variance between HR6 tumor groups (0.01 and 
0.02, respectively; p<0.05). Tz failed to induce a decreased collagen alignment in HR6 tumors 
over time or between control and trastuzumab-treated tumors (Fig. F.3c). A significant reduction 
in collagen alignment (p<0.05) was detected in control HR6 tumors compared with control BT474 
tumors on days 5 and 14.  A significant reduction in the trichrome score was detected in Tz-treated 
HR6 tumors compared to control tumors at every time point (Fig. F.3d). 
Correlation analysis was performed between collagen endpoints from control BT474 and 
HR6 tumors using matched tumor data to investigate relationships between SHG imaging 
endpoints and trichrome scores.  Neither the collagen density nor the coefficient of alignment 
determined from SHG images (Fig. F.4a) correlated with trichrome score.  Furthermore, none of 
the endpoints, trichrome score, SHG density, or SHG coefficient of alignment, correlated with 
tumor volume (Fig. F.4b-d).   The SHG density did not correlate with the coefficient of alignment 
(Fig. F.4e).  However, a significant correlation was detected between SHG density and the age of 
the tumor (Fig. F.4f).  
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Figure F.4. Correlations between SHG endpoints and trichrome. (a) Correlation between 
trichrome score and SHG density.  (b) Correlation between trichrome score and tumor volume.  
(c) Correlation between SHG density and tumor volume.  (d) Correlation between SHG coefficient 
of alignment and tumor volume.  (e) Correlation between SHG density and SHG coefficient of 
alignment.  (f)  Correlation between SHG density and age of tumor.  r is Spearman’s correlation 
coefficient.  ns = not significant.  Tumor volume measurements were obtained from paraffin 
embedded tumors which results in tissue shrinkage. 
 
F.5   Discussion 
 
 Tz is a HER2-targeted antibody prescribed clinically for treatment of breast cancers that 
overexpress HER2.  While many studies have characterized the effects of Tz on the tumor 
epithelium, few studies have investigated the effects of Tz on the tumor microenvironment.  This 
study investigated the effects of Tz on breast tumor collagen in both Tz-responsive and Tz-resistant 
tumors.   
 Representative collagen SHG images demonstrate the typical size, alignment, and density 
of collagen fibers within the tumors over time and with treatment (Figs. F.1a, F.2a, F.3a).  These 
images were acquired from a microscope system designed for multiphoton fluorescence imaging 
and fluorescence lifetime imaging.  The only modifications necessary to image collagen SHG was 
249 
 
the addition of a narrow emission filter at one-half the wavelength of the incident near infrared 
light. Collagen SHG imaging is sensitive to the polarization of the incident light.  The incident 
light in our experimental set-up is attenuated by a Pockel cell to vary the power of the illumination 
light, which results in an elliptically polarized beam.  Therefore, we should capture collagen fibers 
at all angles, but the intensity of the fibers may be direction-dependent due to the polarization of 
the incident beam.  In order to account for this bias in intensity with fiber orientation, we applied 
an intensity threshold to our images for further analysis so that our endpoints are independent of 
absolute pixel intensity. Collagen SHG images were analyzed to extract collagen density and 
relative fiber alignment (Figs. F.2b-c, F.3b-c).  
 Analysis of the collagen SHG images revealed a statistically significant increase in the 
density of collagen in control BT474 and HR6 tumors over time (Figs. F.2b, F.3b).  Correlation 
analysis (Fig. F.4) does not show a correlation between larger tumors and collagen density.  
However, there is a significant correlation between SHG density and tumor age.  These results 
suggest increased fibrillar collagen within aging tumors, which is consistent with previous reports 
of increased collagen content in malignant and progressing tumors (1).  Upon treatment with Tz, 
the BT474 tumors shrink over 14 days (25), and the collagen density within these tumors showed 
no significant change over the time course (Fig. F.2b). This suggests that Tz decreases the amount 
of fibrillar collagen in parallel with decreases in tumor volume in responsive tumors, thus 
maintaining constant collagen density over time.   
 The relative alignment of collagen fibers is associated with tumor invasion and progression, 
with radially aligned fibers characteristic of aggressive disease (1-3).  To assess collagen fiber 
alignment, a coefficient of alignment was determined for each image using CurveAlign.  Images 
with perfectly parallel fibers would have an alignment coefficient of 1 while images with 
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perpendicular fibers, a value of 0.  The Tz-treated BT474 tumors showed a significant decrease in 
coefficient of collagen alignment compared to control BT474 tumors on day 14 (Fig. F.2c), 
suggesting less aggressive characteristics upon treatment with the therapeutic antibody.  No change 
in collagen alignment was detected in the HR6 tumors treated with Tz, suggesting no significant 
effect of Tz on the collagen fiber alignment of these non-responding tumors.  A significant 
reduction in collagen alignment was detected in control HR6 tumors compared with control BT474 
tumors on days 5 and 14.  This may be due to differences in the characteristics and behavior of 
these two tumors.  The HR6 tumors grow at a faster rate than the BT474 tumors which may 
influence microenvironment composition (25).  HR6 cells also express higher levels of EGFR and 
P-EGRF compared to the BT474 cells (22), which may influence tumor behavior and 
microenvironment composition (26, 27).   
 Histological analysis of collagen stained with trichrome dye revealed significant reductions 
in collagen content in BT474 tumors treated with trastuzumab at all time-points (Fig. F.2d).  The 
trichrome staining score is a sum four measures, diffuse and dense collagen both intra and extra 
tumoral, and all four individually show similar trends.  Trichrome stains all forms of collagen, 
including fibrillar collagen.  Tumors contain multiple types of collagen, including type I, II, III, 
and IV.  Collage type IV is particularly important within tumors because it composes the basal 
membrane and is involved in tumor invasion (28, 29).   
The HR6 SHG and trichrome results suggest that Tz may have direct effects on the tumor 
microenvironment.  The Tz-treated HR6 tumors did not show an increase in SHG density over the 
14 day study, consistent with the Tz-treated BT474 tumors and contrary to the control HR6 and 
BT474 tumors (Fig. F.2b, F.3b).  Furthermore, the trichrome scores revealed significantly reduced 
scores at all time points for the Tz-treated HR6 tumors compared to the control HR6 tumors (Fig. 
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F.3d).  Few studies have investigated the effects of Tz treatment on non-responsive tumor cells 
and tumor microenvironment.  In a study of a novel glaucoma surgical intervention, Tz was tested 
as an anti-scar agent (30), revealing that Tz suppressed fibroblast proliferation and reduced tissue 
levels of TGF-, FGF-, and PDGF (30). This and the HR6 results suggest that Tz may affect the 
collagen content of tumors by directly modifying fibroblasts behavior or by modulating paracrine 
growth factors secreted by tumor cells.  Furthermore, our previous studies of Tz effects on the 
tumor vasculature of BT474 and HR6 tumors revealed significant decreases in vessel oxygen 
saturation with 5 days of Tz-treatment in both tumor models (24).   Our studies and these previous 
results suggest that Tz treatment may affect the tumor microenvironment independent of its effects 
on the tumor cells. 
 The correlation analysis (Fig. F.4) indicates that the SHG endpoints, collagen density and 
coefficient of alignment, do not correlate with the trichrome staining score or with each other.  
These results agree with findings of Strupler et al, who directly compared sequential slides of 
collagen SHG and trichrome strain and reported that trichrome is less specific at identifying 
fibrillar collagen and difficult to score and compare with SHG (31).  This suggests that SHG 
density, SHG coefficient of alignment, and trichrome score are different measurements.  The 
inconsistencies between trichrome staining and SHG may be due to the source of contrast.  
Trichrome stains all collagen, including fibrillar and non-fibrrillar collagen as well as other 
components of the extracellular matrix, while only certain fibrillar collagen strands will exhibit 
SHG (31).  Tumors can have increased content of non-fibrillar collagens, in particular, collagen 
IV (28, 29), which does not exhibit SHG (31). Additionally, discrepancies between SHG density 
and trichrome staining may be due to sampling error in either the SHG measurements or trichrome 
imaging, both of which are limited to a small fields of view and are thus only probing a small 
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portion of the tumor.  Imaging additional trichrome stained histological slices of the tumor or 
obtaining 3D stacks of SHG images may provide increased representation of the tumor and more 
accurate measurements. 
 The results of this study highlight several changes in the collagen content and organization 
of the tumor microenvironment both in growing tumors and with Tz-treatment.  However, there 
may be confounding factors that influence the composition of the tumor microenvironment and 
the effectiveness of Tz.  The tumor extracellular matrix can affect drug diffusion (18, 32, 33) and 
extracellular proteins such as laminin can co-localize with HER2 and limit the efficacy of Tz (34).  
Therefore, the initial composition of the tumor extracellular matrix may influence Tz treatment.  
Furthermore, variability in tumor growth rates may cause variable vascular instability, which may 
affect the tumor microenvironment, collagen measurements, and Tz-delivery and effectiveness 
(35).   In this study, variability across tumors was controlled by the use of a single batch of cells 
to initiate tumors, the use of age-matched mice, injection of the same number of cells per tumor, 
and the use of mouse weight to determine Tz dose.  However, some variability occurred between 
tumors within groups due to experimental error and biological variance.  This inherent variability 
may mask some effects of Tz on the tumor microenvironment and may limit the effectiveness of 
Tz inhibition of HER2. 
 In conclusion, these studies suggest that Tz treatment may affect the tumor 
microenvironment independent of its effects on the tumor cells. We have also demonstrated that 
collagen SHG and histological trichrome staining analysis of collagen provide complementary 
endpoints of tumor collagen content and morphology.  Collagen SHG imaging can be performed 
in vivo through window chambers for longitudinal studies (24, 36) while trichrome staining is 
inherently post-mortem, potentially limiting the number of time points and increasing animal 
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burden and expense.  Trichrome staining revealed decreased collagen content in both Tz-
responsive and non-responsive tumors treated with Tz. Furthermore, collagen SHG imaging 
revealed similar trends in collagen density in both Tz-responsive and non-responsive tumors 
treated with Tz, suggesting consistent effects of Tz on the tumor microenvironment irrespective of 
Tz-induced tumor size reduction. However, there was a decrease in the alignment of collagen fibers 
of Tz-treated responsive tumors only after 14 days of treatment.  These results highlight the 
changes occurring within the collagen compartment of the tumor microenvironment following 
systemic Tz treatment. 
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